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CHAPTER I
Aim and outline of the thesis
1. Aim
Neurodegenerative diseases are complex human diseases that are still 
poorly understood in terms of their etiology and pathogenesis. The objective 
of this work is to zoom in on the molecular and cellular events that lead to 
a distinctive characteristic shared by several neurodegenerative diseases: 
protein aggregation. We take advantage of the nematode Caenorhabditis 
elegans (C. elegans) to discover genes that modify protein aggregation and 
toxicity (proteotoxicity) and to further examine how these genes contribute to 
the aggregation process. In addition, we aim to validate our observations in the 
mammalian system, by testing whether the mammalian orthologs of the new 
genes have similar effects on protein aggregation. Ultimately, we hope that the 
discovery of these modifiers will add to insights in the field, thereby providing 
a better understanding of how the aggregation process works, which cellular 
functions are involved and, importantly, how these are affected in the context 
of disease. 
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2. Outline of the thesis
In Chapter II we start this thesis by highlighting the importance of a balanced 
proteome and describing the cellular processes involved in its proper 
maintenance. We then explain how this balance is disrupted when protein 
misfolding and aggregation occurs, exemplified by neurodegenerative diseases. 
Next, we demonstrate the value of using small model organisms  including 
yeast, nematode and fly  when identifying genetic modifiers of proteotoxicity 
and highlight the validation of such modifiers in higher organisms. From 
a different perspective, we also present an emerging concept, namely the 
contribution of non-coding RNAs to neurodegeneration, and exemplify how 
impaired RNA metabolism can lead to neurological disorders.
In Chapter III, we focus on C. elegans models of neurodegenerative diseases 
and explain how these can be used to discover modifiers of proteotoxicity in 
high-throughput genetic screens. We describe the two most frequently applied 
methods of genetic screening – EMS mutagenesis and RNA interference – and 
compare these methods by explaining the advantages and disadvantages 
relative to each other. We conclude by providing examples of genetic screens 
that enabled the identification of modifiers of proteotoxicity in C. elegans 
models of Parkinson’s, Alzheimer’s and polyglutamine disease.
In Chapter IV, we describe the characterization of MOAG-2, a modifier 
of aggregation that was previously identified in a forward genetic screen 
performed in a C. elegans model of polyglutamine diseases. We discovered that 
MOAG-2 corresponded with LIR-3, a protein of unknown function previously 
identified in C. elegans. We observed that a mutation or a partial deletion in 
this gene suppressed aggregation in our model. MOAG-2/LIR-3 has two non-
canonical C2H2 domains, which are commonly found in transcription factors. 
This suggested that MOAG-2/LIR-3 might regulate protein aggregation by 
functioning as a transcription factor. We discovered that MOAG-2/LIR-3 is 
indeed an RNA Polymerase III-associated transcription factor that regulates 
the transcription of small non-coding RNAs, including small nucleolar RNAs 
and transfer RNAs. In this study, we discovered that polyglutamine expansion 
proteins suppress MOAG-2/LIR-3-mediated transcriptional regulation and 
convert the MOAG-2/LIR-3 protein into an aggregation-promoting factor.
In Chapter V, we focus on how cells respond to proteotoxic stress provoked by the 
expression of aggregation-prone proteins. To investigate the cellular pathways 
involved in this stress response, we performed whole transcriptome profiling in 
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wild type worms and worms expressing polyglutamine expansion proteins. By 
combining differential gene expression analysis with gene ontology enrichment 
analysis, we found that the genes that responded to the presence of aggregation-
prone proteins in the cell were genes involved in the unfolded protein response, 
the immune response and oxidative stress. Parallel to this, we also found that 
aggregation-prone proteins affect C. elegans development.
Another modifier of aggregation identified during previous genetic screens was 
MOAG-4. MOAG-4 has two human orthologs: SERF1A has 50% amino acid similarity 
to MOAG-4 and SERF2 has 54%. In Chapter VI we follow up on previous studies of 
SERF2 by Van Ham et al. We aimed to study the effect of SERF2 on amyloid-beta 
aggregation in the brain of mice and discovered that a full-body Serf2 knockout 
resulted in embryonic lethality with incomplete penetrance. Indeed, we observed 
that the Serf2 knockout allele was not segregated according to the expected 
Mendelian ratios, suggesting a crucial function for Serf2 in mouse development. 
This observation led us to generate a brain-specific Serf2 knockout mouse, which 
is viable and fertile.
 
In Chapter VII, we critically analyze this work and discuss how it has helped to 
address our initial aims. We further address any questions that remain open and 
discuss future perspectives that may follow from this work. 
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Abstract
Protein homeostasis is fundamental for cell function and survival, because 
proteins are involved in all aspects of cellular function, ranging from 
cell metabolism and cell division to the cell’s response to environmental 
challenges. Protein homeostasis is tightly regulated by the synthesis, folding, 
trafficking and clearance of proteins, all of which act in an orchestrated manner 
to ensure proteome stability. The protein quality control system is enhanced 
by stress response pathways, which take action whenever the proteome is 
challenged by environmental or physiological stress. Aging, however, damages 
the proteome, and such proteome damage is thought to be associated 
with aging- related diseases. In this review, we discuss the different cellular 
processes that define the protein quality control system and focus on their 
role in protein conformational diseases. We highlight the power of using 
small organisms to model neurodegenerative diseases and how these models 
can be exploited to discover genetic modulators of protein aggregation and 
toxicity. We also link findings from small model organisms to the situation 
in higher organisms and describe how some of the genetic modifiers 
discovered in organisms such as worms are functionally conserved throughout 
evolution. Finally, we demonstrate that the non- coding genome also plays 
a role in maintaining protein homeostasis. In all, this review highlights the 
importance of protein and RNA homeostasis in neurodegenerative diseases. 
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Protein homeostasis
Protein folding
Maintaining a healthy proteome is important to ensure cell survival and 
function. The cell maintains a healthy proteome through a series of complex 
and tightly regulated surveillance systems (Fig. 1). These systems ensure that 
each protein is properly folded or assembled in a state that is required for it to 
perform its function in the cell.
After the synthesis of a nascent polypeptide chain, the protein’s amino acid 
sequence determines whether or not the protein becomes folded, and whether 
or not chaperone proteins are required for its folding (Fig. 1a, b). Some proteins 
are thought to exist in a predominantly “unfolded”, “disordered” or “intrinsically 
unstructured” state ([1], also reviewed in [2, 3]). Such proteins are typically 
involved in transcription, in signaling pathways and in protein networks ([4], 
also reviewed in [5, 6]). In mammals, about half of all possible proteins are 
predicted to have long disorganized regions and about 25% are estimated as 
being intrinsically unstructured [2]. Other proteins have domains within their 
amino acid sequence that can fold spontaneously, whereas other large, multi-
subunit proteins require molecular chaperones to assist in folding to their 
native state, as shown in in vitro studies [7-11].
The molecular chaperones that cooperate in the de novo folding or refolding 
process are subdivided into different classes, which include the Hsp70 system, 
the small chaperones, the chaperonins and the Hsp90 system [11-14]. In the 
case of de novo synthesis, chaperones protect the nascent polypeptide chain 
from aberrant contacts with other domains of the same proteins and from 
aggregation with other proteins (Fig. 1b) ([13, 14] , also reviewed in [12, 15]). As 
a protein is synthesized, it is transiently unfolded and its hydrophobic regions 
are exposed. Hsp70 is able to recognize these regions and it binds to the protein 
substrate via its peptide-binding site in an ATP-dependent manner (reviewed 
in [12, 15, 16]). Hsp70 holds the substrate in an extended conformation, 
stabilizing it and preventing premature misfolding and aggregation. Next, 
the substrate can be transferred to another chaperone system, such as the 
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chaperonins, where folding takes place and a three-dimensional structure is 
acquired (reviewed in [12, 16, 17]). 
When misfolded proteins accumulate, unfolded protein responses can increase 
the levels of chaperones, which are then able to restore the proteins to their 
properly folded form (Fig. 1c, d, reviewed in [16], [18-21]). Such an accumulation 
of misfolded protein is just one of the types of stress that can trigger unfolded 
protein responses. Unfolded protein responses are mechanisms that are highly 
conserved from yeast to humans and that are induced upon environmental 
and physiological stress, such as thermal or oxidative stress (reviewed in 
[22-24]). In one of these pathways thought to respond to the accumulation 
misfolded proteins in the cytosol, heat shock factor 1 (HSF-1) acts as a master 
transcriptional regulator. HSF-1 is activated upon phosphorylation, after which 
it translocates from the cytosol to the nucleus to bind to so-called heat shock 
elements, thereby upregulating the transcription of heat shock genes. These 
genes are then translated into proteins that assist in the refolding of misfolded 
proteins into functionally active proteins, in preventing unspecific interactions, 
or in mediating their degradation (Fig. 1d) (reviewed in [19, 22]).
Another strategy used by the cell to restore protein homeostasis is the unfolded 
protein response that is associated with the endoplasmic reticulum (ER) 
(Fig. 1e, also reviewed in [18, 25, 26]). The ER is the organelle where proteins 
enter the secretory pathway to acquire post-translational modifications, after 
which they are delivered to their corresponding organelle, fixed in the plasma 
membrane or shuttled outside of the cell to perform their function [27]. If 
misfolded proteins accumulate, the ER-associated degradation (ERAD) pathway 
is activated through signal transduction pathways that are mediated by three 
upstream effectors: inositol-requiring protein 1 (IRE1), activating transcription 
factor (ATF)-6 and PKR-like endoplasmic reticulum kinase (PERK).
IRE1, ATF-6 and PERK mediate three distinct pathways. Firstly, IRE1 is a 
transmembrane protein kinase that activates itself by auto-phosphorylation 
and mediates splicing of Hac1 in yeast and XBP-1 in eukaryotes [28-32]. 
IRE1 is known to promote the transcription of three groups of genes: stress-
responsive genes including molecular chaperones and folding enzymes, genes 
17
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Figure 1. Quality control of cellular proteins. When a protein is synthesized, it can acquire its native state in a 
chaperone-independent (a) or dependent (b) manner. Upon environmental stress or mutations, the protein 
may either not acquire its native state or lose it, both leading to misfolding (c). Here, the misfolded protein 
can be refolded back to its functional conformation with the aid of chaperones (d); or sent to degradation via 
the ERAD (e), the ubiquitin-proteasome system (f) or autophagy (g). Alternatively, it can be redirected to the 
JUNQ for posterior refolding or degradation by the proteasome (h) or it can be permanently sequestered in 
the IPOD (i) or aggresome (j).
involved in ERAD and genes involved in ER trafficking [33-35]. Secondly, ATF-6 
is a transmembrane protein with a transcription factor domain (leucine zipper) 
that translocates from the ER lumen to the Golgi apparatus to be cleaved by 
proteases [36, 37]. This proteolysis releases the ATF-6 cytosolic fragment, which 
then enters the nucleus to induce the transcription of ER-resident chaperones 
and the transcription factor XBP-1, thereby increasing ER protein quality 
control capacity [29, 37-39]. Thirdly, PERK is a transmembrane kinase protein 
that phosphorylates the alpha-subunit of the eukaryotic translation initiation 
factor 2a (eIF2a), thus preventing the binding of the initiator tRNA(Met) to the 
ribosomal complex, necessary for translation initiation [40-42]. This results in an 
overall reduction in protein synthesis, thereby attenuating the accumulation of 
misfolded proteins at the ER.
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Protein degradation
If an aberrant protein cannot be folded back into its native state by the 
molecular chaperones, then it can be eliminated by two proteolytic systems, 
the proteasome and autophagy (Fig. 1f, g). In the degradation via the ERAD 
pathway, the ER cooperates tightly with the ubiquitin-proteasome system 
(UPS) to recognize, mark and traffic the misfolded proteins to the cytosol for 
degradation (Fig. 1e, reviewed in [18, 43-45]). The exact mechanisms that allow 
the cell to discriminate misfolded proteins from correctly folded proteins are 
not fully understood (reviewed in [44, 46, 47]). However, the current notion is 
that misfolded proteins can be recognized by molecular chaperones (the HSP70 
family of proteins) and co-chaperones (the DnaJ/HSP40 family of proteins) [48-
51].
An example that illustrates this recognition is the immunoglobulin binding 
protein (BiP), an HSP70 chaperone that recognizes and binds to the hydrophobic 
regions of misfolded proteins, thereby preventing their aggregation [49-53]. 
The binding of the ERAD substrate to BiP and its subsequent release depends 
on the conversion of ADP to ATP, a process regulated by ERdj proteins, which 
are part of the DnaJ/Hsp40 family of co-chaperones, and the nucleotide 
exchange factors GRP170 and BAP/Sil1 [48, 52]. These factors stimulate the 
ATPase activity of BiP and stabilize its binding to the misfolded protein [54-58]. 
The ERdj co-chaperones have also been shown to bind directly to unfolded 
proteins, thus maintaining them in a soluble state to be later recruited by BiP 
[48, 59]. After the misfolded protein has been identified, it is poly-ubiquitinated 
to be subsequently targeted for degradation [60-62].
Ubiquitination is a sequential three-step process that marks proteins destined 
for the proteasome (Fig. 1f ). It starts with the activation of ubiquitin (a small 
76 amino acid protein) by the activating enzyme E1, followed by binding of 
ubiquitin to the active site of the ubiquitin-carrier protein E2 and, finally, transfer 
of the ubiquitin molecule to the substrate in a reaction catalyzed by the ubiquitin 
protein ligase E3. At least four ubiquitin molecules must be bound to the ERAD 
substrate for it to be later recognized by the proteasomal machinery [63, 64]. 
Following this step, the misfolded proteins are delivered to the proteasome (a 
process called retrotranslocation) and the ubiquitin molecules are removed 
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from the substrate prior to degradation by the deubiquitinating enzymes and 
recycled [65-67]. The proteasome is a barrel-shaped, multicatalytic proteinase 
where proteolysis occurs and proteins are cleaved into peptides 2 to 30 amino 
acid long [68].
The second proteolytic system, autophagy (“self-eating”), is a cellular 
degradation mechanism that eliminates cytosolic components, organelles and 
pathogens via lysosomes (Fig. 1g, [69-72]). It is the part of the cell that ensures 
protein and organelle turnover, where old cellular components are degraded 
and recycled molecules become available for cell metabolism [70, 71, 73]. For 
the purpose of this review, we discuss only the role of autophagy as a protein 
quality control system.
Autophagy can be classified into three categories: macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA). In 
macroautophagy, a newly formed double membrane vesicle engulfs the 
cytosolic material, forming the autophagosome. The autophagosome then 
fuses with an endosome or lysosome, giving rise to the autolysosome where 
degradation takes place through the action of hydrolytic enzymes (Fig. 1g) [71]. 
The double membrane that surrounds the autophagosome is derived from the 
ER, the mitochondria or the plasma membrane [74-78]. In yeast, autophagy 
is a multi-step process that requires at least 37 autophagy-related (ATG) 
genes [79-89]. The majority of the ATG genes have shown to be functionally 
conserved in mammals [90, 91]. In microautophagy, small molecules from the 
cytoplasm are internalized by the lysosome through invagination of its own 
membrane [70, 73]. In contrast to autophagy and CMA, much less is known 
about microautophagy [92].
CMA differs from the former two forms of autophagy in that it does not involve 
membrane reorganization. Instead, substrates with a KFERQ amino acid motif 
are recognized by an HSP70 cytosolic chaperone, Hsc70, that binds and delivers 
them to the CMA receptor at the lysosome [93-96]. Here, the substrate is unfolded 
before it is translocated into the lumen of the lysosome for degradation, which 
is assisted by Hsc73, an intralysosomal HSP70 chaperone [97, 98].
20
Chapter II
Cross talk exists between the UPS and autophagy. Chronic low-level proteasomal 
inhibition is known to be sufficient to activate autophagy and it has been 
suggested that ubiquitinated proteins may also be eliminated through this 
pathway [99-101]. It has also been proposed that macroautophagy may occur 
as a compensatory mechanism when either the UPS or CMA is impaired [102, 
103].
Protein compartmentalization
An alternative pathway for misfolded proteins is the sequestration into 
specialized protein quality control compartments where they can be either 
recovered or permanently sequestered (Fig. 1h, i, j) ([104-109], also reviewed 
in [110, 111]). Distinct quality control compartments harbor different species 
of misfolded proteins and are evolutionary conserved from yeast to mammals 
[105, 107-109, 112, 113]. Ubiquitinated misfolded cytosolic proteins are assigned 
to the juxtanuclear quality control compartment (JUNQ, Fig. 1h). These soluble, 
mobile misfolded proteins can subsequently be recovered by the molecular 
chaperone Hsp104 and either refolded back into functionally active proteins 
or degraded by the proteasomes localized nearby (Fig. 1h) [108, 112]. Non-
ubiquitinated misfolded proteins – comprising amyloidogenic proteins – are 
redistributed to the insoluble protein deposit (IPOD, Fig. 1i). This compartment 
is localized at the cell periphery and is known to contain insoluble and immobile 
species, which are not recoverable and seem to remain terminally sequestered 
there (Fig. 1i) [108]. More recently, it has been proposed that there are no pre-
existing compartments in the cell, and that soluble ubiquitinated misfolded 
proteins (but not the non-ubiquitinated amyloidogenic type) may coalesce 
and form transient structures termed ‘Q bodies’ that eventually mature into the 
JUNQ compartments [104].
Much research has focused on finding out whether the redistribution of 
misfolded proteins to these spatial cytosolic compartments is a random event 
or whether it depends on the concerted action of sorting factors. Evidence 
suggests that the latter is the case, and that sorting factors interact with 
chaperones to deliver misfolded proteins to each compartment [105]. For 
example, upon physiological stress, Btn2 (a Hook family protein involved in 
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linking organelles to microtubules) was shown to associate either with the 
yeast small heat shock protein Hsp42 to assign misfolded proteins to the IPOD 
or with the chaperone Sis1 to guide misfolded proteins to the JUNQ [105, 107].
Another type of cytosolic compartment – the aggresome – is localized at the 
microtubule organizing center (MTOC) and is formed when the proteasome is 
unable to clear misfolded proteins properly (Fig. 1j) [114]. Aggresome formation 
is accompanied by redistribution of vimentin, an intermediary filament that 
acquires a cage-like structure in the aggresome. Ubiquitinated misfolded 
proteins depend on microtubules to be transported to the aggresome, this 
being done by the dynein/dynactin complex (Fig. 1j) [115]. Interestingly, the 
JUNQ shares several similarities with the aggresome, including its perinuclear 
localization, the presence of chaperones and ubiquitinated misfolded proteins 
[108, 114]. It was also recently shown to functionally associate with the MTOC 
and vimentin [112]. Indeed, the overwhelming accumulation of misfolded 
proteins to the JUNQ is thought to render it an immobile, insoluble aggresome 
over time [112].
Similar structures to aggresomes are the so-called aggresome-like induced 
structures (ALIS), which were originally discovered in dendritic cells but were 
later also found in other type of cells [109, 116]. The ALIS is a transient structure 
with peripheral and juxtanuclear localization. It is induced under a wide variety 
of stress conditions (e.g. heat shock, starvation, oxidative stress, inflammation) 
and clusters newly synthesized, ubiquitinated misfolded proteins [106, 109]. 
ALIS substrates can also be cleared by the proteasome and lysosome [106].
Cell division could be considered as yet another protein quality control system 
that sequesters misfolded, aggregated proteins (reviewed in [117, 118]). Studies 
in bacteria and yeast have shown that accumulation of protein aggregates 
reduces the fitness of these cells, a problem partially resolved by asymmetric 
division: these protein deposits are retained in the aging mother cell while 
the daughter cells are freed from damaged proteins, a process also known as 
replicative rejuvenation [119-123]. In budding yeast, it has been shown that 
misfolded proteins sorted either to the JUNQ or IPOD remain in the mother 
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cell after asymmetric cell division, thus avoiding passage of these species onto 
the daughter cells [124]. Follow-up work from the same group extended this 
observation to mammalian cells, where the JUNQ (but not the IPOD) continues 
to be inherited asymmetrically, thereby always freeing one of the two daughter 
cells from proteotoxicity [112].
While much is now known about the sophisticated quality control mechanisms 
that the cell has evolved to ensure proper protein homeostasis, several 
questions remain to be answered. We know that the cell counts on the 
concerted action of chaperones to avoid an unfolded or misfolded protein 
interacting aberrantly with other proteins until it can be refolded back into 
its native state. In case this is not possible, the aberrant protein is sent to be 
degraded via the ubiquitin-proteasome system or by autophagy. However, it is 
still not known how the cell chooses one mechanism of degradation over the 
other or whether the two mechanisms occur simultaneously. Another unknown 
relates to protein compartmentalization – yet another strategy for putting away 
proteins that need to be degraded or permanently sequestered. It has not yet 
been established how the cell can differentiate between degradable and non-
degradable proteins and shuttle them to different subcellular compartments. 
Finally, another important question is how protein quality control changes 
during aging. Aging itself may be the contributing factor for progressive 
deterioration of protein homeostasis, impairing the ability of the protein 
quality control system to handle the equilibrium between protein folding and 
degradation.
Protein misfolding and aggregation in neurodegenerative 
diseases
The effects of progressive deterioration of protein homeostasis are thought to 
play a role in age-related neurodegenerative diseases. The presence of protein 
aggregates in the brain is namely a hallmark shared by several neurodegenerative 
diseases, including Parkinson’s (PD), Alzheimer’s (AD) and Huntington’s disease 
(HD) (reviewed in [125, 126]). In these diseases it is not yet clear why proteins 
accumulate into aggregates and how this relates to pathogenesis. 
Protein aggregation and its relationship to aging and neurodegeneration have 
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also been widely studied in animal models. Evidence from several animal models 
suggests that, as the animal ages, the cell’s stress response systems become less 
efficient and less capable of maintaining a balanced proteome [127-133]. This 
could lead to the progressive accumulation of cytotoxic aggregation-prone 
disease proteins that cannot be cleared, ultimately resulting in toxicity and 
cell death [100, 134-137]. In the roundworm Caenorhabditis elegans, a model 
organism much used to study aging, protein aggregation has been shown 
to occur during aging and to affect the lifespan of the organism [138-140]. 
As previously discussed, when a protein misfolds it exposes its aggregation-
prone domains to the cellular environment – domains that would otherwise 
be structurally concealed – thereby facilitating the likelihood of aberrant 
interactions with other proteins, potentially leading to proteotoxicity. Such 
proteotoxicity is proposed to play a role in protein conformational diseases in 
humans, including PD, AD and HD.
The type of aggregates that are formed varies for different neurodegenerative 
diseases. Frontotemporal lobar degeneration with fused in sarcoma is an 
example of a neurodegenerative disease that is characterized by the presence 
of amorphous, non-amyloidogenic aggregates ([141, 142], also reviewed in 
[143]). On the other hand, the common neuropathological feature of PD, AD 
and HD is the presence of an aggregation-prone disease protein that acquires 
amyloidogenic properties, causing it to form intracellular amyloid aggregates 
or extracellular amyloid plaques in the brains of patients (reviewed in [125, 
126, 144]). The amyloids present in these neurodegenerative diseases can be 
distinguished from other amorphous, unstructured aggregates because they 
are organized, insoluble fibrils with a cross-beta structure and because they can 
be detected by specific amyloid-binding dyes, namely Congo red and thioflavin 
T (reviewed in [145, 146]). It is interesting to note that—despite their differences 
in amino acid sequence and function—several unrelated aggregation-prone 
disease proteins have one thing in common: in disease they are present as 
amyloid. This suggests that their ability to form amyloid is related to disease 
and that they may cause proteotoxicity in a similar manner.
In vitro studies have made clear that virtually any protein can form amyloid fibrils 
under certain conditions. Such conditions include low pH, high temperature 
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and high pressure [147-154]. Native proteins are known to exist in equilibrium 
with their partially unfolded state, and when they are destabilized by certain 
conditions or mutations, the equilibrium shifts towards amyloid formation. 
Predicting aggregation-prone regions in proteins is now possible using 
bioinformatic tools. Examples of such tools are TANGO, which can specifically 
identify regions prone to form beta sheets, and Waltz, which can distinguish 
between amyloid sequences and amorphous beta-sheet aggregates [155, 156].
A proposed mechanism for amyloid formation is depicted in Fig. 2. Most of our 
understanding of this pathway has come from in vitro studies of aggregation-
prone proteins, including amyloid-beta (seen in AD) and alpha-synuclein (seen 
in PD) but also from studies of globular proteins, including human lysozyme, 
superoxide dismutase 1, transthyretin and the acylphosphatase from the 
archaea Sulfolobus solfataricus (reviewed in [125, 146]). One common step of 
amyloid formation appears to be the conversion of the monomeric, native 
state protein into an oligomeric intermediate state (Fig. 2). An oligomer is a 
small and transient cluster of protein molecules that has no fibrillar structure 
and is of low molecular weight [157-159]. These oligomers can then form 
protofibrils, which are fibrils 6 to 8 nm in diameter, about 200 nm in length 
and known to contain beta sheets detectable by Congo red and thioflavin T 
staining (Fig. 2) [160, 161]. Protofibrils can then convert into amyloid fibrils (Fig. 
2) [160]. Of all these aggregation intermediates, it is currently thought that 
the early ones are cytotoxic and that aggregation may be a neuroprotective 
response to permanently sequester these intermediates, thereby preventing 
potentially toxic interactions with other proteins in the cellular milieu [162-
165]. In support of this hypothesis, it has been shown that proteins rich in beta-
sheet structures aggregate with newly synthesized proteins that have not yet 
become folded or with intrinsically unfolded proteins, thereby reducing the 
availability of these proteins to perform their normal function [135]. Further 
evidence demonstrating that oligomeric or protofibrillar forms of aggregation-
prone disease proteins contribute to cell toxicity and death is reviewed 
elsewhere [144, 146, 166-168].
In a nutshell, the amyloid pathway has only just started to be described and 
it is not fully understood how protein aggregation correlates with disease. At 
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Figure 2. Proposed mechanism for amyloid formation. A protein loses its monomeric native state by 
conversion into an oligomer which can grow further into amyloidogenic fibrils and ultimately into insoluble 
amyloid aggregates.
the clinicopathological level, it is striking that there are individuals with high 
AD pathology (i.e. abundant amyloid deposits and neurofibrillary tangles) 
and yet do not display any cognitive impairment (reviewed in [169]). This fact 
makes it difficult to discern what are the boundaries between normal aging 
and disease pathogenesis. At the cellular and molecular level, what structural 
properties do aggregation-prone proteins acquire that make them toxic? This 
question is further complicated by the fact that aggregation-prone proteins 
such as amyloid-beta, huntingtin or alpha-synuclein do not share sequence, 
structure or function. A second question is that of how long neuronal cells can 
deal with these aggregation-prone proteins. And is their slow accumulation in 
the brain a reflection of an impaired protein quality control system? Finally, the 
majority of our knowledge about aggregation intermediates has come from in 
vitro studies. It remains to be shown whether oligomeric and fibrillar species 
exist in vivo and what their relevance to pathogenesis is.
Genetic modifiers of proteotoxicity
Genetic screens in small model organisms for protein aggregation 
in disease
The current understanding of how protein misfolding and aggregation 
contributes to neurodegeneration is far from complete. Molecular and cellular 
mechanisms that may regulate neurodegenerative disorders have been 
discovered in small organisms, the major ones being yeast (Saccharomyces 
cerevisiae), fly (Drosophila melanogaster) and nematode (C. elegans) 
(Table 1). In general, these small organisms are easy to grow and manipulate; 
their genomes are fully sequenced and accessible in public databases; and they 
provide information relatively quickly due to their short life cycle. Moreover, 
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the availability of resources such as genome-wide mutant libraries (deletion, 
overexpression or RNAi-based) further adds to the attraction of using these 
organisms as powerful genetic tools. Indeed, well-established models of several 
neurodegenerative diseases, including AD, PD and polyglutamine diseases, 
have now been generated in each of these small organisms [170]. Of note is 
that expression of an exogenous aggregation-prone protein typically exclusive 
to mammals can faithfully mimic some neuropathological features, namely the 
protein aggregation and toxicity phenotype seen in the diseased brain [170, 
171]. And it is this that makes models in small organisms so attractive in the 
search for evolutionary conserved modifiers of proteotoxicity. These modifiers 
will provide insight in disease pathology and can be further explored as targets 
for therapy.
Finding modifiers of proteotoxicity in such models can be relatively quick: 
researchers can take advantage of high throughput screening techniques 
using genome-wide overexpression, deletion, or RNAi libraries or using 
chemical mutagenesis. These resources are unbiased methods that can be 
used to screen for genes that – when mutated, overexpressed or suppressed 
– contribute to an increase or decrease of protein aggregation and toxicity. 
Some of the hits that result from these screens may very well be genes that 
have already been associated with disease in humans. On the other hand, it 
is also a way of identifying previously unknown regulators of proteotoxicity – 
such findings may provide mechanistic insights into that particular disease. It 
should be noted, however, that genes shown to strongly suppress or enhance 
aggregation in one model do not always have a similar effect in other models, 
possibly due to the inherent differences between species or between the 
methods employed. Nevertheless, functionally conserved genetic modifiers of 
aggregation and toxicity have been identified across species.
In the end, to establish the value of genes discovered to be involved in 
aggregation and toxicity in small organisms, the results will have to be 
reproduced in human neurons and in mammalian animal models. If the 
function of modifiers of proteotoxicity identified in small organisms is 
evolutionarily conserved, their mammalian counterparts may become 
therapeutic targets worthy of future pharmacological investigation 
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(Table 1). At the same time, small model organisms provide a simple platform 
that can be used not only to understand the basic mechanisms underlying the 
causal gene of disease but also as a pharmacological screening tool. Below we 
describe examples of genetic modifiers that have been studied in different 
model organisms for PD, AD and polyglutamine diseases.
Parkinson’s disease models
Alpha-synuclein is the major constituent of the protein aggregates found in 
the brains of PD patients, which are also known as Lewy bodies [172]. It is a 140 
amino-acid protein that is mostly expressed in the brain and is thought to have 
a function at the synapse (reviewed in [126, 173]).
The aggregation phenotype is successfully recapitulated in the budding yeast 
S. cerevisiae, where heterologous expression of alpha-synuclein induces toxicity 
in a concentration-dependent manner and is associated with the formation of 
cytoplasmic protein aggregates similarly to those observed in the human brain 
[174]. The characteristics that make yeast a powerful genetic tool for studying 
neurodegenerative disorders are reviewed elsewhere [171, 175].
In yeast, Cooper et al demonstrated that overexpression and subsequent 
accumulation of alpha-synuclein impairs vesicle transport from the ER to the 
Golgi  (Table 1) [176]. In the same study, a genome-wide overexpression screen 
identified the small GTPase Ypt1 as a modifier of alpha-synuclein toxicity. 
Overexpression of Ypt1p was sufficient to prevent alpha-synuclein toxicity, 
by enabling forward trafficking from the ER to the Golgi. This observation 
was further extended to Drosophila and C. elegans models of PD as well as 
in rat midbrain primary neurons, where Rab1 – the functionally conserved 
orthologue of Ypt1p – suppressed dopaminergic neuron loss (Table 1) [176].
Another modifier of proteotoxicity identified from the same original yeast 
screen was YPK9, an orthologue of the human lysosomal P-type ATPase 
ATP13A2 (also known as PARK9), an enzyme known to be associated with early 
onset parkinsonism (Table 1). YPK9 overexpression prevented alpha-synuclein-
induced toxicity by reducing intracellular aggregation and restoring alpha-
synuclein localization to the plasma membrane [177]. The same study showed 
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that the C. elegans orthologue CATP-6 partially prevented dopaminergic 
neuron loss, and that knockdown of CATP-6 increased alpha-synuclein 
misfolding in an age-dependent manner. Finally, in rat primary neuron 
cultures transduced with a lentivirus carrying the familial alpha-synuclein A53T 
mutation, heterologous expression of human ATP13A2 prevented neuronal 
loss (specifically dopaminergic neurons). Notably, this study was the first to 
show a link between environmental and genetic causes of PD, since YPK9 
protected against manganese toxicity in yeast, a heavy metal thought to be risk 
factor for PD. Indeed, YPK9 was later shown to regulate manganese tolerance 
via diverse cellular processes, such as vesicle transport, vacuolar organization 
and chromatin remodeling in yeast (Table 1) [178].
The important role of vesicle-mediated transport in alpha-synuclein toxicity 
has also been demonstrated by other studies [179, 180]. In a screen performed 
by Kuwahara et al, the authors discovered ten neuroprotective genes, four 
of which were involved in endocytosis. Knockdown of two of these genes 
(apa-2 and aps-2, encoding two different subunits of the AP-2 adaptor protein 
which mediates clathrin-dependent endocytosis) revealed that deficiencies at 
synaptic vesicles led to alpha-synuclein neurotoxicity [179]. 
Several modifiers of proteotoxicity have also been identified using RNAi screens 
in C. elegans models of PD [179-181]. Follow up on this work has revealed tdo-2 
as a general regulator of proteotoxicity and lifespan [182]. 
Genetic screens not only help us to identify novel modifiers of proteotoxicity, 
they can also be useful for rediscovering genes that were previously known to be 
associated with disease. Such an example comes from work by Hamamichi et al, 
where an RNAi screen identified the autophagy-related gene Atgr7 as protecting 
against alpha-synuclein-induced toxicity in C. elegans dopaminergic neurons 
[181]. The mammalian orthologue of Atgr7 has previously been implicated in 
neurodegeneration in mice, where it was found to cause axonal degeneration 
and dystrophy when ablated, thereby highlighting the importance of neuronal 
autophagy in preventing degeneration (Table 1) [183]. 
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Alzheimer’s disease models
The brains of patients with AD are characterized by the presence of 
amyloid plaques and neurofibrillary tangles, which develop as a result of an 
accumulation of extracellular deposition of two different proteins: amyloid-
beta in the plaques and intracellular hyperphosphorylated tau in the tangles 
(reviewed in [184, 185]). The disease can be caused by a mutation in the gene 
for amyloid precursor protein (APP), or in presenilin 1 or presenilin 2, all of 
which alter amyloid production (reviewed in [184, 186]).
C. elegans has been a fundamental tool for dissecting the pathways that link 
lifespan to AD (Table 1). Specifically, one of the major pathways that regulates 
lifespan is the insulin/IGF-1 signaling (IIS) pathway – a pathway that has been 
validated in nematodes, flies and mice and strongly implicated in humans [187-
193]. In one of the models that recapitulates AD, C. elegans expresses a human 
amyloid-beta protein fragment (peptide 3-42) in the body wall muscle and 
progressive paralysis is used as readout for amyloid-beta toxicity [194]. In this 
model, knockdown of the insulin/IGF-1 receptor DAF-2 not only significantly 
extended lifespan but also prevented amyloid-beta toxicity by delaying the 
onset of paralysis, identifying a link between the mechanisms of aging and 
proteotoxicity [195]. Modulation of lifespan by DAF-2 was also found to be 
highly dependent on HSF-1 and DAF-16, two transcription factorsknown to 
drive the expression of longevity genes [196]. Curiously, while both blocked 
proteotoxicity, they did so through opposing effects: while HFS-1 promoted 
disaggregation, DAF-16 pushed aggregation forward, possibly as a means of 
sequestering the amyloidogenic protein from the cellular milieu [195].
The observation that inhibition of the IIS pathway protects against proteotoxicity 
was further confirmed in an AD mouse model with haploinsufficiency of 
IGFR-1, the mammalian orthologue of DAF-2 (Table 1) [197]. Here, reducing 
only half the expression of IGFR-1 (and thereby the IIS pathway) was sufficient 
to prevent amyloid-beta toxicity, namely by reducing inflammation and neuron 
loss. The AD mice with reduced IGFR-1 also performed better in memory and 
learning tasks than their age-matched AD controls did and this was found to be 
correlated with the formation of densely packed aggregates in the brain. This 
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supports the idea that aggregation is a protective mechanism to permanently 
sequester smaller, soluble oligomeric amyloid-beta species that are proteotoxic.
The importance of modeling neurodegenerative diseases in small organisms 
has been further reinforced by Treusch et al, who have identified modifiers of 
amyloid-beta toxicity that are conserved from yeast to humans (Table 1) [198]. 
Taking advantage of a yeast model of AD, they performed an unbiased genetic 
screen for modifiers of amyloid-beta toxicity. Of the identified modifiers, six were 
found to be risk factors for AD in humans – either validated or potential – that 
had been previously identified from family-based genome-wide association 
studies (GWAS). These modifiers were specific to amyloid-beta, in that in yeast 
they did not prevent toxicity induced by another aggregation-prone protein, 
alpha-synuclein.  Another modifier of amyloid-beta toxicity identified by 
Treusch et al is YAP1802, a suppressor of amyloid-beta proteotoxicity that is 
involved in clathrin-mediated endocytosis. Its human homolog PICALM is also 
involved in endocytosis and has been validated as a high risk factor for AD (Table 
1). YAP1802 prevents amyloid-beta toxicity in yeast and the human homolog 
PICALM prevents amyloid-beta toxicity in rat cortical neurons. Notably, this 
study identifies a causal gene for susceptibility to AD and proposes defective 
endocytosis as a contributing factor in AD pathology, with a possible role for 
PICALM.
In another independent study, GWAS data for AD was combined with a functional 
screen in Drosophila (Table 1) [199]. From a set of GWAS variants obtained from 
patients with AD, Shulman et al found 19 evolutionarily conserved orthologues 
in the fly that either enhanced or suppressed neurotoxicity associated with 
tau. Six of these interacted with tau in vivo, including the glucose transporter 
GLUT1, found to be functionally conserved in the human orthologue SLC2A14, 
further supporting a role for this risk factor as a disease modifying factor 
(Table 1) [199].
Polyglutamine disease models
In addition to models for PD and AD, there are several other models for 
aggregation-prone proteins, which include those for human polyglutamine 
diseases such as Huntington’s disease. In polyglutamine diseases trinucleotide 
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repeats cause expanded tracts of the amino acid glutamine in the encoded 
protein. In one C. elegans model, the animals express expanded glutamine 
repeats fused to a fluorescent protein in the body wall muscle. Expression of 
35 to 40 glutamines is sufficient to cause aggregation, which increases with 
aging and is correlated with toxicity [200]. This model has been used in at 
least two genome-wide RNAi screens performed to search for suppressors 
and enhancers of proteotoxicity [201, 202]. These screens identified genes 
involved in RNA metabolism, as well as in protein synthesis, folding, trafficking 
and degradation as polyglutamine modifiers. In a subsequent screen to look 
for more modifiers, it was found that polyglutamine aggregation is not always 
coupled with proteotoxicity [201].
In an EMS screen to find genes that drive aggregation, Van Ham et al identified 
MOAG-4 (modifier of aggregation) as an aggregation-promoting factor in 
disease models expressing polyglutamine, alpha-synuclein and amyloid-beta, 
establishing MOAG-4 as a general regulator of proteotoxicity (Table 1) [203]. 
MOAG-4 is thought to be active during the early steps of the aggregation 
process, where it drives the formation of compact aggregation intermediates 
[203].  MOAG-4 is functionally conserved in two human orthologues, SERF1A 
and SERF2, which have the same aggregation-promoting function in human 
cell-based models of polyglutamine diseases (Table 1) [203]. Recent insights 
into the function of one of these proteins, SERF1A, suggest that it acts as an 
amyloid-promoting factor [204]. In this study, SERF1A recognized a broad 
range of aggregation-prone proteins (alpha-synuclein, huntingtin, amyloid-
beta, prion protein) and mediated their conversion into amyloid in vitro [204]. It 
was further demonstrated that, to do this, SERF1A interacted directly with the 
monomeric form of the protein to seed amyloid growth, therefore supporting 
the hypothesis that MOAG-4/SERF1A acts on the early intermediates of 
the amyloid pathway [204]. SERF1A did not promote aggregation of non-
amyloidogenic proteins.
An RNAi screen performed by Lejeune et al identified 662 modifiers that 
regulate polyglutamine-induced proteotoxicity in C. elegans touch receptor 
neurons, 49 of which were found to be differentially expressed in two mouse 
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models of HD (Table 1) [205]. 
Another protein originally identified as a suppressor of polyglutamine 
aggregation in a C. elegans model is the chaperonin CCT [202]. It is composed 
of eight subunits and, together with HSP70, is involved in de novo folding of 
newly synthesized proteins [12]. Its orthologue, TRiC (also known as TCP), was 
shown to cooperate with HSP70 to prevent proteotoxicity by promoting the 
formation of non-toxic, soluble polyglutamine oligomers in a yeast model 
[206]. TRiC also modulated proteotoxicity in mouse and human cell models 
(Table 1) [207]. The subunit CCT1 was also shown to physically interact with 
polyglutamine to suppress aggregation in vitro, supporting the hypothesis 
that TRiC binds to polyglutamine to prevent it from acquiring a potentially 
toxic conformation [207].
Finally, a modifier identified in yeast is the kynurenine 3-monooxygenase BNA4, 
whose deletion prevented proteotoxicity induced by mutant huntingtin [208]. 
Follow-up work showed that genetic ablation or pharmacological inhibition 
of the orthologue KMO prevented toxicity in a fly and mouse model for HD 
(Table 1) [209, 210].
In summary, small model organisms including yeast, flies and nematodes 
are powerful tools for identifying genes involved in protein aggregation and 
toxicity. Several examples where small animal organisms complement findings 
from human cell models or mouse models further validate the importance of 
using these small animal models. 
Non-coding RNA in neurodegeneration
When the Human Genome Project started in 1990, it was estimated that 30,000 
to 40,000 protein coding genes would be found in the human genome [211]. 
When the project was completed in 2001, researchers were surprised to find far 
fewer protein coding genes than expected, namely 21,000, representing only 
about 2% of the total genome – with the remaining 98% being considered 
as “junk DNA” [212, 213]. However, it soon became clear that this “junk DNA” 
actually contained regulatory elements such as non-coding RNA (ncRNA), 
transcription factor binding sites or certain chromatin structures that govern 
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gene expression. These conserved functional elements in the human genome 
were subsequently comprehensively identified and characterized [214]. Within 
these conserved functional elements, many classes of ncRNA were identified 
and the list has been growing ever since ([215, 216], also reviewed in [217]). 
Indeed, the number of ncRNA transcripts are far greater than those coding for 
proteins and the list of all existing ncRNAs is not yet complete [218]. What we 
do know is that there are different classes of ncRNA with essential functions 
in gene transcription, RNA processing and translation, a selection of which 
is presented in Table 2 (a more complete list can be found in [217]). Indeed, 
impaired RNA metabolism has been correlated with several neurodegenerative 
diseases. For example, abnormal expansion repeats in the non-coding regions 
of disease-related genes induce toxic RNA gain-of-function in myotonic 
dystrophy, amyotrophic lateral sclerosis and frontotemporal dementia [219, 
220]. For the purpose of this review, we focus on a few examples of ncRNAs that 
have been directly implicated in neurological or neurodegenerative diseases 
(Table 2).
microRNAs
Over the past few years, it has become evident that ncRNAs are key players 
in the development and maintenance of the nervous system. Of all classes of 
ncRNAs identified so far, microRNAs (miRNAs) are those that have been most 
extensively studied and documented. The function of miRNAs is to bind to the 
3’-untranslated region (3’ UTR) of messenger RNA and inhibit its translation or 
target it for degradation (Table 2) [221]. In situ hybridization studies in mouse 
and zebrafish have revealed miRNA to be expressed throughout the brain; these 
studies have also demonstrated that miRNA expression is spatiotemporally 
controlled, supporting a biological function for miRNAs in the central nervous 
system [222-224]. Indeed, several hundreds of miRNAs are involved in brain 
development [225–229]. miRNAs play a role in virtually every aspect of brain 
function including neurogenesis, neural differentiation and maintenance, and 
synaptic plasticity, all of which are described extensively elsewhere [230–232].
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miRNAs have also been associated 
with various aspects of aging 
and neurodegenerative diseases 
(Table 2) [233– 237]. For example, 
Northern blotting experiments in 
the hippocampi of fetuses, adults 
and AD patients have shown that 
miRNA expression changes during 
development and during aging [237]. 
In these experiments, miR-9 and 
miR- 128 were upregulated in the AD 
hippocampus relative to age-matched 
controls, hinting that these miRNAs 
may be regulating the expression of 
genes required for pathogenesis. 
At least two other human studies 
have shown an association between 
miRNAs and the beta-site APP cleaving 
enzyme 1 (BACE-1), which is responsible 
for cleaving APP into the amyloid-beta 
1-42 toxic species [235, 236]. In these 
studies, the expression of miR-107, 
miR-29a and miR-29b-1 was decreased 
in the AD brain while expression of 
BACE-1 was increased (Fig. 4a) [235, 
236]. Since these miRNAs target the 30 
UTR of BACE-1, it follows that miRNAs 
can reduce BACE-1 mRNA levels and, 
therefore, amyloid-beta 1-42 generation 
in the brain, an effect that is lost in the 
diseased brain due to the reduced 
expression of these miRNAs (Fig. 4a) 
[235, 236]. In a mouse model for AD, 
miR-34a is thought to 
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inhibit bcl-2, an anti-apoptotic gene that prevents cell death 
provoked by amyloidogenic species (Fig. 4b) [234]. Additionally, 
miR-124 has been found to regulate APP alternative splicing in neurons [233].
In PD, downregulation of the miR-34b/c cluster is correlated with downregulation 
of DJ-1 and Parkin, two genes implicated in the pathogenesis of PD, although a 
causal link has yet to be determined [238]. It has recently been shown in a cell 
model that this same cluster directly represses alpha-synuclein mRNA levels 
and consequently aggregate formation, establishing that miRNAs can have a 
direct effect on the expression of an aggregation-prone protein [239].
Several miRNAs have also been found to be dysregulated in polyglutamine 
diseases (Table 2) [240–244]. In HD, REST is a transcription factor that negatively 
regulates neuronal gene expression and has been found to repress brain-
specific miRNAs in mouse and human brains [241, 242]. Two of these miRNAs, 
miR-9 and miR-9*, have been identified as targeting the REST complex in a 
negative feedback loop [244]. In a cell model of spinocerebellar ataxia type 1, 
miR-19, miR-101 and miR-130 cooperatively regulate ataxin-1 expression levels 
by binding to its 30 UTR [243]. Inhibition of these miRNAs leads to ataxin-1 
accumulation in cells and subsequent cell death [243].
tRNAs
Transfer RNAs are essential for mRNA translation into a protein, as they are 
responsible for transporting the cognate amino acid to the nascent polypeptide 
chain (Table 2) [245, 246]. Due to the degeneracy of the genetic code, there can 
be up to five tRNAs per amino acid—termed isoacceptors—that have distinct 
anticodons for recognizing the same amino acid [245, 246]. On the other hand, 
tRNAs that share the same anticodon but have distinct body sequences are 
termed isodecoders, and their number vary greatly [246].
Growing evidence suggests that mutations in individual tRNAs—or in 
the enzymes involved in their biosynthesis— are a contributing factor in 
neurodegeneration (Fig. 3) [247–252]. For example, a point mutation (4274T>C) 
in the mitochondrial tRNA for isoleucine was identified in a patient suffering 
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from motor neuron disease, although the mechanism by which this mutation 
might lead to disease is unknown (Fig. 3a) [252]. In a recent study, loss of 
function of one of the brain-specific tRNA isodecoders for arginine was found 
to be correlated with neurodegeneration in mice (Fig. 3a) [247]. Specifically, a 
point mutation (50C>T) in the T loop of the arginine tRNA provoked ribosome 
stal- ling, which is normally offset by GTPBP2. However, simultaneous 
impairment of GTPBP2 in these mice disabled its function as a so-called rescue 
factor, subsequently resulting in neurodegeneration [247]. 
Other impairments in the tRNAs biosynthesis pathway are seen in pontocerebellar 
hypoplasia (PHC). PHC is an autosomal recessive neurodegenerative disorder 
that has six subtypes (PHC1-6) and is generally characterized by hypoplasia 
and atrophy of the cerebellum and pons [253]. PHC2 and PHC4 arise from 
impaired tRNA splicing endonuclease (TSEN) activity. TSEN is composed of 
two catalytic subunits (TSEN 2 and TSEN34) and two non-catalytic subunits 
(TSEN54 and TSEN15) (Fig. 3c) [250, 254]. It is thought that mutations in both 
Figure 3. Mutations in the tRNA biosynthesis pathway that lead to neurodegeneration. The point mutation 
(50C>T) in the T loop of one tRNA isoacceptor for arginine (Arg) provokes neurodegeneration. Another 
described point mutation (4274T>C) in the mitochondrial tRNA for isoleucine (Ile) has also been associated 
with motor neuron disease (a). Following transcription, the 50 leader sequence of the pre-tRNA is removed 
by RNAseP, the 30 end is processed by RNAse Z and the trinucleotide CCA is added to the 30 end by a 
nucleotidyl transferase (b). Different bases of the RNA transcript can undergo chemical modifications (c). The 
introns of the pre-tRNA are spliced out by a tRNA splicing endonuclease (TSEN). Mutations in these enzymes 
have been associated with pontocerebellar hypoplasia (PHC) and mutations in their co-factor CLP-1 with 
motor neuron loss (d). Finally, the mature tRNA is loaded with an amino acid (aa) via tRNA synthetases (e).
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catalytic subunits and in TSEN54 may prevent proper complex formation, 
leading to misplicing of premature tRNAs (pre-tRNAs) into their mature form, 
thereby unbalancing the tRNA repertoire for protein synthesis [248, 250]. PHC6 
results from a mutation in the intronic region of the mitochondrial pre-tRNA 
synthetase gene for arginine [251]. 
Finally, CLP-1 is a mammalian kinase that cooperates with the TSEN complex 
to remove the intronic loop of pre-tRNAs (Fig. 3c) [255]. Loss of CLP-1 results 
in severe impairment of spinal motor neurons in mice, ultimately leading 
to respiratory failure [255]. CLP-1 mutations inaffected patients have been 
correlated with neurodevelopment and neurological symptoms in both the 
central and peripheral nervous system [256, 257].
In summary, these studies demonstrate a crucial role for tRNAs in neuronal 
function, as either mutations in their transcript or defective post-transcriptional 
modifications can affect their proper processing and function, ultimately 
leading to neurodegeneration.
Other ncRNAs
The other non-coding RNAs shown in Table 2 have been less well studied 
but are nevertheless worthy of mention. Long non-coding RNAs (lncRNAs) 
are more than 200 nucleotides long and are mostly expressed in the 
nervous system (Table 2) ([223], also reviewed in [258]). Three lncRNAs 
have been suggested to be involved in neurodegenerative diseases. 
Firstly, BACE-1 anti-sense transcript is an lncRNA that competes with 
miR-485-5p for binding to the BACE-1 mRNA to stabilize it (Fig. 4c) [259]. In 
AD, the levels of BACE-1 anti-sense transcript are elevated, thereby stabilizing 
BACE-1 mRNA and enhancing its expression, which further promotes the 
generation of toxic amyloid-beta 1–42 (Fig. 4c) [259]. Secondly, in spinocerebellar 
ataxia type 7 (SCA7), lncSCA-7 crosstalks with miR-124 to regulate transcript 
levels of atxn7 [260]. Thirdly, Abhd11os is an lncRNA that has been shown to 
be neuroprotective against mutant huntingtin in two mouse models for HD, 
although the exact mechanism of how this occurs remains to be determined 
[261]. 
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Small nuclear RNAs (snRNAs) exist as small nuclear ribonucleoproteins (snRNPs) 
and are major components of the pre-mRNA splicing machinery (Table 2) 
[262, 263]. The survival motor neuron protein (SMN) is directly involved in the 
generation of snRNPs [264]. In a mouse model of spinal muscular atrophy, 
SMN deficiency affects the snRNA pool in a tissue-specific manner, ultimately 
leading to pre-mRNA splicing defects in a diverse range of genes [264]. Further 
evidence for the involvement of snRNAs in neurodegeneration comes from 
work by Jia et al., who revealed that a mutation in a U2 snRNA gene impairs 
alternative splicing of pre-mRNA which is directly responsible for neuron loss 
in the cerebellum and hippocampus of mice [265].
Figure 4. Impaired BACE-1 regulation contributes to AD. miR-107, miR-29a and miR29-b-1 were 
shown to be decreased in the brain of AD patients while BACE-1 mRNA and protein levels were 
elevated (a). In an AD mouse model, elevated levels of miR-34a negatively correlate with BCL-
2 protein levels, which normally prevent apoptosis induced by amyloid-beta (b). BACE-1 anti-
sense transcript was reported to be upregulated in the brain of AD patients. BACE-1 anti-sense 
transcript stabilizes BACE-1 mRNA thereby facilitating its expression, which ultimately results in 
the generation of more amyloid-beta (c).
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Neurodegeneration is clearly not exclusively caused by imbalances in protein 
coding genes—it can also arise from dysregulation of ncRNAs. Over the 
past two decades, we have begun to understand that ncRNAs are not just 
‘‘transcriptional noise’’ and have started to define their role in the CNS and 
in neurodegeneration. Several reports have shown that different classes of 
ncRNAs influence the expression levels of the disease protein and that each 
class of ncRNA does so either by affecting the protein post- transcriptionally or 
through crosstalk with other classes of ncRNAs (miRNAs, lncRNAs). Maintaining 
a proper environment for protein synthesis is crucial to ensure that each mRNA 
molecule is effectively spliced and translated into a protein (through tRNAs 
and snRNAs). To establish the causal relationships between changes in ncRNAs 
and disease phenotypes, the targets of these ncRNAs need to be uncovered. 
Understanding the role of ncRNAs will provide insight into the mechanisms 
of neurodegenerative diseases, which enables the identification of targets for 
therapeutic interventions. 
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Abstract
Caenorhabditis elegans comprises unique features that make it an attractive 
model organism in diverse fields of biology. Genetic screens are powerful 
to identify genes and C. elegans can be customized to forward or reverse 
genetic screens and to establish gene function. These genetic screens can 
be applied to “humanized” models of C. elegans for neurodegenerative 
diseases, enabling for example the identification of genes involved in protein 
aggregation, one of the hallmarks of these diseases. In this review, we will 
describe the genetic screens employed in C. elegans and how these can be 
used to understand molecular processes involved in neurodegenerative 
and other human diseases. 
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Box 1:
Advantages of using Caenorhabditis elegans as a model organism
1. small size (1-1.5 mm long) 
2. short reproductive cycle 
3. short lifespan 
4. translucent body 
5. precise, predetermined anatomy 
6. ease of culture 
7. small genome 
8. whole genome sequenced 
9. RNAi library available 
10.deletion mutant database 
1. Introduction
1.1 Caenorhabditis elegans as a model organism
Sydney Brenner first introduced the nematode C. elegans as a genetic model 
organism in 1965 and since then the model has been extensively used in very 
diverse fields of research, from developmental biology to ecotoxicology, aging 
and neuroscience [1]. This has resulted in several breakthroughs in biomedical 
science, which include the discovery of genetic regulators of programmed 
cell death, the use of the green fluorescent protein as a protein marker, and 
the discovery of RNA interference. Indeed, this nematode combines a number 
of characteristics that make it an advantageous model, anatomically and 
genetically, which are summarized in Box 1. Moreover, the characteristics of this 
invertebrate make it an easy experimental model to study biological processes 
in a relatively cheap, quick, and easy way.
C. elegans is a small, free-living nematode of about 1–1.5 mm in length that 
can be found in temperate soil environments feeding on different bacteria, 
including Escherichia coli. It exists in two sexual forms, as a hermaphrodite or 
as a male. The former is self-fertile, able to produce its own sperm and eggs 
and is the predominant adult form. Although males are rare (about 0.02%), 
their abundance in the offspring can be increased to 50% by mating with 
Box 1
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hermaphrodites [2]. The length of the life cycle of wild type N2 C. elegans 
strains and its lifespan depends on the growth temperature. Grown at 20°C, 
hermaphrodites usually lay 300–350 eggs and once the eggs hatch, it takes 
about three days to develop from a larva to an adult. The average lifespan of 
this organism can vary between 18 and 20 days [3,4]. At higher temperatures, 
the life cycle is shortened and the lifespan decreased. One major advantage 
of C. elegans is that it has a well-dissected and predetermined anatomy. The 
adult hermaphrodite has exactly 959 somatic cells and 302 neurons [1,5,6]. 
Its transparent body enables one to easily follow cell fate or expression of 
fluorescently tagged proteins of interest in the living animal. Moreover, 
C. elegans was the first multicellular organism to have the complete genome 
sequenced and this gave rise to several databases and resources that are 
currently available online for the scientific community ([7], see “Online links” at 
the end of this article).
Genetic screens are widely used in C. elegans to discover gene function. It 
can be easily applied to discover which gene mutations are responsible for 
a specific phenotype of interest (forward genetics) or, conversely, the gene 
function can be purposely altered to assess what is the consequence in terms 
of development, behavior or alterations in specific biological processes (reverse 
genetics). The two major genetic screens employed are ethyl methane sulfate 
(EMS) screens and (genome-wide) RNAi screens. They have been fundamental 
not only to dissect nematode genetics but also to identify genes involved in 
aging, development, DNA damage response, and signal transduction, amongst 
other biological processes [8–13].
1.2 C. elegans homology to humans
For the scope of this review, we shall explore the rationale and the basic 
procedures for both methods not only highlighting their advantages but also 
pinpointing the drawbacks. Next, we will explore how genetic screens can help 
us gain insight into the molecular and cellular mechanisms of human diseases. 
Specifically, we will focus on the application of genetic screens to discover 
potential disease-modifier genes by exemplifying studies on C. elegans models 
for neurodegenerative diseases.
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There are a significant number of proteins that are evolutionary conserved 
between C. elegans and humans. At the time that the C. elegans genome 
sequencing was complete, 36% of C. elegans proteins (from a set composed 
of 18,891 protein sequences) were found to have homologs in humans (set 
composed of 4979 protein sequences), by pairwise comparison (The C. elegans 
Sequencing Consortium, 1998 [7]). Thereafter, this percentage was increased 
to 83% due to the much larger human gene dataset available to perform 
the comparison [14]. A more recent study estimated that 38% of the 20,250 
C. elegans protein-coding genes had unique corresponding functional orthologs 
in humans (7663 unique hits) [15]. In a nutshell, biological processes unraveled 
in the invertebrate C. elegans can provide insight into human biology. 
2. Genetic screens
Genetic screens in C. elegans are well-established and commonly used to 
assess gene function in any biological process of interest. High-throughput 
(semi-) automatized setups and screening methods enable hundreds of 
parallel experiments in microtiter plates. In a screen, wild type animals are 
mutagenized or treated with RNAi and then scored for phenotypical changes. 
Below we describe two types of genetic screens that are most frequently used: 
EMS mutagenesis and RNA interference (RNAi). The characteristics of both type 
of screens are summarized in Table 1. 
Table 1. Features of EMS mutagenesis versus RNA interference.
EMS mutagenesis RNA interference
Inactivation or alteration of gene function Reduction or depletion of gene function
Requires identification of gene mutation Candidate gene is known
Permanent mutation 
Possible to select developmental stage for depletion
No effects on embryos in the first generation 
Can select for non-essential genes
Can identify roles of essential genes in a post-
developmental process
Limited penetrance to neurons 
Limited efficiency if the protein that is encoded by 
the targeted gene is very stable 
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2.1 EMS mutagenesis
The most commonly used method to mutate the genome of C. elegans is the 
treatment with EMS. The mutagen induces mutations in the sperm and oocytes 
of hermaphrodites. Sydney Brenner tested systematically different mutagens, 
but researchers are mostly using EMS because of its relatively low toxicity 
and relatively good efficiency (summarized in [16]). The hermaphroditism of 
C. elegans allows easy maintenance of a mutation, as a homozygous worm will 
pass it to all the progeny through self-fertilization.
Mutations can be identified using a simple F2 screen firstly described by 
Brenner in 1974 [1]. Thousands of copies of any particular gene can be analyzed 
in a typical EMS screen. The frequency of a null mutation at any particular locus 
of the genome is one for every 2000 copies by using standard concentrations 
(50 mM) of the mutagen. That means that one can expect to identify 6 mutations 
per particular gene in a typical experiment of 12,000 haploid genomes 
(reviewed in [16]). The mutagenized worms are placed on Petri dishes and 
grown for two generations to produce homozygous mutants (Fig. 1). Worms 
from the F2 generation showing a specific phenotype of interest are further 
singled to new plates to determine whether the phenotype is transmitted to 
the next generation.
Once a worm with a specific phenotype is isolated, the responsible mutation 
needs to be identified. By using single nucleotide polymorphisms (SNPs) of the 
Hawaiian wild type strain in comparison to the Bristol strain (natural variation 
wild type) it is possible to map a mutation first to a certain chromosome [17] 
and then in several steps to a specific region on that chromosome. When a 
mutation is mapped to a gene region, sequencing or the specific knockdown 
of every single gene in that area by RNAi can be used to identify the mutated 
gene. The development of new sequencing methods like deep sequencing in 
the last decade facilitates the identification of mutations and can save laborious 
fine mapping [18–20]. It is important to keep in mind that an isolated, mutated 
animal can have several mutations at different loci. For further interpretation, 
it is therefore necessary to backcross the animals several times with wild type 
strains. The importance for controlling the genetic background was shown by 
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Burnett and colleagues. They demonstrated that a described lifespan extension 
[21] by overexpression of SIR-2 disappeared after several backcrossings 
[22]. Tissenbaum and Guarente further showed that the overexpression of 
SIR-2.1 slightly increases lifespan but to a much lesser extent than the transgenic 
animals used in their first publication [23]. Deep sequencing methods can be 
Figure 1: High-throughput mutagenesis screen in C. elegans: Animals (P0) are treated 
with a mutagen (e.g. EMS) to produce progeny (F1) containing mutations in alleles of 
different genes. These animals get progeny (F2) of different genotypes by self-
fertilization which are further scored for a specific phenotype. Positive evaluated animals 
are singled to validate a homozygous mutation by breeding through of the phenotype to 
the next generation (F3). Once a mutant is isolated, the mutation site needs to be mapped 
to a specific genomic site to continue with functional studies. (adapted from Jorgensen 
and Mango, 2002) 
Figure 1. High-throughput mutagenesis screen in C. elegans: Animals (P0) are treated with a mutagen (e.g. 
EMS) to produce progeny (F1) containing mutations in alleles of different genes. These animals get progeny 
(F2) of diff rent geno ypes by self-fertilization whi h are further scored for a specific phenotyp . Positive 
evaluated animals are sin led to validate a homozygous mutati  by breeding through of the phenotype 
to the next generation (F3). Once a mutant is isolated, the mutation site needs to be mapped to a specific 
genomic site to continue with functional studies (adapted from [16]).
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used to monitor mutations in the background. Preferentially, one should use 
independent mutant or deletion alleles of a gene to confirm results.
In the first EMS screens, 619 mutants were identified with visible phenotypes 
especially from the uncoordinated class [1]. This group of genes impairs wild type 
movements when mutated. Under laboratory conditions proper moving is not 
essential as food is plentiful and sex is dispensable so therefore maintenance and 
characterization of mutants that may not survive in non-laboratory conditions 
are possible. Many of these mutants have revealed important information 
about molecules and mechanisms involved in human disease. For example, one 
gene of the uncoordinated class is unc-2 (uncoordinated 2) and encodes for a 
homolog of the voltage-sensitive calcium-channel alpha-1 subunit (human P/Q 
calcium channel CACNA1A) [24]. Missense mutations in the CACNA1A calcium 
channel in humans are associated with a rare form of migraine [25], which is 
often associated with low levels of serotonin [26]. unc-2 mutants show neuronal 
migration defects similar to serotonin-deficient mutants [27] and UNC-2 is 
required for the desensitization to the two neurotransmitters dopamine and 
serotonin [28]. Studies using C. elegans showed that UNC-2 interacts with the 
transforming growth factor (TGF)-β, a pathway that is required for movements 
through regulation of serotonin levels probably through the modulation of 
the expression of tph-1 (tryptophan hydroxylase), the enzyme that converts 
tryptophan into serotonin [29]. There are elevated levels of TGF-β1 in migraine 
patients compared to those of pain-free individuals [30]. 
In addition to mutations in the uncoordinated class, Brenner also identified 
mutants with aberrant appearance like animals with small bodies, blistered 
cuticles, twitching muscles, rolling locomotion, long bodies, dumpy bodies, 
forked heads or bent heads [1].
EMS screens are often used to identify different mutations with the same 
phenotype to further investigate if those genes function in the same processes. 
Using this approach, John Sulston and H. Robert Horvitz searched e.g. for 
mutants that show defects in the differentiation of a vulva from epidermal cells 
[31]. Molecular follow-up studies revealed that animals that lack a vulva had 
Genetic screens in Caenorhabditis elegans models  for neurodegenerative diseases
63
mutations in two signaling pathways: the epidermal growth factor (EGF)/RAS 
pathway and the Notch signaling pathway (reviewed in [32–34]), both having 
major roles in cell fate determination. These studies in C. elegans have increased 
the understanding of these molecular pathways involved in oncogenesis in 
humans (reviewed in [35,36]).
Another possibility to find genes of the same genetic pathways are enhancer 
or suppressor screens. In this case the mutagenesis occurs on a non-wild type 
strain whose genetic composition is known and causes a defined phenotype. 
Like this, one can screen for mutations in this genetic background that enhance 
or suppress (reverse) that phenotype. With this approach one is able to show 
that two genes not only act in the same pathway but also their hierarchy 
which means that one is acting upstream of the other (summarized in [16]). 
However, one should still keep in mind that it might also be possible that some 
proteins result in the same phenotype when mutated even though they do not 
necessarily function in the same pathway.
Although EMS mutagenesis is a powerful tool to generate a high number of 
mutations and high-throughput screens to identify mutants with a specific 
phenotype it also has some limitations. It has been estimated that about 30% 
of the genes in C. elegans can be mutated to a visible phenotype [37] (some 
mutations might result e.g. in a lethal phenotype as it is the case for a number of 
developmental genes) and it needs to be mentioned that the identification of 
the same mutations which indicates a saturation of the screen is no guarantee 
that some other genes might be missed in this screen. High-throughput screens 
are only a starting point for further detailed experiments at molecular levels.
2.2. RNA interference
RNA interference was first discovered and investigated in C. elegans and 
published in 1998 by Andrew Fire et al. [38] (Nobel Prize in Physiology and 
Medicine in 2006). The discovery of dsRNA-mediated gene silencing has 
revolutionized genetic studies in C. elegans, as well as in other model organisms. 
Similar to EMS screens, RNAi screens can be used to identify genes that, when 
depleted, result in a certain phenotype or enhance or suppress a mutant 
phenotype.
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RNAi in C. elegans is systemic, which, to date, is not the case for any other animal 
models. Therefore it is sufficient to introduce dsRNA into one specific tissue 
to get RNA silencing also in distant cells because of an amplification process 
called transitive RNAi [39]. This systemic effect is advantageous for large-scale 
genome-wide RNAi screens in C. elegans.
There are different methods that describe how to silence gene expression 
in C. elegans. The dsRNA can be delivered into the worm by (1) injection into 
any region [38], (2) feeding with dsRNA-producing bacteria [40], (3) soaking in 
dsRNA [41] or (4) in vivo production of dsRNA from transgenes under the control 
of specific promotors [42]. Cell-specific factors seem to regulate thereby the 
entry and export of dsRNA [39,43,44]. Some cell types (e.g. neurons) seem not 
to respond well to systemically delivered RNAi [42]. The use of RNAi enhanced 
mutants (e.g. eri-1 mutant or mutants of the retinoblastoma pathway that are 
described to enhance RNAi especially in nervous tissue) might circumvent 
this problem [45,46]. In addition, Calixto and colleagues generated transgenic 
animals overexpressing the transmembrane protein SID-1 which is an essential 
component for systemic RNAi in the neurons. This modification increased the 
response to dsRNA delivered by feeding. It seemed that the expression of 
SID-1 in the neurons, on the other hand, decreased the RNAi effect on non-
neuronal cells which might be useful for studying the function of essential 
genes in the neurons. This effect could be even increased when using a 
sid-1 mutant background [47]. Durieux and colleagues further used this mutant 
that is insensitive for systemic RNAi to investigate the knockdown of one of the 
cytochrome c oxidase-1 subunits in specific tissues by controlling the expression 
of dsRNA via tissue-specific promotors [48]. The tissue-specific expression 
of SID-1 (not only in neurons) in a sid-1 knockout background probably also 
enables to study tissue-specific effects especially of essential genes. 
Especially the possibility to feed animals with dsRNA-producing bacteria 
enables to perform high-throughput RNAi screens in C. elegans (Fig. 2) [49,50]. 
For efficient induction of RNA interference the choice of the dsRNA-coding 
region is essential. In C. elegans, long dsRNA fragments (more than 100 bp) 
trigger gene silencing via RNAi. For most genes dsRNA is about 200–1000 
nucleotides or even longer and covers exon-regions of the targeted gene. The 
Genetic screens in Caenorhabditis elegans models  for neurodegenerative diseases
65
fragment should only target one gene. Once the coding region is chosen it can 
be cloned into a specific vector encoding the production of the specific dsRNA 
(summarized in [51]). The L4440 vector contains two bacteriophage T7 RNA 
polymerase promotors flanking the multiple cloning site in which the cDNA of 
a specific gene has been inserted. The construct can be transformed into E. coli 
strain HT115 (ED3). This strain is deficient for the bacterial RNA polymerase III 
and its production of bacteriophage T7 polymerase from the construct can be 
induced by the addition of isopropyl β-D-1- thiogalactopyranoside (IPTG). The 
bacteria are then synthesizing two complementary RNA strands that form a 
duplex RNA which can mediate RNAi [38].
RNAi libraries are commercially available which includes one library of bacteria 
clones containing cDNAs of 17,575 genes which represents about 87% of the 
C. elegans genome [49] and one library including clones of 11,800 C. elegans 
genes [52]. Positive scored clones subsequently can be sequenced to confirm 
that they target the predicted gene. To prevent any further off-target effects of 
the dsRNA and therefore false-positive results, one should consider generating 
a second RNAi construct targeting the mRNA of the same gene [52]. Besides the 
coding regions, the 3’UTR of mRNA might as well be a suitable target as RNA 
localization elements for the transport of the mRNA or regulation elements of 
Figure 2. High-throughput RNAi screen in C. elegans: Age-synchronized animals are transferred to microtiter 
plates containing different clones of HT115 E. coli bacteria. Every clone produces a specific dsRNA which 
is taken up by the nematodes and induces a knockdown of the corresponding gene. Positive hits in the 
phenotypic screen are finally confirmed by sequencing the bacterial clone and repeating the specific 
knockdown in single experiments. Starting point of the RNAi feeding (possible at any developmental stage) 
and time point of the phenotypic scoring depend on the experiment setup
Figure 2: High-throughput RNAi screen in C. elegans: Age- synchronized animals are 
transferred to microtiter plates containing diff rent clo es of HT115 E. coli bacteria. 
Every clone produces a specific dsRNA which is taken up by the nematodes and induces 
a knockdown of the corresponding gene. Positive hits in the phenotypic screen are finally 
confirmed by sequencing the bacterial clone and repeating the specific knockdown in 
single experiments. Starting point of the RNAi feeding (possible at any developmental 
stage) and time point of the phenotypic scoring depend on the experiment setup.  
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eukaryotic gene expression are typically located in this region (summarized in 
[53,54]).
Dissolving adult hemaphrodites with hypochloride (bleach) will yield only 
fertilized eggs and can be used to age-synchronize the animals for a screen. 
Gene knockdown by RNAi can be induced at different developmental stages in 
contrast to EMS mutagenesis, which generates stable mutations that are present 
at all stages. Thus, the examination of the function of a gene that is transcribed 
at different developmental stages is possible. This is especially interesting when 
an active gene is essential at early developmental stages [55]. To investigate the 
effect of gene depletion by RNAi during embryonic development it is necessary 
to feed the parental worm with the specific bacterial strain.
Another possibility to study the effect of gene depletion at a certain 
timepoint was previously described by Calixto and colleagues, by performing 
a temperature-sensitive conditional knockdown. They could induce the 
knockdown of a gene by controlling via temperature the expression of 
RDE-1, a C. elegans argonaut protein which is required for RNA interference. 
This resulted in active RNAi at 15°C but not at 25°C. Furthermore, they observed 
that the switching ON and OFF is much faster than transferring animals from 
RNAi-mediating bacteria to non-RNAi inducing bacteria and vice-versa [56].
The dilution of bacteria containing a specific RNAi construct with non-RNAi 
mediating bacteria may decrease the efficiency of knocking down a certain 
gene. In that case of mild RNA interference, lethality effects and other very 
strong phenotypes are reduced and it might still be possible to study the 
function of these special genes.
The target of RNAi is known. This is one major difference to EMS mutagenesis 
that cannot be directed to specific genes. Therefore, besides genome-wide 
RNAi screens, one can also screen in a smaller subset of candidate genes for 
example based on previous microarray data, GWAS data, interactome studies, 
etc. Colaiácovo and colleagues performed for example a RNAi screen to 
check for germline phenotypes in a subset of genes that were generated by 
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a previous microarray analysis of Reinke et al. that was focusing on germline-
enriched gene expression [57,58]. In another screen we were looking for genes 
that, when knocked down, increased the number of alpha-synuclein inclusions 
in a Parkinson’s disease C. elegans model [59]. This group of 80 genes was then 
further used for a second RNAi screen in order to find candidates that, when 
knocked down, induced motility changes in the disease background [60].
RNAi efficiency of bacterial clones in the library can differ. Whereas some 
dsRNAs induce gene silencing closely to a knockout of a gene, others only 
generate a mild knockdown. One should always be aware that RNAi is only 
silencing gene activity and that it is not a full knockout of a gene. It is estimated 
that about 10–30% of candidates are scored as false negatives as the RNAi is 
not efficient enough to result in an obvious phenotype. On the other hand the 
percentage of false positives is relatively low (0.4%) [61]. It is also important to 
keep in mind that RNA interference is acting at the mRNA level and therefore 
only influencing the expression of a protein. That means that the stability of a 
protein is highly influencing the RNAi effect as already generated proteins and 
their activity are not affected anymore.
Results can also differ from one experiment to the other using the same bacteria 
clone to silence a specific gene. For example the freshness of the material 
can be crucial (IPTG, Ampicillin, RNAi construct containing bacteria) [51]. In 
contrast, a knockout mutant e.g. by EMS mutagenesis has the advantage that 
it results in a stable genotype. Results of the RNAi screen should therefore be 
confirmed by single experiments with the candidate genes, preferentially with 
a gene mutant strain.
A clear phenotype for scoring is mandatory for any successful screen. An obvious 
easy-to-recognize phenotype as well as automation of scoring facilitates the 
screening process.
The small size of the animals, the variety of simple phenotypes that are 
often results of one single gene disruption or silencing, the hermaphroditic 
reproduction, the homology to higher organisms (see above) and the 
knowledge of the C. elegans genome, cell-distribution and nematode anatomy 
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make this animal an optimal model organism to identify the function of genes 
via any kind of high-throughput screen. 
3. From genome to function: what have genetic screens 
taught us?
One of the advantages of C. elegans is that it is amenable to generate 
“humanized” models of human diseases. For the purpose of this review, we 
will describe as an example C. elegans models of neurodegenerative diseases. 
Neuropathological hallmarks found in the human brain can be successfully 
recapitulated in the nematode, such as protein aggregation [62]. Indeed, one 
of the common features in neurodegenerative diseases is the presence of 
protein aggregates in the brains of affected patients. These structures originate 
from protein misfolding and aggregation of so-called “aggregation-prone 
proteins”. To name a few, these can be the amyloid-beta in Alzheimer’s disease 
(AD), mutant huntingtin in Huntington’s disease (HD) and alpha-synuclein in 
Parkinson’s disease (PD) [63]. By mechanisms that are still to be unraveled, these 
aggregation-prone proteins adopt a distinct conformation, which is thought be 
a toxic gain-of-function [64,65]. The general understanding is that aggregation 
(or inclusion formation) renders cellular protection by sequestering misfolded 
proteins, therefore preventing potentially toxic protein–protein interactions 
[65,66].
Several nematode models have been generated to recapitulate molecular 
aspects of diseases, including HD, PD, AD and muscular dystrophy [59,67–72]. 
Although they do not feature clinical aspects of the disease, they provide the 
means to understand the molecular mechanisms in these diseases. Genetic 
screens performed in some of these models represent quick, unbiased methods 
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that have enabled insights into the underlying mechanisms of 
neurodegeneration. Indeed, many of the disease modifiers discovered in 
C. elegans were found to be reproducible in human cell-based models and 
other animal models such as mice, strengthening the validity of using this 
small organism to study complex human diseases, as summarized in Table 2 
[69,73–78].
3.1. C. elegans models for polyglutamine diseases
Polyglutamine diseases comprise a subset of neurodegenerative disorders that 
include HD, spinocerebellar ataxias (− 1, − 2, − 6, − 7, −17), Machado–Joseph 
disease (also know as spinocerebellar ataxia 3) and spinobulbar muscular 
atrophy [79]. The common characteristic of polyglutamine diseases is an 
abnormal expansion of CAG triplets (which encode glutamine) in the coding 
region of the disease gene. Although the length of the CAG repeat may vary 
from individual to individual, the threshold to develop disease is around 40 
CAG repeats (except for SCA6), which cause a polyglutamine expansion in the 
protein that is prone to aggregate. The larger the CAG repeat the earlier onset 
will occur and the more severe the disease phenotype will be. A more detailed 
and complete information on polyglutamine diseases is reviewed elsewhere 
[79]. In C. elegans, several different models have successfully recapitulated 
protein aggregation. Similarly to what occurs in humans, the length of the 
CAG repeats also determines the aggregation phenotype in C. elegans. At 
least three models have been generated to induce polyglutamine-associated 
toxicity in neurons by expressing expanded polyglutamine stretches in ASH 
sensory neurons, touch receptor neurons or the entire nervous system of 
C. elegans [68,80–82]. Polyglutamine aggregation has been modeled in the 
body wall muscle cells of C. elegans [68]. In this model, expanded polyglutamine 
stretches are fused to a yellow fluorescent protein (YFP) under the unc-54 
promotor, which is specific to the body wall muscle. The aggregation and 
toxicity phenotype is polyglutamine length-dependent. As the animal ages, 
the accumulation of protein aggregates increases, which is associated with 
toxicity [68]. This model has been widely used for genetic screens to discover 
enhancers and/or suppressors of polyglutamine proteotoxicity. Two genome-
wide RNAi screens revealed modifier genes and classified them according to 
their biological function [83,84]. In the first screen, Q35 animals were fed with 
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dsRNA-producing bacteria and scored for genes that, when downregulated, 
provoked premature polyglutamine aggregation [83]. The major functional 
classes included RNA synthesis and processing, protein synthesis, folding, 
transport and degradation and components of the proteasome. In the second 
screen, the authors sought for genes that drive aggregation in Q35 animal and 
therefore the selection was made for genes that suppressed polyglutamine-
induced aggregation when downregulated [84]. With this study, a new subset 
of modifier genes was recently found to belong to broader biological functions, 
namely cell cycle, cell structure, protein transport and energy and metabolism 
[83,84]. Therefore, proteotoxicity is not derived only from protein-related 
processes but rather a more diverse spectrum of biological functions that also 
have an effect on protein misfolding and aggregation. Interestingly, nine of 
these recently identified modifier genes were able to fold misfolded proteins 
back into the native state when constitutively expressed in misfolding mutants 
[84].
Forward genetics have also been used to identify modifiers of proteotoxicity. 
One such screen consisted in treating Q40-expressing worms with EMS. The 
aim was to find positive regulators of aggregation by selecting genes that 
suppressed protein aggregation when chemically mutated by EMS. The 
screen revealed MOAG-4 (modifier of aggregation) as a general aggregation-
promoting factor in polyglutamine, Parkinson’s and Alzheimer’s disease models 
[76]. Inactivating MOAG-4 alleviated from polyglutamine-induced aggregation 
and toxicity; moreover, this effect was functionally conserved in the human 
orthologs SERF1A and SERF2. A recent follow-up on one of these orthologs 
showed that SERF1A is a specific aggregation-promoting factor, since it was 
able to bind specifically to amyloidogenic proteins, including alpha-synuclein, 
prion protein, amyloid-beta and huntingtin, but not to non-amyloidogenic 
proteins [85]. 
Genetic screens have also been used to find regulators of proteotoxicity using 
the C. elegans neuronal system. An RNAi screen performed in a C. elegans model 
expressing 128 polyQ stretches in the touch receptor neurons resulted in 662 
genes that either enhanced or suppressed neuron toxicity, as measured by loss 
of touch response [77]. Comparison of these disease modifier genes to gene 
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expression data in two mouse models of HD showed that there was an overlap 
of 49 genes that were dysregulated in the striatum of either model, emphasizing 
the power of using C. elegans to find novel regulators of proteotoxicity relevant 
in human diseases. 
3.2. C. elegans models for Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative 
disease (after Alzheimer’s disease) that affects 1% of the population over the 
age of 50. Clinically, it is characterized by resting tremors, rigidity, bradykinesia 
and postural instability [86,87]. The defects in the motor system result from 
the progressive loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc), which project and innervate the neurons in the caudate and 
putamen. Consequently, there is a reduction of dopamine levels, which is the 
neurotransmitter that plays a role in the coordination of body movements. 
Besides motor disabilities, PD patients can experience non-motor symptoms 
such as autonomic dysfunction, sleep disturbances and neuropsychiatric 
symptoms [88]. Most cases of PD are sporadic (about 95%) with unknown 
etiology. It has been suggested that disease can result from the accumulation 
of toxins (pesticides and heavy metals) over the years. Only 5% of PD has a 
familial origin and is associated with genetic mutations [88]. However, there 
are neuropathological hallmarks common to both sporadic and familial forms 
of PD. These are the loss of dopaminergic neurons in the SNpc, that result 
from the degeneration of the nigrostriatal pathway which leads to the motor 
symptoms described earlier as well as the formation of intraneuronal protein 
aggregates known as Lewy bodies and Lewy neurites in the surviving neurons, 
which contain alpha-synuclein. 
 
Alpha-synuclein is a small (140 amino acids) natively soluble, monomeric 
protein that is predominantly expressed in the brain and is enriched in 
presynaptic terminals [89]. Although the precise function of this protein 
remains unclear, it is thought to be involved in the regulation of dopamine 
neurotransmission, vesicular trafficking and modulation of synaptic function 
and plasticity [90–92]. Three different mutations in the alpha-synuclein gene 
(A53T, A30P and E46K) cause autosomal-dominant PD [93–95] and genomic 
duplications and triplications of the gene have also been identified; suggesting 
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that overproduction of wild type alpha-synuclein is sufficient to cause disease 
[96,97].
Genetic screens performed with this model have been supporting an 
important relationship between alpha-synuclein and vesicle transport. The 
“humanized” model of C. elegans for PD expresses the human alpha-synuclein 
fused to YFP in the body wall muscle. Phenotypically, immobile YFP-positive 
foci can be seen in the muscle cells and these foci increase in number and 
correlate with age-dependent toxicity. An unbiased genome-wide RNAi screen 
with this model showed 80 modifier genes that, when suppressed, provoked 
premature alpha-synuclein inclusion formation [59]. A follow-up on those 
modifier genes revealed tdo-2, a gene involved in tryptophan degradation, 
as a general regulator of protein homeostasis during aging [60]. Moreover, 49 
of the original 80 modifier genes had human homologs, which were enriched 
for genes related to vesicular trafficking functions. In another screen using 
a similar model, nematode genes orthologous to human familial PD genes 
were preselected to perform a hypothesis-based RNAi screen [69]. A subset of 
candidate genes from the initial screen was then further analyzed in another 
C. elegans model, expressing alpha-synuclein in the dopamine neurons, in 
order to assess their relevance at the neuronal level. This study revealed five 
candidate genes that were able to protect from alpha-synuclein-induced 
dopaminergic neurodegeneration. Again, the most representative class of 
genes here was associated with vesicular trafficking, with the exception of 
the autophagy-related gene Atgr7, of which the mammalian ortholog (Atg7) 
was previously implicated in neurodegeneration in mice [78]. Also, a serine/
threonine kinase involved in axonal elongation, UNC-51, was found to be 
homologous to the previously associated risk factor ULK-2, as revealed by a 
genome-wide association study performed in PD patients [98]. Parallel to these 
findings, Kuwahara et al. were able to pinpoint two genes, apa-2 and aps-2, 
that when knockdown by RNAi increase alpha-synuclein-induced neurotoxicity 
in a C. elegans model expressing the transgene in the whole nervous system 
[70]. These two genes encode for subunits of the AP-2 adaptor complex, which 
mediates the internalization of cargo into the cell from the extracellular space 
via clathrin-mediated endocytosis [99]. 
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3.3. C. elegans models for Alzheimer’s disease 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, 
which is predicted to affect 66 million people worldwide by 2030 [100]. It 
represents the most common form of dementia, leading to clinical symptoms 
such as memory loss and mood swings. Aging and lifestyle are risk factors for 
development of AD, but 70% of the cases are attributable to genetics [101]. The 
main neuropathological features are the presence of extracellular amyloid-beta 
plaques, which consist of an accumulation of aggregated amyloid-beta, and 
intraneuronal tangles of hyperphosphorylated tau. Mutations in several genes 
can lead to the development of AD, including mutations in genes encoding 
for the amyloid-precursor protein (APP), presenelin 1 (PSEN1) and presenelin 
2 (PSEN2). These genes are part of the APP cleavage pathway and mutations 
in these genes promote the processing of APP towards the amyloidogenic 
pathway, promoting the formation of amyloid-beta. Amyloid-beta peptides can 
have different lengths, including 40 or 42 amino acids. Amyloid-beta 42 is the 
most common species found in the amyloid plaques, indicating its propensity 
to rapidly aggregate in comparison to amyloid-beta 40.
Tau is encoded by the microtubule-associated tau protein (MAPT) gene and 
predominantly expressed in the nervous system. As to its function, it is known 
to associate and stabilize microtubules. It has been already classified as one of 
the risk genes for developing AD by at least two independent studies [102,103].
There are several models in C. elegans that express either human amyloid-beta 
or tau. In the first case, the worms express amyloid-beta 3–42 in the body wall 
muscles which causes the progressive accumulation of amyloid-beta 3–42 
in the muscle cells and paralysis, which worsens with aging [71,104]. There 
have been several variations to this model, either combined with inducible 
systems, driving expression in neurons or, more recently, expressing full-length 
amyloid-beta 1–42 [105–107]. On the other hand, tau-expressing models 
have been specific to neuronal cells and the phenotype is either worsening 
of uncoordinated movement or insensitivity to the touch response due to 
transgene expression [75,108,109].
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Genetic screens in C. elegans models for AD have been scarce. So far, there has 
been no genetic screen performed in any of the models expressing amyloid-
beta. There is only one report on genome-wide RNAi done in a tau-expressing 
model [75]. Sixty modifier genes were discovered to belong to several functional 
classes including, kinases, chaperones, proteases and phosphatases. Of these, 
38 had homologs in humans but, more importantly, 6 had already been 
associated with disease, either in humans or other animal models. One of these 
modifiers was the nicotinic acetylcholine receptor alpha-7 (nAchR), a ligand-
gated ion channel expressed in the human brain and known to contribute to 
tau phosphorylation [110].
4. Final considerations
Genetic screens are powerful means to find genes involved in a certain 
biological process of interest and their function. The fact that C. elegans is a 
tractable system to model human diseases further allows one to perform 
genome-wide screenings in a relatively quick and unbiased manner. Genetic 
screens can have two outcomes, both being equally informative. On the one 
hand, new genes are discovered and therefore novel pathways are implicated, 
giving fresh perspectives on the biological process being studied. On the other 
hand, genetic screens that reveal genes already known to be associated with 
disease strengthen the importance of those genes in pathogenesis. Many 
screens that start with a genome-wide approach end up with an extensive list 
of candidate genes that are classified according to their functional class. From 
here, a selection of these genes should be refined and prioritized in order to 
study further their individual contribution to pathogenesis. One of the critical 
points is considering those that might have significance at the mammalian level. 
Additionally, if the human gene can replace the function of the endogenous 
one, it demonstrates evolutionary conservation of function and enables one 
to extrapolate findings from small organisms to complex human diseases. It is, 
therefore, essential to validate the genes from the screen in higher organisms. 
However, it is also often that a screen might reveal genes that do not have a 
direct sequence homolog in mammals. Nevertheless, they may be indicators of 
other genes that may be functional orthologs or otherwise regulators of genes 
with a role in human disease (e.g. transcription factors).
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Another contribution of genetic screens may be to provide novel targets for 
drug development [111]. Although not all features of a complex human disease 
are fully recapitulated in the nematode, one can argue that its simplicity can be 
advantageous. Especially, because analysis of the expression of the causative 
gene and its interactors or modifiers can be done without other confounding 
factors inherent to the complexity of the human biology.
Genome-wide association studies (GWAS) have gained importance in the 
last ten years, becoming one of the forefront strategies to find common 
genetic factors associated with susceptibility to develop disease. One 
challenge now is to establish the functional consequences of these genetic 
variations. Coupling genetic screens or candidate gene approach in 
C. elegans to find causative genes may represent a quick and inexpensive way 
to assess functional relevance of associated variations and consequently obtain 
concrete targets to act upon. For instance, a genome-wide toxicity screen 
in yeast revealed 6 modifiers of amyloid-beta toxicity that were previously 
identified as risk factors in GWAS [112]. Importantly, those modifiers were 
functionally conserved from yeast, to C. elegans and to rat. Another study by 
Shulman et al. showed, for the first time, a link between an AD risk factor and a 
causative gene by functional screening in the fly [113].
Although this review focused in C. elegans models for neurodegenerative 
diseases, it should be noted that C. elegans is a model organism for other human 
diseases as well. C. elegans has been used to model certain aspects of cancer, 
diabetes, obesity, polycystic kidney disease, muscular dystrophy and innate 
immunity, to name a few. A more complete view of these different disease 
models is summarized elsewhere [111].
All in all, genetic screens in small organisms such as C. elegans can not only 
aid to dissect fundamental biological questions but also have the versatility of 
being adapted to model complex human diseases, such as neurodegenerative 
diseases. Moreover, its attributes make it a tractable system to drug target 
discovery and compound screening, emphasizing the potential of this organism 
to extrapolate findings from small organisms to higher vertebrates.
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Online links
– Textpresso, a full text literature searches of C. elegans  
(http://www. textpresso.org/) 
– Worm Interactome Database  
(http://interactome.dfci.harvard.edu/ C_elegans/index.php) 
– The Caenorhabditis Genetic Center, with an extensive list of strains  
(http://www.cbs.umn.edu/CGC/) 
– Wormbase, a complete database of genetics, genomics and biology of  
C. elegans (www.wormbase.org) 
– Wormbook, a comprehensive, open-access collection of original, peer-
reviewed chapters covering topics related to the biology of C. elegans and 
other nematodes (http://wormbook.org) 
– C. elegans Gene Knockout Consortium, which creates knockout strains
 
(http://celeganskoconsortium.omrf.org/) 
– National Bioresource Project, which generates, collects, stores and 
distributes deletion mutants of C. elegans  
(http://www.shigen.nig. ac.jp/c.elegans/index.jsp) 
– Wormatlas, a database of behavioral and structural anatomy of C. elegans  
(http://www.wormatlas.org) 
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Abstract
Aging-related protein aggregation is one of the hallmarks of neurodegenerative 
disorders such as Alzheimer’s, Parkinson’s and polyglutamine diseases. The 
cellular processes that drive protein aggregation in these diseases have 
remained largely unknown. Using a forward genetic screen in a C. elegans model 
for polyglutamine aggregation, we here identified lin-26-related gene 3 (lir-3) as 
modifier of protein aggregation (moag-2) that promotes protein aggregation. 
A mutation or a deletion in moag-2/lir-3 reduced protein aggregation. 
moag-2/lir-3 encodes a protein of unknown function with a putative 
nuclear localization domain and two domains that are homologous to 
nucleotide-binding C2H2 zinc finger domains. By combining chromatin 
immunoprecipitation sequencing and RNA sequencing, we found that 
MOAG-2/LIR-3 is preferentially associated with promoter regions of RNA 
Polymerase III-regulated non-coding RNAs and regulates their expression in 
wild type N2 nematodes. This regulation is lost in worms that express proteins 
with expanded polyglutamine tracts. These results suggest that, by driving 
polyglutamine aggregation, MOAG-2/LIR-3 can no longer execute its normal 
function thus resulting in a transcriptional change of small non-coding RNAs. 
Together, our results show that aggregation-prone disease proteins can turn 
benign cellular proteins into aggregation-promoting factors, at the expense of 
their biological function. The functional switch can be explored as a therapeutic 
target to interfere with aggregation events in neurodegenerative diseases.
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Introduction
Neurodegenerative diseases like Alzheimer’s, Parkinson’s or polyglutamine 
diseases are a major health concern and demand a better understanding of 
the disease pathogenesis in order to make disease-modifying treatments 
available. One core pathological hallmark of neurodegenerative diseases is 
the presence of protein aggregates in different brain areas of affected patients 
[1]. These insoluble, macromolecular structures are particularly enriched in 
aggregation-prone proteins which, by exposing regions of their amino acid 
sequence, begin to self-associate or aggregate with other proteins of the cell, 
thereby hampering normal cellular function [2-4]. Depending on whether 
these proteins remain soluble and misfolded or acquire amyloidogenic 
properties they will be localized to different cellular compartments where they 
can either be degraded and recycled by the ubiquitin-proteasome machinery 
or form insoluble aggregates [5, 6]. It is not resolved whether these protein 
aggregates are causing disease. The current view is that soluble oligomeric or 
fibrillar precursors to these aggregates are cytotoxic and that aggregation is a 
protective measure to sequester these harmful species [7-10].
The cellular factors that drive protein aggregation are poorly understood. 
Direct aggregation-promoting factors have been identified [11-14]. SH3GL3 (or 
endophilin-3) is a SH3-domain GRB2-like 3 protein that was suggested to interact 
directly with the polyglutamine stretch within exon 1 of the huntingtin gene 
to promote aggregation [14]. This interaction was proposed to be dependent 
on the polyglutamine length of mutant huntingtin or its aggregated form [14, 
15]. MOAG-4/SERF was identified as a direct modifier of polyglutamine, alpha-
synuclein and amyloid-beta-induced aggregation [11, 12]. MOAG-4/SERF is 
a predominantly disordered protein of unknown function that was shown 
to drive aggregation by transient binding to aggregation-prone proteins at 
the early stages of the aggregation pathway [11, 12]. Cell non-autonomous 
regulation of protein aggregation has been described with the example of 
unc-30, a homeodomain transcription factor involved in the synthesis of the 
inhibitory neurotransmitter GABA [16]. Mutation of unc-30 impairs neuronal 
signaling at the neuromuscular junction and enhances protein aggregation in a 
C. elegans model for polyglutamine diseases [16].
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A wide variety of genetic screens have been performed to find genes that 
regulate aggregation and aggregation-associated toxicity in animal models for 
neurodegenerative diseases [12, 17-22]. Here, we describe a forward genetic 
screen where we sought for genes that normally drive protein aggregation in 
a C. elegans model for polyglutamine diseases. We identified moag-2/lir-3 as a 
modifier of aggregation that, when mutated, reduced aggregation up to 51% in 
a polyglutamine model. We demonstrate that MOAG-2/LIR-3 is a transcriptional 
regulator that promotes the transcription of small non-coding RNAs (ncRNA), 
including small nucleolar RNAs (snoRNAs) and transfer RNAs (tRNAs), in wild 
type nematodes. We propose that MOAG-2/LIR-3 shifts its role in the presence 
of polyglutamine from a transcriptional regulator of ncRNAs to an aggregation-
promoting factor.
Results
Inactivation of MOAG-2/LIR-3 reduces polyglutamine aggregation
To identify genes that drive protein aggregation, we performed a forward 
genetic screen in a C. elegans model that expresses an aggregation-prone 
polyglutamine stretch of 40 residues fused to YFP (Q40-YFP) in the body-
wall muscle cells [12]. We screened for mutants that reduced polyglutamine 
aggregation, which we named modifiers of aggregation (moag) ([12] 
and unpublished data). moag-2(pk2183) (hereafter designated simply as 
“lir-3(pk2183)”) presented a 51% reduction in the number of aggregates relative 
to the wild type Q40 animals in their fourth larval stage (Figure 1A, B). SNP-
mapping and genome sequencing allowed us to fine-map the causal mutation 
and revealed six genes as putative candidates for moag-2 (Figure S1B). For one 
of these, which mapped to lir-3 (lin-26 related; sequence: F37H8.1; accession 
number: NC_003280), the causative mutation was in the start codon, replacing 
the first methionine with an isoleucine (Met1Ile) (Figure 1C, S1B). lir-3 encodes 
a LIN-26-like zinc finger protein of unknown function (http://wormbase.org, 
March 2014). It is predicted to have two zinc finger domains of the C2H2 
type (residues 191-214 and 224-247) at the carboxyl terminus (Figure S1C) 
and a nuclear localization signal spanning amino acid residues 132 to 141 
(http://nls-mapper.iab.keio.ac.jp/, March 2014). LIR-3 shares two non-canonical 
C2H2 zinc finger motifs with LIN-26 (31 to 35% identical), LIR-1 (20 to 31% 
identical) and LIR-2 (25% identical) [23].
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To assess whether moag-2 was lir-3, we generated a lir-3(tm813) deletion 
mutant (hereafter designated simply as “lir-3(tm813)”) and crossed it with the 
polyglutamine animals. This strain has a 795 bp deletion that spans residues 
276 to 1070 of the F37H8.1 sequence that causes a premature stop codon 
(Figure 1C, S1C). The partial deletion of lir-3 caused a 35% reduction of 
aggregates relative to the wild type animals (Figure 1D). Animals heterozygous 
for the lir-3 deletion allele exhibited a similar number of aggregates as wild 
type, supporting that the reduction of aggregation was recessive and due to 
the loss of function of lir-3 (Figure 1D). We next asked whether overexpression 
Figure 1. Identification of moag-2/lir-3 as an aggregation-promoting factor. (A) Number of aggregates 
in Q40 animals and Q40;moag-2(pk2183) animals. (B) Representative images of Q40 animals and 
Q40;moag-2(pk2183) animals. Scale bar, 75 μm (C) Chromosomal location of lir-3 (F37H8.1, Chromosome 
II, reverse strand of assembly; http://www.wormbase.org, WS248), showing the point mutation in the 
start codon (red arrowhead), the partial deletion (red bar) and the rescue fragment (green). (D) Number 
of aggregates in Q40 animals with wild type, heterozygous and homozygous deletion for the lir-3(tm813) 
allele. (E) Number of aggregates in Q40 animals and Q40;lir-3(tm813) animals, with and without transgenic 
overexpression of an injected lir-3 construct, using its endogenous promoter. (F) Filter retardation assay with 
five-fold serial dilutions of crude protein extract from Q40 animals and Q40;moag-2/lir-3 mutant animals. 
See also Figure S1D. Q40-YFP and α-tubulin expression were included as controls. (G) Q40-YFP transcript 
expression detected by RNA seq in L4 animals and protein expression detected in urea-treated L4 and day 
one adult animals. In all panels, aggregate counting, representative images and filter retardation assay were 
performed at the L4 stage and represented is the average of three biological replicates. Data are represented 
as mean ± SEM and significance was calculated using one-tailed unpaired t-test. **p<0.01; ***p<0.001
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of lir-3 could restore the aggregation phenotype. We injected a rescue construct 
with full-length lir-3 including a 1.5 kb sequence upstream of the start codon to 
include its endogenous promoter as well as 330 bp downstream to include the 
3’ UTR (Figure 1C). The expression of the lir-3 rescue fragment in Q40;lir-3(tm813) 
animals was able to restore the aggregation phenotype by 2-fold (p<0.05), 
therefore confirming lir-3 as the gene responsible for driving aggregation in 
our polyglutamine model (Figure 1E). In summary, these results demonstrate 
that lir-3 is the moag-2 gene.
One property of aggregates in the brains of neurodegenerative disease 
patients, which is also captured by the C. elegans polyglutamine model, 
is that they are typically resistant to strong detergents, such as sodium 
dodecyl sulfate (SDS) [24-26]. To establish whether MOAG-2/LIR-3 promoted 
aggregation of SDS-insoluble polyglutamine aggregates, we performed 
a filter retardation assay on lysates of wild type and moag-2/lir-3 mutant 
polyglutamine animals [27, 28]. This assay enables the detection of SDS-
insoluble protein aggregates while smaller, soluble species are not captured. 
Both Q40;moag-2/lir-3(pk2183) and Q40;moag-2/lir-3(tm813) mutants 
presented less SDS-insoluble aggregates than their corresponding Q40 
controls (Figure 1F). The reduction of SDS-insoluble aggregates was more 
pronounced in the point mutant (43%; p=0.491) than in the deletion mutant 
(26%; p=0.1828) (Figure S1D). Mutation or partial deletion of moag-2/lir-3 
did not detectably reduce the transcription or the protein expression level of 
Q40-YFP, indicating that moag-2/lir-3 does not reduce aggregation by reducing 
expression level of the Q40-YFP protein (Figure 1F, G). Together, these results 
indicate that moag-2/lir-3 drives the formation of SDS-insoluble aggregates.
MOAG-2/LIR-3 is C2H2-domain protein associated with RNA 
Polymerase III promoters 
Having established that mutation of moag-2/lir-3 reduces polyglutamine 
aggregation, we next investigated the endogenous function of the protein. 
C2H2 zinc finger domains are predominantly associated with DNA-binding 
transcription factors but may also have other functions such as mediating 
protein-protein interactions or binding to RNA [29-31].  Bioinformatic 
analysis combined with manual curation predicted MOAG-2/LIR-3 to be a 
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Figure 2. MOAG-2/LIR-3 preferentially binds to promoters of small ncRNAs. (A) Comparison between the 
composition of the gene biotypes bound by MOAG-2/LIR-3 (1kb around TSS) and those distributed genome-
wide. See also Figure S2A. (B) MOAG-2/LIR-3 binding sites within -1000 and +1000 bp from TSS for protein-
coding, ncRNA, tRNA and snoRNA genes. (C) Enriched consensus DNA motifs for MOAG-2/LIR-3 with p value. 
(D) Number of MOAG-2/LIR-3 binding sites containing Box A and Box B. (E) Heat map showing the binding 
of different transcription factors to promoters of C. elegans protein-coding, snoRNA and tRNA genes. The 
hierarchical clustering was generated using the average linkage cluster method with a binary metric distance.
Chapter IV
92
transcription factor [32, 33]. To explore this possibility, we took advantage 
of chromatin immunoprecipitation followed by deep sequencing (ChIP 
seq) as previously described, using L4-staged animals that express an 
integrated construct of lir-3 fused to a GFP tag [34, 35]. This analysis yielded 
a total of 678 unique MOAG-2/LIR-3 binding sites, of which 404 overlapped 
with 813 C. elegans genes. Further analyses of these genes revealed that 
MOAG-2/LIR-3 binding was enriched in the transcription start sites (TSS) of 
tRNA genes (35.7%, p<0.001), snoRNA genes (6.3%, p<0.001), rRNA genes 
(2.5%, p<0.001) and snRNA genes (2.2%, p<0.002) (Figure 2A, B, S2A). While 
MOAG-2/LIR-3 was also found in the vicinity of protein-coding and other ncRNA 
genes, this binding was not significantly enriched (Figure 2A, B). 
We then asked whether the binding sites were enriched in any consensus 
sequence motif that could be recognized by MOAG-2/LIR-3. From the 678 
binding sites initially identified in our ChIP seq, more than half of the sites 
contained Box A and Box B sequence motifs, 301 of which contained both 
motifs (Figure 2C, D). Box A and Box B constitute the canonical type 2 promoter 
site recognized by the RNA Polymerase (Pol) III complex [36, 37]. Pol III is 
responsible for the transcription of structural or catalytic small nuclear RNAs 
(snRNAs), of tRNAs and of snoRNAs, which mediate chemical modifications of 
other RNA molecules [37-40]. 
These findings led us to hypothesize that MOAG-2/LIR-3 could bind to the 
same target promoters as Pol III. Several C. elegans transcription factors have 
been shown to bind in the proximity of non-coding genes, including PHA-
4, PQM-1 and GEI-11 [41]. This prompted us to ask whether the association 
of MOAG-2/LIR-3 with the RNA Pol III complex resembled the binding of 
these transcription factors to the promoters of non-coding genes. To answer 
this question, we collected publicly available ChIP seq data for known 
transcription factors of C. elegans (http://www.modencode.org; September 
2014) and analyzed their binding to the promoters of protein-coding genes, 
snoRNA and tRNA genes (Figure 2E). While there is little association of 
MOAG-2/LIR-3 with the promoters of protein-coding genes, there is a strong 
similarity of MOAG-2/LIR-3 binding profile with a group of factors clustered 
together with representative components of the RNA Pol III complex, including 
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Pol III, the TATA binding protein (TBP-1), two subunits of the transcription factor for 
Pol III C (TFC-1 and TFC-4) and the nuclear pore proteins NPP-3 and NPP-13, 
which were recently shown to associate with the RNA Pol III complex to regulate 
tRNA and snoRNA splicing [36]. The binding of these factors is very abundant in 
the promoters of snoRNAs as well as tRNAs (Figure 2E, arrowhead), in contrast 
to the majority of the other transcription factors. Together, we demonstrated 
that MOAG-2/LIR-3 binds to the promoters of small ncRNA genes suggesting 
that MOAG-2/LIR-3 is associated with Pol III transcription.
MOAG-2/LIR-3 is a positive regulator of the RNA Pol III-mediated 
transcription of small ncRNAs
Because MOAG-2/LIR-3 bound to the promoters of small ncRNA genes, we 
next asked what consequence this binding would have for the transcription of 
the Pol III downstream targets. We therefore compared the RNA expression in 
wild type animals to moag-2/lir-3 mutant animals by transcriptome profiling. 
In line with the absence of MOAG-2/LIR-3 at Pol II promoter sites, we did 
not find any differentially expressed protein-coding genes in the mutants 
compared to the wild-type N2 animals, thereby excluding MOAG-2/LIR-3 as a 
transcriptional regulator of protein-coding genes (Figure 3C, S3A). Mutations in 
moag-2/lir-3, however, did result in the downregulation of snRNAs (p<0.001), 
snoRNAs (p<0.001) and tRNAs (p<0.001) in both mutants, demonstrating that 
MOAG-2/LIR-3 is required for Pol III-mediated transcription of these small ncRNAs 
(Figure 3C, S3A). We next asked where MOAG-2/LIR-3 was positioned relative 
to RNA Pol III complex, by comparing the positions of the ChIP seq signals of 
MOAG-2/LIR-3 relative to the different components of the RNA Pol III complex. 
For both the tRNA and snoRNA genes, all factors localized to the Box A and 
Box B containing promoter region, consistent with previous reports 
(Figure 3A, B) [36]. MOAG-2/LIR-3 was positioned to the same sites 
(Figure 3A, B). Together, these results indicate that MOAG-2/LIR-3 functions 
as a positive regulator of the Pol III-mediated transcription of small ncRNAs in 
C. elegans.
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Figure 3. MOAG-2/LIR-3 regulates transcription 
of small ncRNAs. (A) Boxplot showing the 
relative expression of different gene biotypes in 
lir-3(pk2183) relative to the wild type N2 
background. Coding: protein coding genes; 
ncRNA: non-coding RNA; Pseudo: pseudogenes; 
snRNA: small nuclear RNA; snlRNA: snRNA-like 
RNA, snoRNA: small nucleolar RNA; tRNA: transfer 
RNA. See also Figure S3A. ***p<0.001 (B) Positions 
of ChIP seq signal maxima relative to TSS (right y 
axis) with maximum normalized read count (left y 
axis) for the 51 snoRNA genes and the 290 tRNA 
genes picked in this study. Bottom box represents 
the motif position of Box A and Box B relative to 
snoRNA and tRNA genes. See also Figure S2B. (C) 
Diagram showing the positions of the RNA Pol III 
factors and MOAG-2/LIR-3 estimated from data 
presented in panel (B). 
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Regulation of protein aggregation by MOAG-2/LIR-3 is independent 
of its role as a transcriptional regulator
Next, we asked whether MOAG-2/LIR-3 regulated protein aggregation via 
the RNA Pol III–mediated transcription of the small ncRNAs. We therefore 
knocked down by RNAi, one-by-one, the individual components of the RNA 
Pol III complex in both the wild type and the moag-2/lir-3(pk2183) mutants. 
To confirm RNAi knockdown, we also looked for RNAi-associated phenotypes 
other than aggregation. If Pol III-mediated transcription would play a role, 
this would result in a reduction in the amount of aggregates in the wild type 
Q40 animals but not in the moag-2/lir-3 mutants. As a control, knockdown of 
Pol II decreased the amount of aggregates in both the wild type and the 
mutant animals, indicating that a reduction in the expression of coding 
genes has an effect independent of moag-2/lir-3 (Figure 4A). Knockdown of 
Pol III, TBP-1, TFC-1 and TFC4 did not alter aggregation in the Q40 nor in the 
Q40;moag-2/lir-3 mutant strains, indicating that reduction of Pol III-mediated 
transcription in the absence of moag-2/lir-3 is not responsible for the reduction 
of aggregation (Figure 4A). Reduction of npp-13 or of tRNA processing enzymes 
also did not alter the aggregation phenotype, indicating that neither small 
RNA processing nor the availability of mature tRNAs plays a role in reduction of 
aggregation (Figure 4A, B). These results indicate that the regulation of protein 
aggregation by MOAG-2/LIR-3 is separate from its role in RNA transcription 
with the RNA Pol III complex. 
Polyglutamine expansion proteins suppress transcription of small 
ncRNAs
We next aimed to address why the role of MOAG-2/LIR-3 in driving protein 
aggregation was independent of its role as a transcriptional regulator. We 
therefore first compared the RNA expression profiles of wild type Q40 animals 
to moag-2/lir-3 mutant Q40 animals. In contrast to wild type N2 animals, in 
the presence of polyglutamine there was no longer a change in the relative 
expression levels of the small ncRNAs (Figure 4C). When we then measured the 
absolute levels of all RNAs, we found that, in contrast to the protein-coding 
RNAs, pseudogenes and other ncRNAs, the expression of snRNAs, snoRNAs 
and tRNAs was already strongly reduced in wild type Q40 animals, indicating 
that polyglutamine expansion proteins downregulated ncRNA expression 
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Figure 4. MOAG-2/LIR-3 drives aggregation by converting into an aggregation-promoting factor. 
(A) Number of aggregates measured upon RNAi knockdown of individual components of the RNA 
Pol III complex in Q40 and Q40;lir-3(pk2183) animals. Aggregate counting was performed at young adult 
stage. As an internal quality control for RNAi, squares indicate penetrance (100% [closed] and 0% [open]) 
of all associated visible RNAi phenotypes other than aggregation. See also Figure S4A. (B) Number of 
aggregates measured upon RNAi knockdown of tRNA processing enzymes in Q40 and Q40;lir-3(pk2183) 
animals.  Aggregate counting was performed at L4 stage. In panels A and B, data are represented as 
mean ± SEM and significance was calculated using two-tailed unpaired t-test. (C-E) Boxplot showing 
the relative expression of different gene biotypes in (C) Q40 and Q40;lir-3(pk2183); in (D) N2 and Q40 
wild type animals (Q40 wild type outcrossed from pk2183); and in (E) lir-3(pk2183) in the N2 and Q40 
genetic backgrounds. See also Figure S4C-D. Coding: protein coding genes; ncRNA: non-coding RNA; 
Pseudo: pseudogenes; snRNA: small nuclear RNA; snlRNA: snRNA-like RNA, snoRNA: small nucleolar RNA; 
tRNA: transfer RNA.*p<0.05; **p<0.01; ***p<0.001, ns is not significant. In all panels, the average of three 
biological replicates is represented. (F) Working hypothesis for the role of MOAG-2/LIR-3 as an aggregation-
promoting factor. In wild type animals, MOAG-2/LIR-3 normally regulates the transcription of small ncRNAs, 
namely snRNAs, snoRNAs and tRNAs. However, when polyglutamine expansion proteins are expressed, 
MOAG-2/LIR-3 switches its function from transcriptional regulator to an aggregation-promoting factor, 
thereby driving polyglutamine aggregation.
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(p<0.001; Figure 4D). We observed this reduction in expression to a lesser 
extent in the moag-2/lir-3 mutant Q40 animals compared to the mutant N2 
animals, suggesting that part of the downregulation in the wild type animals 
was caused by polyglutamine inhibition of MOAG-2/LIR-3 (p<0.001; Figure 4E). 
Indeed, this finding explained why mutations in moag-2/lir-3 could no longer 
reduce the expression in these Q40 animals (Figure 4C, S4C).
Altogether, these data suggest a switch of function of MOAG-2/LIR-3 in presence 
of polyglutamine expansion proteins from its biological role as a transcriptional 
regulator to a pathological role as an aggregation promoter at the expense of 
its own function (Figure 4F).
Discussion
Aggregation-prone disease proteins have been found to cause age-related 
neurodegenerative diseases but the cellular processes that drive their 
aggregation and toxicity are still not fully understood.  Using a genetic screen 
in a C. elegans model for disease, we here identified MOAG-2/LIR-3 as regulator 
of RNA Pol III transcription that — in presence of polyglutamine expansion 
proteins — turns into a positive regulator of polyglutamine aggregation. 
The role of MOAG-2/LIR-3 as a transcription factor has been previously 
suggested by others [23, 32, 33]. Its initial discovery as a putative transcription 
factor was due to its structural similarity to the C2H2 zinc fingers of LIN-26, a 
fate regulator responsible for the differentiation of non-neuronal ectodermal 
cells and somatic gonad epithelium [23, 42, 43]. By combining ChIP seq with 
RNA sequencing, we provide the first experimental evidence of MOAG-2/LIR-3 
being a regulator of transcription.
In C. elegans, several transcription factors have been shown to bind to more 
than 10% to the promoters of small ncRNAs, but only one (GEI-11) is predicted 
to regulate ncRNAs [41]. We showed that MOAG-2/LIR-3 is required for the 
transcription of snRNA, snoRNA and tRNA genes and — unlike the majority 
of the other transcription factors — MOAG-2/LIR-3 bound to the same target 
genes as the RNA Pol III complex.
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MOAG-2/LIR-3 expression in C. elegans has been described to localize to 
the nucleus of body wall muscle cells, the vulval muscles, the spermatheca, 
the head and tail ganglia and the ventral nerve cord, from embryogenesis 
throughout adulthood (www.transgeneome.mpi-cbg.de, March 2014 and 
[32, 33]). A microarray performed in two distinct mechanosensory neurons 
— the touch receptor neurons and the FLP neurons — revealed that 
moag-2/lir-3 was upregulated in the FLP sensory neurons, suggesting that 
moag-2/lir-3 is required for FLP differentiation [44]. Because the expression of 
MOAG-2/LIR-3 is limited to a subset of cell types, this suggests that MOAG-2/LIR-3 
could be a tissue-specific regulator of transcription rather than a core component 
of the RNA Pol III machinery. Such cell type specific regulators of RNA Pol III have 
been described for human cells and proposed to accommodate tissue-specific 
needs for small non-coding RNAs ([45, 46], also reviewed in [39, 47]). Whether 
MOAG-3/LIR-3 has a similar role remains to be established.
In C. elegans, the nuclear pore protein NPP-13 has been described to 
associate with the RNA Pol III complex, which regulates the efficient 
processing of snoRNA and tRNA transcripts [36]. Knockdown of 
NPP-13 results in abnormally long snoRNA and tRNA transcripts that cannot 
be processed into their mature form [36]. We did not find unprocessed 
transcripts neither for snoRNA nor tRNAs in moag-2/lir-3 mutant animals 
(data not shown), which excludes the possibility that MOAG-2/LIR-3 is 
required for RNA Pol III transcript processing. Moreover, knockdown of 
NPP-13 did not alter aggregation, which suggests that mutations in 
moag-2/lir-3 do not alter aggregation by interfering with the nuclear pore 
complex.
In this study, expression of an aggregation-prone protein downregulated 
the levels of snRNAs, snoRNAs and tRNAs, demonstrating that aggregation-
prone proteins also affect the non-coding genome. One explanation for 
this downregulation is that the aggregation-prone proteins sequestered or 
changed the localization of MOAG-2/LIR-3, and perhaps also components of 
the RNA Pol III complex. Several intrinsically disordered proteins, which include 
proteins involved in transcriptional regulation, are known to be sequestered 
by aggregation-prone proteins into aggregates [3, 48-51]. One example 
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is Sp1, which can no longer bind to its DNA targets due to sequestration 
by mutant huntingtin [52, 53]. Because MOAG-2/LIR-3 is a small (284 aa), 
predominantly disordered protein (75.5%) (http://bip.weizmann.ac.il/fldbin/
findex, June 2015), its sequestration could explain the lower levels of small 
ncRNAs observed in presence of aggregation-prone proteins. Nevertheless, 
the fact that aggregation-prone proteins affect small ncRNA expression poses 
the interesting question whether this is correlated their toxicity. It will also be 
interesting to find whether the cellular downregulation of small ncRNAs is a 
consequence specific for polyglutamine expansion proteins or shared by other 
aggregation-prone proteins such as alpha-synuclein and amyloid-beta.
Individual knockdown of the components of the RNA Pol III complex did not 
affect aggregation in Q40 animals, indicating that RNA Pol III transcription is 
not related to the effect of moag-2/lir-3 mutations on protein aggregation. 
Impaired processing of precursor tRNA into its mature form or mutations in the 
tRNA body sequence have been implicated in neurodegeneration [54-59]. In 
C. elegans, mutations in the tRNA body sequence can result in protein 
misfolding, protein aggregation and neurological defects [60, 61]. We found, 
however, that knockdown of tRNA processing enzymes as well as factors known 
to cooperate with those enzymes (rtcb-1, clpf-1 and gtbp2 homolog) did not 
alter the aggregation phenotype in Q40 animals, also indicating that impaired 
tRNA processing is not the cause for protein aggregation in our model. The 
glutaminyl tRNA that specifically recognizes the CAG codon is required in high 
demand during translation of the expanded CAG tract in huntingtin, eventually 
resulting in its depletion [62]. According to our data, there is no evidence for a 
preferential enrichment or depletion of glutaminyl pre-tRNAs in Q40 animals 
(data not shown). In addition, while we cannot account for mature tRNAs 
present in the body wall muscle cells, which would require detection in a 
tissue-specific manner, the polyglutamine expression levels are not decreased 
in the moag-2/lir-3 mutant animals, reducing the possibility that the availability 
of glutaminyl tRNAs plays a role. 
Several transcription factors have been implicated in protein aggregation, but 
none with known function related to RNA Pol III transcription [53, 63]. Our results 
indicate that MOAG-2/LIR-3 regulated protein aggregation independently of its 
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role in small ncRNA transcription and processing, as shown by RNAi knockdown 
experiments. One possibility is that MOAG-2/LIR-3 drives aggregation directly. 
Precedents for aggregation-promoting factors include SERF1A, which can drive 
aggregation of a variety of disease proteins via a transient direct interaction 
with early aggregation intermediates and SH3GL3, which was shown to bind 
physically to the huntingtin protein or its mutated form through the SH3 
domain [11, 12, 14, 15]. 
Components of the RNA Pol II complex have been reported to be part of protein 
aggregates. Such an example comes from TBP, which was localized to nuclear 
inclusions of SCA-1, -2, -3 and neurofibrillary tangles of Alzheimer’s disease [64-
66]. A regulatory role for TBP in protein aggregation, as we observe here for 
MOAG-2/LIR-3, however, has not been reported.
In summary, this work reveals that protein aggregation can affect the non-
coding genome by altering the expression of ncRNA genes available in the cell. 
Secondly, this work opens yet another perspective on how aggregation-prone 
disease proteins can impair cellular homeostasis by inhibiting transcription of 
non-coding RNAs and converting normal cellular proteins into aggregation-
promoting factors at the expense of their function. 
Methods
Strains and genetics
Standard methods were used for culturing C. elegans at 20ºC [67]. The 
LIR-3::GFP strain (OP312) was generated by biolistic transformation to produce 
an integrated, low-copy transgene of the WRM0637aB05 fosmid, recombineered 
with GFP:3XFLAG in frame at the carboxy terminus of the lir-3 locus [34]. To 
synchronize animals, eggs were collected from gravid hermaphrodites by 
hypochlorite bleaching and hatched overnight in M9 buffer. The desired 
amount of L1 animals were subsequently cultured on nematode growth 
medium agar plates (#633185, Greiner Bio-One) seeded with OP50 bacteria. 
The following strains were used or generated: wild type N2 (Bristol), AM141 
rmIs133[P(unc-54)Q40::YFP]X [68],  OP312 wgIs312[P(lir-3)::TY1::EGFP::3xFLAG 
+ unc-119(+)] [35, 69], OW1002 lir-3(tm0813)II , OW1003 rmIs133[P(unc-54)
Q40::YFP]X;lir-3(tm813)II, OW1004 rmIs133[P(unc-54)Q40::YFP]X, OW1019 
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moag-2 (pk2183), OW1020 rmIs133[P(unc-54)Q40::YFP]X;moag-2(pk2183)II, 
OW1021 rmIs133[P(unc-54)Q40::YFP]X, OW1086 rmIs133[P(unc-54)::Q40::YFP]X, 
OW1087 rmIs133[P(unc-54)::Q40::YFP]X; zgEx221[P(myo-3)::CFP + P(lir-3)::lir-3]; 
lir-3(tm813)II, OW1090 rmIs133[P(unc-54)::Q40::YFP]X, OW1091 rmIs133[P(unc-
54)::Q40::YFP]X; zgEx226[P(myo-3)::CFP + P(lir-3)::lir-3]; lir-3(tm813)II, OW1100 
rmIs133[P(unc-54)::Q40::YFP]X; wgIs312[P(lir-3)::TY1::EGFP::3xFLAG + unc-119(+)].
EMS Mutagenesis and Mapping 
Mutagenesis was performed using standard C. elegans ethyl methanesulfonate 
(EMS) methodology [70]. Eight thousand mutagenized genomes were 
screened for suppressors of aggregation. moag-2(pk2183) was identified by 
single-nucleotide polymorphism mapping to a region between base 9,400,743 
and 11,827,697 on linkage group II [71]. Next generation sequencing was 
performed in that region to identify candidate genes for moag-2. CLC Bio 
(Qiagen, http://www.clcbio.com) and MAQGene softwares were utilized for 
mapping the mutation in F37H8.1 [72].
Creation of transgenic strains
For the rescue experiment, a genomic construct of lir-3 spanning 1500bp 
upstream to 330bp downstream of F37H8.1 was amplified from N2 
genomic DNA by nested PCR using primers F1: CGCTCACAGTCAACGTCG; 
R1: CCATGCGATTTGACACATTTCG; F2: CGGCATTGCTCTTGTCGTGC and R2: 
GCATCTCATGAAACCAGACGC. The resulting PCR fragment was cloned into the 
pGEM-T Easy Vector (Promega) and sequenced. Transgenic lines were made 
by injecting ~20 ng/ul of construct along with ~10 ng/ul of pPD136.61 [P(unc-
54::CFP)] in N2 animals.
RNAi experiments
RNAi experiments were performed on NGM agar plates containing 1 mM IPTG 
and 50 mg/ml ampicillin that were seeded with RNAi bacteria induced with 
IPTG to produce dsRNA. Animals were synchronized by hypochlorite bleaching 
and L1 animals were grown on RNAi plates (#628103, Greiner Bio-One) and 
used for the experiments at L4 stage, unless stated otherwise.
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Quantification of aggregates
The number of aggregates present in whole animals was counted using a 
fluorescence dissection microscope (Leica Microsystems, Wetzlar, Germany). 
A minimum of 20 animals was counted in three biological replicates, unless 
stated otherwise. 
Filter retardation assay 
The protocol was adapted from Wanker et al [27, 28]. Briefly, crude worm 
lysates from synchronized L4 animals were resuspended in FTA Sample Buffer 
(10 mM Tris-Cl pH 8.0; 150 mM NaCl; 2% SDS) and disrupted using a bead-
beater (FastPrep 24, MP Biomedicals) for 7 cycles of 20 seconds bead beating/5 
minutes rest per cycle. Supernatants were transferred to new 1.5 ml tubes and 
protein concentration was determined using the BCA Protein Assay Kit (#23227; 
Thermo Scientific Pierce). To detect SDS-insoluble aggregates, 100 ug of total 
protein was mixed with 1 M DTT and FTA Sample buffer (final concentration 
40 ug/100 ul) and heated for 98ºC for 5 minutes. Samples were filtered through 
a 0.22 micron cellulose acetate membrane using a Bio-Dot microfiltration 
apparatus (Biorad) and 100 ug of total protein was used followed by five-
fold serial dilutions. Proteins were blocked for 30 minutes with 5% milk in 
TBS-T. Membranes were incubated with GFP (#632381, Clontech) or α-tubulin 
(#T6074-200UL, Sigma) primary antibodies at a 1:5000 dilution overnight at 
4ºC. Incubation with secondary antibody anti-mouse was applied at a 1:10.000 
dilution for 1 hour at room temperature. Antibody binding was visualized with 
an ECL kit (#RPN2232, Amersham).
Chromatin immunoprecipitation sequencing
ChIP assays were conducted as previously described [35, 41]. Worm staging 
was achieved by bleaching and L1 starvation.  Arrested L1 animals were plated 
on peptone-enriched NGM plates seeded with OP50 bacteria and grown 
for 48 hours for L4 collection at 20°C.  Samples were crosslinked with 2% 
formaldehyde for 30 minutes at room temperature and then quenched with 
1 M Tris pH 7.5. The pelleted worms were subsequently flash frozen in liquid 
nitrogen and stored at -80°C. Samples were sonicated using a microtip to obtain 
mostly 200 to 800 bp DNA fragments. For each sample, 2.2 or 4.4 mg of cell 
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extract was immunoprecipitated using a goat anti-GFP, GoatV (gift from Kevin 
White). The enriched DNA fragments and input control (genomic DNA from the 
same sample) for two biological replicates were used for library preparation 
and sequencing as previously described [73]. Briefly, samples were libraried 
and multiplexed using the Ovation Ultralow DR Multiplex Systems 1-8 and 
9-16 (NuGEN Technologies Inc., San Carlos, CA) following the manufacturer’s 
protocol except Qiagen MinElute PCR purification kits were used to isolate the 
DNA. Library size selection in the 200-800 bp range was achieved using the 
SPRIselect reagent kit (Beckman Coulter, Inc., Brea, CA) and sequencing was 
performed on the Illumina HiSeq 2000 platform.  To search for MOAG-2/LIR-3 
specific binding sites, only binding sites consistent across both replicates and 
within a range of -400 bp to +100 bp distance from TSS were considered. In 
addition, we excluded highly occupied target regions to avoid false positives 
in our analysis [74]. The ChIP seq data used was obtained from modENCODE 
DCC (http://www.modencode.org; September 2014). All ChIP-seq data have 
been deposited in Gene Expression Omnibus (GEO), under accession number 
(in preparation). 
RNA sequencing
Worms were grown to L4 stage and total RNA was extracted using TRIzol 
Reagent (Life Technologies) according to the manufacturer’s description. 
For polyA RNA sequencing, the TruSeq Sample Preparation V2 Kit was used 
(Illumina). For non-coding RNA sequencing (mRNA, snoRNA, tRNA and large 
ncRNA), a protocol has been described previously [36]. Briefly, total RNA was 
treated with DNAseI and depleted from rRNA with the Ribominus Eukaryote Kit 
(#A10837-08, Invitrogen). Fragmentation of RNA was performed using a 
Fragmentation Buffer (#AM8740, Ambion) and cDNA was generated using the 
Superscript II Kit (Invitrogen). cDNA libraries were subjected to high-throughput 
single-end sequencing (50 bp) in an Illumina HiSeq 2500 instrument. The RNA 
sequencing dataset has been submitted to GEO, under accession number (in 
preparation).  RNA-sequencing data was mapped to WS220 genome reference 
using TopHat 2.0.9 program [75] and gene annotation from Ensembl release 
66. Per gene expression data was normalized as fragments per million mapped 
(FPM). Data visualization and statistical tests were conducted using R scripts.
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Bioinformatic Analysis 
Conserved domains were identified using SMART (Simple Modular Architecture 
Research Tool) [76, 77]. Prediction of nuclear signal localization was done with 
NLS Mapper [78]. Prediction of protein folding was done with FoldIndex [79]. 
The algorithm used for motif discovery was The MEME Suite [80]. Orthologs 
were identified using protein BLAST search and aligned with T-Coffee multiple 
sequence alignment tool [81]. Amino acid predictions were performed using 
ORF Finder (http://www.ncbi.nlm.nih.gov/gorf/orfig.cgi).
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Supplemental figures
Figure S1. (A) Representative bright field images of L4-staged Q40 and Q40;lir-3(pk2183) animals. Insets 
show a magnification of the vulva. Scale bar, 75 μm (B) List of candidate genes for moag-2 obtained by 
whole genome sequencing. (C) Amino acid sequence of LIR-3 with the predicted nuclear localization 
signal (NLS, residues 132-141) and C2H2 zinc finger domains (residues 191-214 and 224-247). Grey 
shadow indicates location of the point mutation and the deleted residues in the lir-3(tm813) mutant. (D) 
Quantification of filter retardation assays. Immunoblots were quantified by densitometry using ImageJ. 
Presented is the ratio (fold change) between protein levels of Q40;moag-2/lir-3 mutants relative to their 
corresponding wild types (corrected to α-tubulin as a loading control). Filter retardation assay was performed 
at the L4 stage and represented is the average of three biological replicates. Data are represented as 
mean ± SEM and significance was calculated using one-tailed unpaired t-test. *p<0.05
Figure S2. (A) Number of MOAG-2/LIR-3 binding sites per gene biotype and total number of known 
C. elegans genes. p value was calculated by permutation test. (B) Number of MOAG-2/LIR-3 binding sites 
containing Box A and Box B in snoRNA and tRNA genes. (C) Number of snoRNA genes encoded by RNA Pol II 
or III genome-wide and detected in this study.
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Figure S3. Boxplot showing the relative expression of different 
gene biotypes in lir-3(tm813) relative to the wild type N2 
background. Coding: protein coding genes; ncRNA: non-
coding RNA; Pseudo: pseudogenes; snRNA: small nuclear RNA; 
snlRNA: snRNA-like RNA, snoRNA: small nucleolar RNA; tRNA: 
transfer RNA.***p<0.001
significance was calculated using two-tailed unpaired t-test. (C-E) Boxplot showing the relative expression 
of different gene biotypes in (C) lir-3(tm813) relative to its wild type in the Q40 background; in (D) in the N2 
and Q40 wild type animals (Q40 control outcrossed from  lir-3(tm813)); and in (E) lir-3(tm813) in the N2 and 
Q40 genetic backgrounds. Coding: protein coding genes; ncRNA: non-coding RNA; Pseudo: pseudogenes; 
snRNA: small nuclear RNA; snlRNA: snRNA-like RNA, snoRNA: small nucleolar RNA; tRNA: transfer RNA. 
*p<0.05; **p<0.01; ***p<0.001; ns is not significant. In panels B to E, the average of three biological replicates 
is represented. 
Figure S4. (A) Number of aggregates measured upon RNAi 
knockdown of individual components of the RNA Pol III complex 
in Q40 and Q40;lir-3(tm813) animals. Aggregate counting was 
performed in young adult stage. Represented is the average of four 
biological replicates. (B) Number of aggregates measured upon 
knockdown of tRNA synthetases in Q40 and Q40; lir-3(pk2183) 
animals. Asterisk indicates genes previously known to reduce 
protein aggregation. In panels A and B,  an internal quality control 
for RNAi was performed and squares indicate penetrance (100% 
[closed] and 0% [open]) of all associated visible RNAi phenotypes 
other than aggregation. Data are represented as mean ± SEM and 
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Table S1. Overview and statistical analysis of aggregate counting experiments.
Replicates 
(N)
Strain
Mean ± 
SEM
versus
Mean ± 
SEM
p value
Figure 1A
N=3 Q40 33 ± 0.85 Q40;lir-3(pk2183) 17 ± 0.64 < 0.0001
Figure 1D
N=3 Q40 49 ± 1.0
Q40;lir-3(tm813) 31 ± 0.72
< 0.0001
Q40;lir-3(het) 47 ± 1.0 < 0.0001
Figure 1E
N=3 Q40 35 ± 1.32 Q40 + lir-3 overexpression 43 ± 1.26 p = 0.0001
Q40;lir-3(tm813) 13 ± 0.80 Q40;lir-3(tm813) + lir-3 overexpression 27 ± 0.97 < 0.0001
Figure 4A
N=3 Q40 on control RNAi 32 ± 5.85 Q40;lir-3(pk2183) on control RNAi 14 ± 4.99 p = 0.0393
Q40 on ama-1 (Pol II) 20 ± 1.50 Q40;lir-3(pk2183) on ama-1 (Pol II) 5 ± 0.70 p = 0.0004
Q40 on rpc-1 (Pol III) 34 ± 6.65 Q40;lir-3(pk2183) on rpc-1 (Pol III) 15 ± 5.85 p = 0.05
Q40 on tbp-1 (TBP) 36 ± 7.31 Q40;lir-3(pk2183) on tbp-1 (TBP) 16 ± 6.20 p = 0.0479
Q40 on tftc-5 (TFC-1) 39 ± 8.19 Q40;lir-3(pk2183) on tftc-5 (TFC-1) 16 ± 5.36 p = 0.0383
Q40 on npp-13 34 ± 6.89 Q40;lir-3(pk2183) on npp-13 14 ± 5.35 p = 0.0401
Figure 4B
N=3 Q40 on control RNAi 34 ± 1.53 Q40;lir-3(pk2183) on control RNAi 15 ± 0.99 < 0.0001
Q40 on hoe-1 (RNAse Z) 37 ± 1.11 Q40;lir-3(pk2183) on hoe-1 (RNAse Z) 17 ± 0.94 < 0.0001
Q40 on hpo-31 36 ± 2.14 Q40;lir-3(pk2183) on hpo-31 14 ± 0.70 < 0.0001
Q40 on T06D8.9 (TSEN15) 38 ± 1.82 Q40;lir-3(pk2183) on T06D8.9 (TSEN15) 16 ± 1.41 < 0.0001
Q40 on F52C12.3 (TSEN54) 33 ± 1.30 Q40;lir-3(pk2183) on F52C12.3 (TSEN54) 16 ± 1.13 < 0.0001
Q40 on rtcb-1 29 ± 1.47 Q40;lir-3(pk2183) on rtcb-1 16 ± 0.70 < 0.0001
Q40 on xpo-3 39 ± 1.59 Q40;lir-3(pk2183) on xpo-3 16 ± 0.99 < 0.0001
Q40 on pus-1 30 ± 1.58 Q40;lir-3(pk2183) on pus-1 16 ± 0.79 < 0.0001
Q40 on clpf-1 38 ± 1.01 Q40;lir-3(pk2183) on clpf-1 17 ± 1.37 < 0.0001
Q40 on T04H1.2 (GTBP2) 31 ± 1.16 Q40;lir-3(pk2183) on T04H1.2 (GTBP2) 16 ± 0.86 < 0.0001
Figure S4A
N=4 Q40 on control RNAi 26 ± 4.81 Q40;lir-3(tm813) on control RNAi 8 ± 1.34 p = 0.0055
Q40 on ama-1 (Pol II) 20 ± 1.12 Q40;lir-3(tm813) on ama-1 (Pol II) 8 ± 0.88 p = 0.0001
Q40 on rpc-1 (Pol III) 24 ± 2.77 Q40;lir-3(tm813) on rpc-1 (Pol III) 7 ± 1.03 p = 0.0006
Q40 on tbp-1 (TBP) 26 ± 2.91 Q40;lir-3(tm813) on tbp-1 (TBP) 9 ± 1.86 p = 0.0013
Q40 on tftc-5 (TFC-1) 29 ± 3.38 Q40;lir-3(tm813) on tftc-5 (TFC-1) 11 ± 2.16 p = 0.0021
Q40 on npp-13 24 ± 2.25 Q40;lir-3(tm813) on npp-13 8 ± 1.19 p = 0.0004
Figure S4B
N=3 Q40 on control RNAi 23 ± 1.71 Q40;lir-3(pk2183) on control RNAi 11 ± 1.15 < 0.0001
Q40 on cars-1 19 ± 1.42 Q40;lir-3(pk2183) on cars-1 9 ± 0.66 < 0.0001
Q40 on frs-1 20 ± 1.60 Q40;lir-3(pk2183) on frs-1 11 ± 0.74 < 0.0001
Q40 on nrs-1 24 ± 1.70 Q40;lir-3(pk2183) on nrs-1 14 ± 1.28 < 0.0001
Q40 on krs-1 25 ± 1.91 Q40;lir-3(pk2183) on krs-1 9 ± 1.00 < 0.0001
Q40 on aars-1 27 ± 1.88 Q40;lir-3(pk2183) on aars-1 14 ± 2.11 < 0.0001
Q40 on trs-1 20 ± 1.41 Q40;lir-3(pk2183) on trs-1 13 ± 1.04 < 0.0001
Q40 on wrs-2 23 ± 1.06 Q40;lir-3(pk2183) on wrs-2 13 ± 1.47 < 0.0001
Q40 on rrt-1 20 ± 1.44 Q40;lir-3(pk2183) on rrt-1 10 ± 0.79 < 0.0001
Q40 on lrs-1 20 ± 1.28 Q40;lir-3(pk2183) on lrs-1 15 ± 1.61 p = 0.0179
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Q40 on grs-1 15 ± 0.92 Q40;lir-3(pk2183) on grs-1 8 ± 0.60 < 0.0001
Q40 on prs-1 20 ± 1.27 Q40;lir-3(pk2183) on prs-1 10 ± 0.84 < 0.0001
Q40 on dars-1 17 ± 1.34 Q40;lir-3(pk2183) on dars-1 8 ± 0.82 < 0.0001
Q40 on irs-1 19 ± 1.29 Q40;lir-3(pk2183) on irs-1 10 ± 1.03 < 0.0001
Q40 on qars-1 22 ± 1.59 Q40;lir-3(pk2183) on qars-1 10 ± 0.73 < 0.0001
ns - not significant
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Table S2. List of RNAi foods used in knockdown experiments.
Sequence name Gene Description
L4440 - Empty vector
F36A4.7 ama-1 Large subunit of RNA Polymerase II
C42D4.8 rpc-1 Ortholog of the human RNA Polymerase III
T20B12.2 tbp-1 Ortholog of the human TATA-box-binding protein (TBP)
T02C12.3 tftc-5 Ortholog of the human general transcription factor IIIC (TFC-1)
Y37E3.15 npp-3
Nucleoporin required for normal nuclear pore complex distribution 
in the nuclear envelope; also described as being part of the RNA 
Polymerase III complex
E04A4.4 hoe-1 RNAse Z
F55B12.4 hpo-31 Predicted to have tRNA nucleotidyl transferase activity
T06D8.9 - 43% homologous to the human TSEN15 subunit of the tRNA splicing endonuclease
F52C12.3 - 31% homologous to the human TSEN54 subunit of the tRNA splicing endonuclease
F16A11.2 rtcb-1 Ortholog of the human tRNA splicing ligase (RTCB)
C49H3.10 xpo-3 Ortholog of the human importin beta 1
W06H3.2 pus-1 Putative mithochondrial tRNA synthetase
F29A2.4 clpf-1 48% homologous to mammalian RNA kinase protein, recently shown to associate with TSEN and drive tRNA splicing
T04H1.2 - 45% homologous to the human GTB-binding protein 2 protein, recently shown to prevent ribosome stalling
Y23H5A.7 cars-1 Cysteinyl amino-acyl tRNA synthetase
T08B2.9 frs-1 Phenylalanyl amino-acyl tRNA synthetase
F22D6.3 nrs-1 Asparaginyl amino-acyl tRNA synthetase
T02G5.9 krs-1 Lysyl amino-acyl tRNA synthetase
W02B12.6 aars-1 Alanyl amino-acyl tRNA synthetase
C47D12.6 trs-1 Threonyl amino-acyl tRNA synthetase
C34E10.4 wrs-2 Tryptophanyl amino-acyl tRNA synthetase
F26F4.10 rrt-1 Arginyl amino-acyl tRNA synthetase
R74.1 lrs-1 Leucyl amino-acyl tRNA Synthetase
T10F2.1 grs-1 Glycyl amino-acyl tRNA synthetase
T20H4.3 prs-1 Prolyl amino-acyl tRNA synthetase
B0464.1 dars-1 Aspartyl amino-acyl tRNA synthetase
R11A8.6 irs-1 Isoleucyl amino-acyl tRNA synthetase
Y41E3.4 qars-1 Glutaminyl amino-acyl tRNA synthetase
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Abstract
Protein aggregation is a hallmark of neurodegenerative diseases such as 
Alzheimer’s, Parkinson’s and polyglutamine diseases. Polyglutamine diseases 
are characterized by the abnormal expansion of CAG repeats in the disease-
causing gene. Consequently, when the gene is translated into a protein, the 
protein is unable to acquire its native conformation, so that it becomes misfolded 
and aggregation-prone. The aggregation-prone protein interacts aberrantly 
with other normal, functioning proteins in the cell, ultimately disrupting 
protein homeostasis. While most research into polyglutamine diseases has 
focused on the changes that take place after the aggregation-prone protein 
has been translated, less is known about changes at the transcriptional level. 
We therefore sought to identify the transcriptional changes that occur when a 
cell is exposed to aggregation-prone proteins such as polyglutamine expansion 
proteins. We took advantage of a C. elegans model for polyglutamine diseases – 
which recapitulates the protein misfolding and aggregation observed in human 
disease – and performed whole transcriptome analysis at two different stages 
of larval development in both wild type (N2) and polyglutamine-expressing 
animals.
Principal component analysis revealed that the major sources of expression 
variation were related to stage of development (L2/L3 versus L4) followed by 
the genetic background (wild type N2 versus the polyglutamine model). RNA 
sequencing-derived data was analyzed by combining standard differential 
expression analysis with gene ontology enrichment analysis to identify those 
genes whose expression was affected by aggregation-prone proteins. The 
genes thus identified were found to be related to the unfolded protein response, 
oxidative stress and immune response. We also found that aggregation-prone 
proteins slow down the rate of animal development. We propose that this 
combination of events may represent a coping strategy that the organism 
adopts to preserve its fitness as a response to the pathological presence of 
aggregation-prone proteins. 
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Introduction
Polyglutamine diseases are a class of neurodegenerative disorders that include 
Huntington’s disease, spinocerebellar ataxia (types 1, 2, 6, 7, 17), Machado–
Joseph disease and spinobulbar muscular atrophy [1, 2]. Due to a loss of 
neurons, affected patients commonly experience motor dysfunction as well as 
cognitive and behavioral abnormalities [3]. These diseases are characterized 
by an abnormal expansion of CAG repeats in the disease-causing genes. The 
resulting protein has an unusually long stretch of glutamines, which causes 
it to become misfolded and prone to aggregation, ultimately contributing to 
protein aggregation [4]. Despite our knowledge of the underlying causes of 
polyglutamine diseases, we are not yet able to explain why protein aggregation 
occurs in affected patients. If we can understand how the cell copes with protein 
aggregation, we can identify and characterize the cellular pathways implicated 
in pathogenesis and target these for disease-modifying treatments.
Polyglutamine aggregation has been recapitulated in several models in the 
nematode Caenorhabditis elegans [5-8]. In one of those models, an expanded 
polyglutamine stretch containing 40 CAG repeats is expressed in the body 
wall muscle cells, whereby the formation of aggregates is proteotoxic and 
progresses with age [6]. Here we used this model to find answers to the following 
questions: What transcriptional changes occur in the cell upon expression of 
polyglutamine expansion proteins? Which pathways are activated? Does this 
change during the course of worm development? To this end, we performed 
a global integrative analysis of the transcriptome of a C. elegans model of 
polyglutamine diseases, by employing principal component analysis and 
differential gene expression analysis. We aimed to identify the pathways that 
are activated upon pathological overexpression of polyglutamine expansion 
proteins in order to gain insight into the relevant cellular responses.
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Results 
Developmental stage and genetic background account for 
differences in transcriptome profiles 
In our analysis of the transcriptome of polyglutamine-expressing (Q40) animals, 
we selected larval stages two/three (L2/L3) and four (L4), in order to examine 
transcriptome changes during development. To search for the main sources of 
variance in our transcriptome profiling data, we employed principal component 
analysis (PCA). The first principal component yielded a clear distinction between 
L2/L3 and L4 animals, showing that the developmental stage had a strong 
effect in our expression data (Figure 1A, C). The following principal component 
explained the variance between our datasets based on the presence of the 
transgene (Figure 1B, C). Indeed, while the profile of polyglutamine-expressing 
animals was very similar to that of wild type N2 animals at the L2/L3 stage, 
these differences were more pronounced at developmental stage L4 (Figure 
1A-C). These results are consistent with the observation that – under our 
laboratory conditions – expression of polyglutamine expansion proteins 
slows down worm development (Figure 1D). We performed enrichment 
analysis based on gene ontology (GO) using the web-based toolset gProfiler 
(http://biit.cs.ut.ee/gprofiler/, Ensembl 79). This enabled us to learn more about 
the gene set comprising the first principal component, since this component 
explained most of the variance of the data (18.7%). GO term analysis of the first 
principal component revealed that the genes in the first principal component 
were related to developmental processes (Figure 1E). In all, our transcriptomic 
profiling data demonstrated that expression variation was determined firstly 
by developmental stage and secondly by genetic background.
Polyglutamine expansion proteins trigger the ER-associated 
unfolded protein response
We next used differential gene expression analysis to look for genes that 
were significantly up- or downregulated due to the presence of aggregation-
prone proteins. A false-discovery rate (FDR) cutoff of 0.1% was used to identify 
such differentially expressed genes. First, we excluded genes differentially 
expressed between the L2/L3 and L4 stages in the N2 genetic background, 
thus avoiding developmental effects (and therefore false positives) that might 
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Figure 1. Effect of aggregation-prone proteins on the C. elegans transcriptome. (A, B) PCA plots of the 
23 samples included in this study. Different colors indicate the different time points (L2/L3 or L4) and genetic 
backgrounds (Q40 or N2). PC, principal component. (C) Heat map showing the distribution of the 23 samples 
included in this study. The hierarchical clustering was generated using the average linkage cluster method 
with a Euclidean metric distance. (D) Approximate number of hours from egg hatching until L1 and between 
successive developmental stages until adulthood in C. elegans. (E) Gene ontology (GO) term enrichment 
analysis for gene set of the first principal component. (F) Results of differential gene expression analysis as 
measured by the fold change in expression between raw reads of wild type animals in L2/L3 and L4 stage (x 
axis) and N2 and Q40 animals in L4 stage (y axis).  (G) GO term enrichment analysis for genes differentially 
expressed in the presence of aggregation-prone proteins (blue data points from panel (F)), and the number 
of genes associated with each GO term.  (H) GO term enrichment analysis for genes differentially expressed 
in the presence of aggregation-prone proteins (green data points from panel (F)), and the number of genes 
associated with each term.
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mask the contribution of the polyglutamine expansion proteins to the cell’s 
transcriptome (Figure 1F, red). Then, to determine the specific contribution of 
polyglutamine expansion proteins to the cell’s transcriptome, we looked for 
genes that were differentially expressed between the Q40 and N2 animals 
at the L4 stage (Figure 1F, blue). GO term enrichment analysis of this cluster 
identified genes involved in three types of cellular functions, namely the 
unfolded protein response (UPR, 14 genes), the pathogen response (35 genes), 
and the redox process (54 genes) (Figure 1G). Further inspection of the genes 
involved in the UPR pathway revealed significant downregulation of the abu 
and pqn family of genes (Table 1). The abu (activated in blocked UPR) family 
of genes is expressed when the UPR is blocked and it has been suggested that 
their protein products may protect the cell against aberrantly folded proteins 
[9]. Both the pqn and abu genes encode proteins whose amino acid sequences 
contain glutamine/asparagine-rich (Q/N) domains, a common feature of prion-
like domains [10, 11]. This hints at the possibility that polyglutamine expansion 
proteins trigger the UPR to cope with misfolded proteins in the cell, thereby 
downregulating the abu/pqn genes since they are not necessary.
Parallel to this, in Q40 animals we detected upregulation of the cdr-4, gad-3 
and C14B9.2 genes (Table 1), all of which are regulated by xbp-1, a transcription 
factor required for the activation of the UPR [9, 12, 13]. While not much is known 
about cdr-4 and gad-3, C14B9.2 is known to encode a disulfide isomerase. 
Protein disulfide isomerases are important for the formation of native disulfide 
bonds in proteins transiting through the ER, a process known as oxidative 
protein folding (reviewed in [14]). We observed no activation of other canonical 
UPR components, such as the worm homologs of BiP/GRP78 (hsp-3 and hsp-4), 
an ER-associated molecular chaperone [15-17]. Overall, this set of differentially 
expressed genes is consistent with the cellular response pathways known to be 
triggered by misfolded, aggregation-prone proteins in the ER [18].
Curiously, GO term enrichment analysis also identified a cluster of 35 genes 
involved in the pathogen response, including lys-7, sdd-3 and cnc-6 (Table 
1). Aggregation-prone proteins – and in particular polyglutamine expansion 
proteins – are not known to trigger a pathogen defense response. Moreover, 
several genes within this cluster are expressed in the C. elegans gut, suggesting 
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that aggregation-prone proteins can also provoke cell non-autonomous 
effects. Finally, we identified upregulation of genes within the redox cluster, 
including genes known to be involved in oxidative stress (cst-2 and sod-3) 
and belonging to the cytochrome P450 family of monooxygenases, including 
kmo-1 (Table 1). The yeast homolog of kmo-1 – bna-4 – has been identified 
as a potent suppressor of polyglutamine-induced proteotoxicity [19]. Taken 
together, these results point to aggregation-prone proteins inducing cellular 
stress, resulting in activation of cellular stress response pathways.
Table 1. Genes expressed differentially between wild type and polyglutamine-expressing 
animals at the L4 stage (blue data points from Figure 1F).
Cellular 
process (no 
of genes)
Function
(no of genes)
Sequence 
name
Gene 
examples
Fold 
change Short description
Response to 
stress (53)
Unfolded protein 
response (14)
AC3.3 abu-1 -2,66
Transmembrane proteins with a glutamine/
asparagine-rich ("prion") domain
C03A7.7 abu-6 -2,35
C03A7.8 abu-7 -2,28
R09F10.2 abu-9 -2,70
F35A5.3 abu-10 -1,99
T01D1.6 abu-11 -2,16
C03A7.4 abu-15 -2,26
AC3.4 pqn-2 -2,70 Proteins with a glutamine/asparagine-rich 
("prion") domainR09F10.7 pqn-57 -3,15
C14B9.2 - 1,40 Protein disulfide isomerase
K01D12.11 cdr-4 1,79 Predicted transmembrane protein part of the cadmium responsive (CDR) family of proteins
B0222.9 gad-3 1,36 Ortholog of human xanthine dehydrogenase
Pathogen 
response (35)
C02A12.4 lys-7 2,00 Antimicrobial enzyme
T08A9.7 spp-3 1,17 Antimicrobial peptide
Y46E12A.1 cnc-6 7,42 Antimicrobial peptide
Metabolic 
process (91)
Redox process 
(54)
C24A8.4 cst-2 1,00 Protein kinase
C08A9.1 sod-3 2,54 Iron/manganese superoxide dismutase
R07B7.5 kmo-1 1,67 Mitochondrial enzyme
F02C12.5 cyp-13B1 5,75
Membrane-associated, heme-containing 
NADPH-dependent monooxygenases
K09A11.3 cyp-14A2 1,58
R04D3.1 cyp-14A4 3,24
T10B9.7 cyp-13A2 1,77
B0304.3 cyp-23A1 2,45
Polyglutamine expansion proteins affect C. elegans development
While performing differential expression analysis (also using an FDR cutoff of 
0.1%), we identified additional clusters of differentially expressed genes (Figure 
1F, magenta and green). These clusters of genes were significantly upregulated 
during development of wild type animals while slightly downregulated in Q40 
animals. Further inspection of this cluster identified two sub-groups: one sub-
group had more genes that were strongly downregulated (Figure 1F, magenta) 
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while the other had more genes that were clustered but less downregulated 
(Figure 1F, green). Since we suspected that this expression pattern may be due 
to developmental differences provoked by the expression of aggregation-
prone proteins, we performed GO term analysis of each cluster individually. 
For the sub-group with strongly downregulated genes, we could draw no 
conclusions regarding biological processes (Figure 1F, magenta). However, 
the clustered genes (Figure 1F, green) were enriched for development and 
maturation processes, muscle reorganization and lipid storage (Figure 1H). 
The fact that we observed downregulation of developmental genes as a 
response to the presence of aggregation-prone proteins is consistent with the 
aforementioned developmental delay observed in polyglutamine-expressing 
animals (Figure 1D), suggesting that aggregation-prone proteins can also affect 
animal development. In all, expression of aggregation-prone proteins alters the 
expression developmental genes, which slows down C. elegans development.
Discussion
Here we investigated the cellular responses that are elicited by the presence 
of aggregation-prone proteins using a C. elegans model of polyglutamine 
diseases. We used differential gene expression analysis to demonstrate that 
the presence of aggregation-prone proteins – in the form of polyglutamine 
expansion proteins – triggers the expression of ER-associated UPR genes. 
This observation is unexpected since polyglutamine expansion proteins 
do not usually enter the secretory pathway. We speculate that this cellular 
stress response is activated in an attempt to reduce overall protein synthesis 
of misfolded polyglutamine expansion proteins and perhaps that of other 
polyglutamine-rich proteins – thereby explaining the downregulation of abu/
pqn genes – as has been suggested by others [18]. 
The presence of polyglutamine expansion proteins is thought to induce the 
heat shock response (HSR), a cellular stress response that relies on molecular 
chaperones to prevent protein misfolding and aggregation [20, 21]. We did not, 
however, detect any differential expression of genes associated with the HSR. 
One possibility is that the animals in our experiment have undergone adaptive 
evolution, whereby over successive generations of growth in laboratory 
conditions the animals have developed the ability to cope with the constitutive 
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expression of polyglutamine expansion proteins, while maintaining the 
aggregation-associated phenotypes. Such adaptive evolution has for example 
occurred in the wild type strain N2, which after continuous maintenance 
in laboratory conditions has developed “laboratory-derived” alleles as an 
adaptation process ([22, 23] also reviewed in [24]). 
The fact that we saw upregulation of several genes involved in the innate 
immune response suggests that polyglutamine expansion proteins also affect 
immune response signaling pathways. The induction of a defense response has 
not been previously described in polyglutamine diseases. We propose that the 
presence of polyglutamine expansion proteins is perceived by the worms as 
an infection, thereby triggering the innate immune system. This was recently 
shown to be the case for the aggregation-prone proteins TDP-43 and FUS, which 
induce immune responses in C. elegans models of amyotrophic lateral sclerosis 
[25]. It is of interest to note that the UPR is also part of the cellular defense 
in C. elegans and is activated upon pathogen infection, further supporting the 
notion that polyglutamine expansion proteins induce effects in the organism 
similar to those induced by pathogens [26-28].
Our findings relating to the induction of cellular stress pathways are not entirely 
without precedent. Oxidative stress originates from the imbalance between the 
production and clearance of reactive oxygen species (ROS) and has been linked 
to Huntington’s disease [29, 30]. Here we identified several genes with redox 
functions, which points to another cellular stress response activated in the 
presence of polyglutamine expansion proteins. The fact that we observed the 
involvement of the UPR, the immune response and oxidative stress pathways 
suggests that aggregation-prone proteins have a systemic effect in the 
organism. It will be interesting to further address how these cellular pathways 
are functionally affected in mammalian neuronal cell or animal models and 
determine whether these pathways mediate neurodegeneration induced by 
polyglutamine expansion proteins in these systems.
Finally, we found larval development to be significantly affected in 
polyglutamine-expressing animals. Others have reported that expression of 
aggregation-prone proteins slows down the growth rate of yeast [18] and delays 
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development in another C. elegans model expressing polyglutamine expansion 
proteins in the body wall muscle cells [21]. Collectively, these findings point 
towards the tentative notion of a delay in organismal development as a result of 
cell non-autonomous signaling across tissues that is provoked by the presence 
of aggregation-prone proteins. 
In conclusion, we propose that the presence of aggregation-prone proteins 
activates a cellular stress response that – combined with a delay in development 
– may impose a fitness cost in this model. 
Methods
Strains and genetics
Standard methods were used for culturing C. elegans at 20ºC [31]. To 
synchronize animals, eggs were collected from gravid hermaphrodites by 
hypochlorite bleaching and hatched overnight in M9 buffer. The desired 
number of L1 animals were subsequently cultured on agar plates (#633185, 
Greiner Bio-One) containing nematode growth medium and seeded with OP50 
bacteria. The following strains were used or generated: N2 (wild type): AM141 
rmIs133[P(unc-54)Q40::YFP]X [6]; OW1004 rmIs133[P(unc-54)Q40::YFP]X; and 
OW1021 rmIs133[P(unc-54)Q40::YFP]X.
RNA sequencing
Worms were grown to larval stages two/three (L2/3) and four (L4) and total 
RNA was extracted using TRIzol Reagent (Life Technologies) according to the 
manufacturer’s instructions. For polyA RNA sequencing, sequencing libraries 
were prepared using the TruSeq Sample Preparation V2 Kit (Illumina) and 
subjected to high-throughput single-end sequencing (50 bp) in an Illumina 
HiSeq 2500 instrument.
Data analysis
Single-end reads obtained by Illumina sequencing were aligned to the 
C. elegans reference genome (Wormbase, version WB235) using Star Aligner [32]. 
Raw read counts were extracted from the alignments using the HTSeq package. 
The reads were fragment per million (FPM) normalized, log transformed and 
null averaged prior to Principal Component Analysis (PCA). Average clustering 
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was performed using Pearson correlation for the corrected RNA samples 
and complete clustering was performed with euclidean distances for the 
read distance, this was plotted with the heatmap2 function in R. Differential 
expression analysis was performed on the corrected raw reads using EdgeR 
[33], and gene ontology enrichment analysis was performed using the web-
based toolset gProfiler [34, 35].
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Supplemental  Information
Table S1. Top 100 genes upregulated in polyglutamine-expressing animals at the L4 stage 
(blue data points from Figure 1F).
Sequence name Gene False dicovery rate (FDR) Fold change
F01D4.8 4,90E-28 5,33
W02H5.6 srh-271 1,16E-24 6,41
C32C4.7 ugt-35 3,06E-22 9,80
F02C12.5 cyp-13B1 1,14E-21 5,75
Y9C9A.16 6,40E-20 5,80
C33H5.1 9,09E-19 8,87
B0303.14 9,23E-19 3,31
T02B11.4 8,19E-18 2,76
F10B5.3 4,24E-17 4,37
K03H6.2 4,24E-17 3,26
F15B9.1 far-3 4,19E-15 5,26
K09D9.9 4,77E-15 8,34
C52A10.2 1,16E-14 4,33
F49C12.2 2,60E-14 8,37
K08C7.5 fmo-2 3,08E-14 5,38
F26A1.8 3,15E-14 5,20
H22D14.1 nhr-267 7,95E-14 5,73
ZC373.7 col-176 1,29E-13 6,58
D2023.7 col-158 1,63E-13 5,45
F27C8.4 spp-18 4,80E-13 2,73
F49C12.4 5,03E-13 8,81
B0213.6 nlp-31 5,62E-13 2,73
C02A12.1 gst-33 6,50E-13 3,15
F25D1.5 8,49E-13 2,86
Y51A2D.5 hmit-1.2 1,16E-12 2,09
K07C6.4 cyp-35B1 1,31E-12 4,36
Y80D3A.7 ptr-22 3,43E-12 4,98
C33H5.2 4,67E-12 7,73
F48C1.9 4,68E-12 7,44
B0238.12 5,37E-12 2,99
Y38E10A.15 nspe-7 6,50E-12 3,85
K11G9.6 mtl-1 6,99E-12 8,32
Y45F10D.15 9,69E-12 7,29
F53A9.8 1,03E-11 2,66
C50B6.7 1,49E-11 2,12
B0238.1 1,56E-11 3,10
Y48E1B.10 gst-20 1,75E-11 2,85
T03F7.3 srh-46 1,81E-11 6,20
Y71G12B.6 1,86E-11 2,40
M162.5 1,97E-11 2,24
Y54G2A.37 3,26E-11 3,47
D1086.3 4,20E-11 3,58
F49C12.5 4,99E-11 7,28
T27D12.6 5,28E-11 4,83
F14A5.1 nhr-264 6,08E-11 5,49
B0511.1 fkb-7 8,99E-11 3,38
W06H12.1 ztf-6 1,09E-10 2,26
H41C03.1 1,15E-10 3,08
E02H1.7 nhr-19 1,65E-10 2,17
ZK1067.6 sym-2 2,49E-10 2,49
C40D2.1 math-19 3,32E-10 4,27
T22A3.8 lam-3 3,71E-10 2,48
K07C6.3 cyp-35B2 3,78E-10 6,92
M7.3 bcc-1 3,85E-10 2,28
F09C8.1 3,88E-10 3,29
F54F3.3 lipl-1 4,26E-10 3,17
Y49E10.18 4,87E-10 1,78
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Y67A10A.1 oac-56 5,07E-10 5,14
R151.5 dpy-31 5,74E-10 1,80
Y68A4B.1 clec-243 5,80E-10 4,76
T14B4.5 6,80E-10 2,97
R04D3.1 cyp-14A4 7,11E-10 3,24
C35A5.2 ugt-33 8,49E-10 4,19
F59A7.2 1,15E-09 2,37
C06A6.5 1,65E-09 2,31
T03F7.2 srh-45 2,11E-09 5,76
B0238.13 2,30E-09 3,37
R57.2 2,65E-09 3,56
F25D1.3 3,03E-09 4,53
F15B9.2 far-4 3,05E-09 6,33
H14E04.1 3,99E-09 3,35
ZK596.1 4,22E-09 1,85
F39E9.2 btb-16 4,83E-09 2,18
C33C12.3 gba-1 4,98E-09 2,39
F19H8.4 mltn-9 5,04E-09 3,61
C16C4.15 math-10 5,64E-09 4,83
C18D11.6 6,32E-09 7,05
C44B7.7 6,79E-09 1,62
Y57E12B.3 lipl-6 7,99E-09 3,46
F27D9.6 dhs-29 1,03E-08 2,03
Y110A2AL.9 1,27E-08 2,82
F11E6.4 1,68E-08 3,23
W04C9.3 cutl-13 1,91E-08 3,91
F44G3.2 2,10E-08 3,61
F59B10.5 2,21E-08 2,78
F59B10.1 pqn-47 2,21E-08 2,80
R09E10.7 pqn-55 2,28E-08 1,91
K12G11.3 sodh-1 2,41E-08 2,82
T17A3.7 fbxb-84 2,41E-08 6,83
C03G6.14 cyp-35A1 2,46E-08 3,87
F11E6.9 2,66E-08 3,76
Y39A3B.7 2,66E-08 7,09
F54D8.1 dpy-17 2,67E-08 3,68
AC3.5 3,23E-08 2,21
M88.6 pan-1 3,54E-08 2,22
C33A12.6 ugt-21 3,60E-08 2,55
C04F6.5 dhs-27 3,72E-08 2,51
C05E4.14 srh-2 3,75E-08 3,32
Y22D7AL.9 4,35E-08 2,25
K01A2.2 far-7 4,50E-08 1,96
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Table S2. Top 100 genes downregulated in polyglutamine-expressing animals at the L4 stage 
(blue data points from Figure 1F).
Sequence Name Gene False discovery rate (FDR) Fold change
F22F4.4 2,89E-87 -10,36
T09F5.9 clec-47 3,55E-73 -6,09
C30G12.2 6,85E-33 -4,66
F52F10.4 oac-32 1,03E-25 -4,18
F45D11.15 1,41E-21 -6,41
F45D11.14 2,76E-20 -5,64
F22F4.1 7,22E-20 -7,00
F45D11.16 2,32E-19 -5,78
C06G8.1 swt-3 9,43E-17 -2,57
R17.3 5,28E-14 -2,57
K02E2.8 3,62E-13 -4,82
T04C9.4 mlp-1 1,37E-12 -1,70
C04G6.2 2,29E-12 -5,43
Y26D4A.2 hpo-2 3,21E-12 -5,66
ZC581.3 3,99E-12 -2,12
T19A6.4 7,75E-12 -2,68
C41H7.7 clec-3 7,82E-12 -2,96
C18H9.5 7,95E-12 -4,05
T21E8.1 pgp-6 8,63E-12 -2,60
E01G4.3 8,70E-12 -1,70
H32K16.2 4,02E-11 -3,53
T02B11.3 5,28E-11 -1,54
C31C9.7 6,31E-11 -2,07
C35D10.14 clec-5 1,13E-10 -2,55
F23F1.6 1,35E-10 -3,15
W09G10.6 clec-125 1,89E-10 -3,78
R11D1.3 2,05E-10 -3,31
W10G11.3 2,23E-10 -4,74
F07C6.3 2,87E-10 -2,60
K02E11.7 3,88E-10 -2,95
F17C11.5 clec-221 3,88E-10 -3,27
H06H21.8 1,50E-09 -1,67
C29F3.5 clec-230 1,56E-09 -4,35
T07F10.1 7,22E-09 -1,97
C05D9.3 8,65E-09 -1,38
K01C8.3 tdc-1 2,12E-08 -1,65
C10H11.6 ugt-26 2,66E-08 -1,89
K02E2.2 grd-11 3,32E-08 -3,75
C23G10.6 5,55E-08 -2,23
D1025.2 gcsh-1 5,87E-08 -2,07
C12D5.9 7,17E-08 -2,42
Y43F8C.1 nlp-25 8,13E-08 -3,41
K09E2.3 8,69E-08 -1,24
C05E7.2 1,55E-07 -3,01
C28A5.3 nex-3 3,46E-07 -1,67
T14G12.3 tag-18 7,57E-07 -1,18
F14H8.1 obr-2 7,86E-07 -1,29
F56F3.2 ndg-4 8,43E-07 -1,25
C41G11.1 9,56E-07 -2,32
T13F3.6 9,62E-07 -3,11
K11G9.3 1,10E-06 -2,55
R07E3.4 1,10E-06 -1,44
F02D8.4 1,20E-06 -2,07
Y27F2A.3 sri-40 1,21E-06 -2,97
C04C11.1 1,50E-06 -2,79
F23A7.8 1,60E-06 -1,44
T22B7.3 1,70E-06 -2,74
AC7.1 tkr-3 1,97E-06 -2,44
H02K04.1 clec-229 2,98E-06 -4,05
ZK550.2 3,07E-06 -2,43
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Y39G10AR.6 ugt-31 3,13E-06 -1,91
T10B9.1 cyp-13A4 3,39E-06 -2,18
K05B2.3 ifa-4 3,45E-06 -1,47
F54B11.11 4,12E-06 -2,89
T09B9.1 5,15E-06 -2,64
Y38E10A.5 clec-4 5,37E-06 -2,29
C05E11.4 amt-1 5,58E-06 -3,77
T21E8.2 pgp-7 5,80E-06 -2,11
C05A9.1 pgp-5 7,05E-06 -2,02
F43C11.3 decr-1.1 7,05E-06 -4,01
C15F1.1 7,21E-06 -1,96
C01G6.9 8,34E-06 -2,34
Y67D8C.8 cpg-9 1,17E-05 -1,19
ZC266.1 1,25E-05 -2,20
R04B5.9 ugt-47 1,33E-05 -1,09
R09H10.7 1,65E-05 -1,80
C42D4.3 1,73E-05 -2,60
R09F10.7 pqn-57 1,82E-05 -3,15
T05B11.4 1,83E-05 -1,98
F09G8.5 1,92E-05 -1,71
F56D1.6 cex-1 1,96E-05 -1,86
T18H9.1 grd-6 2,07E-05 -2,63
AC3.4 pqn-2 2,22E-05 -2,70
C36B1.1 cle-1 2,96E-05 -0,98
D2096.4 sqv-1 3,18E-05 -1,11
T22B11.1 3,22E-05 -1,86
F07C3.7 aat-2 3,61E-05 -1,25
F38E11.1 hsp-12.3 3,73E-05 -1,90
T06E4.8 3,99E-05 -2,78
K07A1.13 4,07E-05 -1,62
T15B7.1 4,24E-05 -1,15
R05F9.5 gst-9 4,29E-05 -1,54
AC3.3 abu-1 4,35E-05 -2,66
ZC416.6 4,91E-05 -1,36
F53G12.5 mex-3 5,27E-05 -1,31
C11E4.1 gpx-5 5,87E-05 -1,50
C42C1.7 oac-59 6,35E-05 -1,70
H02I12.6 his-66 6,35E-05 -1,73
F15H10.2 col-13 6,46E-05 -2,38
C03A7.7 abu-6 7,17E-05 -2,35
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Abstract
Neurodegenerative disorders such as Parkinson’s, Alzheimer’s and polyglutamine 
diseases are commonly characterized by the presence of protein aggregates 
in specific neurons. How the formation of these proteinaceous inclusions 
occurs is still not fully understood, nor is their role in pathogenesis. A positive 
regulator of aggregate formation has been discovered in C. elegans models 
for aggregation of alpha-synuclein, amyloid-beta and polyglutamine. This 
protein, known as modifier of aggregation MOAG-4, has two human orthologs, 
SERF1A and SERF2, which drive polyglutamine aggregation in human cells. 
This suggests that SERF may drive disease-associated protein aggregation in 
the mammalian brain. To test this hypothesis, we generated a Serf2 knockout 
mouse model in a C57BL/6 background. We found that the homozygous null 
allele is not inherited in Mendelian proportion, but some individuals are able 
to survive until adulthood. Our results suggest that full body knockout of Serf2 
is embryonic lethal with incomplete penetrance. Since such mice will be of 
limited use to study the function of Serf2 in adult mice, we generated mice 
harboring a brain-specific knockout for Serf2. We report that the ablation of 
Serf2 expression from the brain resulted in viable and fertile animals.
We conclude that Serf2 is required for normal mouse development. Mice 
harboring the Serf2 conditional knockout allele can now be used to study the 
biological function of Serf2 in mouse development. Additionally, by mating 
these brain-specific knockout mice with mouse models of neurodegenerative 
diseases, we can also investigate whether Serf2 is indeed a genetic modifier of 
protein aggregation.
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Introduction
While protein aggregation and toxicity are hallmarks of neurodegenerative 
diseases such as Parkinson’s (PD), Alzheimer’s (AD) and polyglutamine 
diseases, their role in these diseases is currently unknown (reviewed in 
[1, 2]). To better understand the role of protein aggregation in disease, 
efforts have been made to identify genes and pathways that regulate 
protein aggregation. The identification of such genes has been aided by 
genetic screens in Caernorhabditis elegans models expressing aggregation-
prone proteins, including alpha-synuclein, amyloid-beta and polyglutamine 
[3-10]. The function of the genetic modifiers identified in these screens has 
been shown to be conserved in human cell models and in mice [5, 11, 12].
In C. elegans models for PD, AD and polyglutamine diseases, we previously 
identified MOAG-4/SERF as a regulator of age-related proteotoxicity [5]. We 
showed that MOAG-4 promotes polyglutamine aggregation and toxicity and 
that its function is evolutionarily conserved in the mammalian orthologues 
SERF1A and SERF2 (small EDRK rich factor 1A and 2) [5]. In human cell models 
expressing polyglutamine, overexpression of MOAG-4/SERF enhanced 
aggregation and cell death [5]. 
The molecular function of the SERF proteins is unknown. These proteins are 
ubiquitously expressed and are therefore predicted to have a role in general 
cellular pathways. SERF1A was first identified in a comparative genomics 
study, where it was found to be a genetic modifier of spinal muscular atrophy 
in human patients [13]. A transcriptome analysis later revealed that SERF1A is 
downregulated in the cerebellum of HD patients [14]. Recently, SERF1A was 
shown to promote amyloid aggregation in vitro [15].
Here we aimed to test the hypothesis that SERF2 drives disease-associated 
protein aggregation in the mammalian brain. To this end, we generated Serf2 
homozygous null mutant mice. By intercrossing Serf2+/- mice, we discovered that 
the segregation of the knockout allele did not follow Mendelian inheritance, 
suggesting that the targeted disruption of Serf2 has fundamental implications 
for mouse development. To overcome this limitation, we generated brain-
Chapter VI
136
specific Serf2 knockout mice that are viable and fertile. We further investigated 
the distribution of Serf2 expression and found that Serf2 is transcribed in various 
tissues, namely brain, heart, intestine, kidney and liver.
Results and Discussion
Deletion of Serf2 results in embryonic lethality with incomplete 
penetrance
To study the function of Serf2, we generated a mouse strain with an integrated 
promoter-driven selection cassette (Figure 1A) [16]. Serf2 has 3 exons and 
spans about 4 kb in chromosome 2. Two loxP sites were inserted around exon 
2 of the Serf2 gene and its expression was prevented by the presence of an 
intronic Neo selection cassette that was surrounded by two loxP sites and two 
FRT sites (Figure 1A). Hprt Cre-induced recombination excised the Neo gene 
and exon 2 of Serf2, thereby generating a heterozygous reporter knockout for 
Serf2, with the lacZ reporter transgene under the control of the Serf2 promoter 
(Serf2+/-, Figure 1A, B).
We next attempted to generate Serf2 null mice (Serf2-/-) by intercrossing Serf2+/- 
mice. The numbers of Serf2-/- progeny obtained were far lower than those 
Figure 1. Gene targeting strategy for the Serf2 knockout model. (A) Diagram of the Serf2 targeting 
vector. The Serf2 exon 2 is flanked by two loxP sites. Expression is prevented by an intronic Neo selection 
cassette surrounded by two loxP sites and two FRT sites. Mating with a Hprt Cre deleter mouse strain removes 
exon 2, resulting in a reporter knockout whereby the lacZ transgene is expressed under the control of the 
Serf2 promoter. Diagram adapted from [16]. (B) Genotype of wild type, heterozygous and knockout Serf2 
transgenic mice. Primers F3 and R3 were used to distinguish the targeted allele (420 bp) from the untargeted 
wild type allele (335 bp), identified with primers F4 and R3. (C) Numbers of mice obtained for each genotype 
from intercrossing Serf2+/- mice or by mating Serf2+/- mice with Serf2-/- mice. Numbers in parentheses represent 
the expected Mendelian ratio for each genotype.
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expected according to Mendelian inheritance and only a small proportion was 
able to survive throughout adulthood, suggesting embryonic lethality with 
incomplete penetrance (Figure 1B, C). When we attempted to mate Serf2+/- mice 
with Serf2-/- mice, Serf2-/- offspring of this cross were also underrepresented 
(Figure 1C). Together, these results demonstrate that Serf2 is essential for mouse 
development.
Serf2 is expressed in disease-related brain areas
To understand the role of Serf2, we next wanted to identify the tissues in 
which Serf2 is normally expressed in Serf2+/+ and Serf2+/- mice. To do so, primers 
specific for Serf2 were used to investigate its expression in the brain, heart, 
intestine, kidney, liver and pancreas by qPCR (Figure 2A). Serf2 was expressed 
in most the tissues examined in this study. mRNA expression in Serf2+/- mice 
Figure 2. Expression of Serf2 in different tissues. (A) Expression of Serf2 in tissues of 3-month-old mice. 
Relative mRNA levels were measured by qPCR in wild type (n=3), heterozygous (n=8) and knockout mice 
(n=1) for Serf2. (B) Protein expression of Serf2 in liver samples obtained from wild type, heterozygous and 
knockout mice by Western blot. (C) Protein expression of Serf2 in the cerebellum (Cer) and hippocampus 
(Hip) of wild type and heterozygous mice by Western blot. In both experiments, actin was used as a loading 
control. (D) Expression of Serf1 in different brain regions of wild type mice (n=5) and mice heterozygous 
for the Serf2 knockout allele (n=5). (E) Expression of Serf2 in different brain regions of wild type mice (n=5) 
and mice heterozygous for the Serf2 knockout allele (n=5). Relative mRNA levels were measured in the 
olfactory bulb, hippocampus, striatum, cortex, cerebellum and brainstem. **** p<0.0001; *** p<0.001; ns is 
not significant.
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was significantly lower (up to 50%) than that in control mice (Figure 2A).  This 
was later confirmed by measuring Serf2 protein levels in the brain and liver 
(Figure 2B, C).
Knowing that Serf2 was expressed in the brain and aiming to use this model to 
later generate a Serf2 knockout in a neurodegenerative disease background, 
we asked in which brain areas Serf2 was expressed. We found that Serf2 was 
expressed in different brain regions, including the brainstem, the olfactory 
bulb, the cerebellum, the striatum and, importantly, the hippocampus and 
the cortex, which are frequently affected in neurodegenerative diseases 
(Figure 2E). We examined 3 and 6-month old mice and confirmed that Serf2+/- 
mice had reduced expression of Serf2 while Serf1a expression was unaltered 
(Figure 2D, E). A reduction in expression of Serf2 was not compensated by the 
expression of Serf1a, supporting the use of this model to study Serf2 function. 
Our findings show that Serf2 is expressed in different tissues, including the 
brain. Specifically, Serf2 is expressed in brain areas relevant to disease and loss 
of Serf2 does not affect Serf1a expression.
Mice with brain-specific knockout for Serf2 are viable and fertile
Since the full body knockout of Serf2 resulted in embryonic lethality, we 
could not take advantage of these mice to study the role of Serf2 in protein 
aggregation in the brain. To overcome this limitation, we specifically eliminated 
Serf2 expression in the brain. First, mice harboring the Serf2 construct 
were crossed with FLP deleter mice to generate a conditional Serf2 allele 
(Serf2flox/flox, Figure 3A). Serf2flox/flox mice express the transgene as wild type 
and have normal appearance (data not shown). To specifically eliminate Serf2 
expression in the brain, Serf2flox/flox mice were mated with mice that express 
the Cre recombinase under the control of the Sox1 promoter, which restricts 
expression of Cre to the central nervous system (Figure 3A). Conditional 
knockout mice (Cre Sox1+ Serf2-/-) derived from this cross were viable and fertile 
(Esther Stroo, personal communication). To demonstrate that Serf2 expression 
was eliminated only in the brain, we measured expression levels of Serf2 in the 
brain and compared them with those in other tissues, including the kidney 
and the liver. When compared with expression in Serf2flox/flox control mice, 
expression of Serf2 in Cre Sox1+ Serf2-/- mice was almost completely abolished 
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in the brain but unaltered in the kidney and liver (Figure 3C). Together, these 
results demonstrate the successful knockout of Serf2 in the brain without its 
expression in other tissues being affected.
To investigate whether the knockout of Serf2 affected Serf1a expression, we also 
measured Serf1a in the brain. We detected a statistically significant increase of 
Serf1a in the brain of Cre Sox1+ Serf2-/- mice, which suggests a compensation 
mechanism by Serf1a in the absence of Serf2 (Figure 3B).
Figure 3. Gene targeting strategy for the brain-specific knockout of Serf2. (A) To generate a conditional 
allele for Serf2, mice harboring the Serf2 targeting vector were mated with a FLP deleter line to excise the lacZ 
transgene and the Neo selection cassette. This resulted in a floxed Serf2 allele (Serf2flox/flox), in which Serf2 is 
expressed as the wild type. Next, Serf2flox/flox mice were mated with Sox1 Cre deleter mice to generate Cre Sox1+ 
Serf2-/- progeny. Diagram adapted from [16]. (B) Quantitative PCR of Serf1 in the brain (n=4), the liver (n=2) 
and the kidney (n=2) of Serf2flox/flox and Cre Sox1+ Serf2-/- mice (5 months old). (C) Quantitative PCR of Serf2 in 
the brain (n=4), the liver (n=2) and the kidney (n=2) of Serf2flox/flox and Cre Sox1+ Serf2-/- mice (5 months old). 
*** p<0.001; ns is not significant.
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Conclusion
In summary, Serf2 is essential for mouse development. We describe the 
generation of brain-specific Serf2 knockout mice that can be used not only to 
further study the role of Serf2 in mouse development but also to determine 
Serf2 involvement in proteotoxicity by mating these knockout mice with mouse 
models of neurodegenerative diseases.
Methods
Expression construct and generation of transgenic mice
The Serf2 targeting vector was generated by the International Knockout Mouse 
Consortium (IKMC, Figure 1A) [16, 17]. Briefly, the exon 2 of Serf2 is flanked by 
two loxP sites its expression is prevented by an intronic Neo selection cassette, 
which is flanked by two loxP sites and two FRT sites. The construct was injected 
into C57BL/6N embryonic stem cells [18]. Two founder lines (B11 and G9) 
were positive for the construct and subsequently expanded for this study. To 
generate a full body knockout of Serf2, both lines were crossed with a Hprt Cre 
deleter mouse strain to remove the PGK-Neo cassette and Serf2 floxed exon. 
Confirmation of correct recombination was performed by PCR genotyping 
analysis of ear biopsy. All mice were heterozygous with respect to the construct. 
Animals were backcrossed into the C57Bl/6J background (Charles River) six 
times. 
Genotyping
DNA was prepared from ear biopsy and processed with prepGEM 
Tissue (#PTI0500, ZyGEM Corporation Ltd). PCR reactions contained 
three primers, one sense primer specific for the Serf2 transgene F3 
(5’-CCGGTCGCTACCATTACCAG-3’); a second sense primer specific for genomic 
Serf2 F4 (5’-GATGATGGGCTTTCTGCTGC-3’); and one antisense primer present 
in the transgene and mouse Serf2 R3 (5’-CTTGATATGTGAAGCCCCTGC-3’). The 
knockout allele was identified with pair F3 and R3, generating a 420 bp product; 
and the wild type allele was identified with pair F4 and R3, generating a 335 bp 
product. Cycling conditions were 2 min at 94ºC; 35 cycles of 30 sec at 94ºC; 30 
sec at 60ºC; 1 min at 72ºC; and 7 min at 72ºC.
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Quantitative PCR
Total RNA was extracted using TRIzol Reagent (Life Technologies) according 
to the manufacturer’s description. Total RNA quality and concentration were 
assessed using a NanoDrop 2000 spectrophotometer (Thermo Scientific/
Isogen Life Science). cDNA was made from 1.5 ug (tissues) or 2 ug (brain 
regions) total RNA with a RevertAid H Minus First Strand cDNA Synthesis kit 
(Life Technologies) using random hexamer primers. 
Quantitative real-time PCR was performed using a Roche LightCycler 
480 Instrument II (Roche Diagnostics) with SYBR green dye (Bio-Rad 
Laboratories) to detect DNA amplification. Relative transcript levels 
were quantitated using a standard curve of pooled cDNA solutions. 
Expression levels were normalized to 18S mRNA levels. The primers for 
RT-PCR used were Serf1 F2 (5’-TGGCCCGTGGAAATCAAAGAGAAA-3’); 
Serf1 R2 (5’-TGCATGATCTCTGAATCCCTCTGCT-3’); Serf2 F2 
(5’-CCGCGGTAACCAGCGAGAGC-3’); Serf2 R2 (5’-TCCGAGTCCCTCTGCTTGCG-3’); 
18S F1 (5’- CGGACAGGATTGACAGATTG-3’); 18S R1 
(5’-CAAATCGCTCCACCAACTAA-3’).
Western Blot
Frozen tissue was homogenized in RIPA buffer (10mM Tris-Cl pH 8.0; 1mM EDTA; 
0.5mM EGTA; 1% Triton X-100; 0.1% sodium deoxycholate; 0.1% SDS; 140mM 
NaCl). Samples were homogenized with a tissue grinder pestle and incubated 
on ice for 30 min, followed by centrifugation at high speed for 30 min at 4ºC. The 
supernatant was transferred to a new tube and protein was quantified using 
the Pierce BCA Protein Assay kit (#23225, Life Technologies). Approximately 130 
ug (cerebellum and hippocampus) or 40 ug (liver) of protein were loaded onto 
15% SDS-PAGE gels. Proteins were transferred to nitrocellulose membranes 
and blocked with 5% BSA in PBS-T. Membranes were incubated with primary 
antibodies for SERF2 at 1:1500 dilution overnight (#11691-1-AP, Proteintech) 
or actin at 1:10.000 dilution overnight (#3134S, Cell Signaling Technology). 
Washes were performed with PBS-T. Incubation with secondary anti-rabbit for 
SERF2 or anti-mouse for actin was done at 1:10.000 dilution for 1 hour at room 
temperature. Antibody binding was visualized with an ECL kit (Amersham). 
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Many neurodegenerative diseases are characterized by clinicopathological 
features that affect motor capacity and cognition in affected patients. Examples 
of such diseases are Alzheimer’s, Parkinson’s, polyglutamine diseases and 
amyotrophic lateral sclerosis (ALS). Unfortunately, no cure is currently available 
and the risk of developing these diseases increases with aging. Interestingly, 
a hallmark of post-mortem biopsies from the brains of affected patients is 
the presence of protein aggregates in neurons. While specific aggregation-
prone proteins have been identified for each neurodegenerative disease, their 
contribution to disease remains unresolved. More specifically, we do not know 
what triggers protein aggregation and how this is mechanistically linked to 
pathogenesis. What we do know is that protein homeostasis is affected in these 
diseases, and understanding how it is altered may help us not only to identify 
the cellular processes involved but also – in the long term – to target them for 
potential disease-modifying treatments.
The aim of the work presented in this thesis was to dissect the cellular and 
molecular aspects of protein aggregation, in order to find mechanisms that 
help to explain how protein homeostasis correlates with pathogenesis. A main 
goal was to discover genetic regulators of protein aggregation in an unbiased 
and hypothesis-free manner, with the expectation of identifying new regulators 
and therefore new mechanisms in protein aggregation.
We were successful in identifying one such new regulator in the form of 
MOAG-2/LIR-3. Chapter IV describes the identification and characterization 
of this modifier of aggregation in a C. elegans model of polyglutamine 
diseases. We discovered that MOAG-2/LIR-3 is an RNA Polymerase 
(Pol) III-associated transcriptional regulator that drives polyglutamine 
aggregation. In this chapter we propose a mechanism whereby aggregation-
prone proteins recruit normally functioning cellular proteins to promote 
their own aggregation. Despite this important finding, this study leaves 
several questions unanswered – these are discussed below, together 
with suggestions for directions of future research in the context of 
MOAG-2/LIR-3 and the link between the non-coding genome and protein 
aggregation.
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1. Aggregation-prone proteins affect the non-coding genome
One surprising finding from this work was that in our model the presence 
of polyglutamine expansion proteins induced the downregulation of small 
non-coding RNAs (ncRNAs) – specifically snRNAs, snoRNAs and tRNAs – 
demonstrating that the non-coding genome is also affected by the presence 
of aggregation-prone proteins. It is still unknown how this downregulation 
occurs and we propose two different possibilities that could explain this 
observation. The first possibility is that misfolded, aggregation-prone proteins 
directly sequester these small ncRNAs into aggregates, thereby reducing 
their abundance in the cell. The second possibility is that aggregation-prone 
proteins sequester MOAG-2/LIR-3, subsequently inhibiting it from driving small 
ncRNA transcription. To experimentally address these hypotheses, it would be 
necessary to isolate the polyglutamine aggregates and detect the presence of 
small ncRNAs (e.g. qPCR) or MOAG-2/LIR-3 (e.g. co-immunoprecipitation).
The next unresolved question is what biological consequences the 
downregulation of small ncRNAs might have. For example, the reduction of 
one type of small ncRNAs in the nucleus – the U1 snRNAs – affects the splicing 
of premature mRNA [1, 2]. In our case, however, downregulation of snRNAs did 
not affect the splicing of premature mRNA (data not shown). Our observations 
so far point to the notion that it is possible to retain functional splicing events 
despite lower levels of splicing factors. The downregulation of another type 
of small ncRNA – the tRNAs – may also have biological consequences, and it 
will be interesting to investigate how tRNA function is affected, if at all (e.g. is 
translation efficiency maintained? does the proteome change?).
Finally, it will also be worth assessing whether the downregulation of small 
ncRNAs is cell type-specific (e.g. do polyglutamine-expressing cells have a 
distinct ncRNA repertoire?) and whether altered ncRNA homeostasis is specific 
to polyglutamine expansion proteins or shared by other aggregation-prone 
proteins (e.g. alpha-synuclein, amyloid-beta).
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2. Is MOAG-2/LIR-3 related to calcium-regulated transcription 
factors?
Once we discovered that MOAG-2/LIR-3 was a transcription factor we were 
interested to know whether it shared homology with other mammalian 
transcription factors. Protein sequence comparisons revealed that 
MOAG-2/LIR-3 is predominantly conserved among the Caenorhabditis genus. It 
does, however, share 27% homology with the human calcineurin B homologous 
protein 1 (CHP1) and 37% homology with the human zinc finger protein 64 
(ZNF64). The presence of these two functional motifs – a calcium-binding 
domain and a zinc finger – is typical of human calcium-regulated transcription 
factors, such as the cAMP-responsive element-binding protein (CREB)-binding 
protein (CBP), the downstream regulatory element antagonist modulator 
(DREAM) and FOXO3A [3]. The combination of these two domains – calcium 
binding and DNA binding – poses the interesting possibility that MOAG-2/LIR-3 
may be a calcium-dependent transcription factor that regulates expression of 
small ncRNAs.
3. What are the proteins that interact with MOAG-2/LIR-3?
We can learn more about MOAG-2/LIR-3 function by identifying the types 
of proteins with which it interacts or forms complexes. We have shown that 
MOAG-2/LIR-3 binds to the same promoters as the RNA Pol III complex. We 
have also shown that inactivation of MOAG-2/LIR-3 reduces the levels of 
transcribed small ncRNAs, suggesting that MOAG-2/LIR-3 cooperates with 
the RNA Pol III complex to promote small ncRNA transcription. The question 
of whether MOAG-2/LIR-3 is physically part of the RNA Pol III complex could 
be answered by using purified MOAG-2/LIR-3 in co-immunoprecipitation 
experiments, followed by mass spectrometry. This approach would also enable 
us to identify other co-immunoprecipitated proteins and establish a protein 
interaction network for MOAG-2/LIR-3, which would tell us more about MOAG-
2/LIR-3 function and whether it cooperates with other co-factors to regulate 
the expression of small ncRNA genes.
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4. Could MOAG-2/LIR-3 be an RNA-binding protein?
The C2H2 zinc fingers of MOAG-2/LIR-3 are structurally homologous to the 
canonical C2H2 zinc fingers of the transcription factor IIIA (TFIIIA) in Xenopus 
laevis [4]. TFIIIA is a promoter-bound recruitment factor that recruits TFIIIB 
which, in turn, recruits Pol III to the promoters of genes encoding of 5S rRNA 
[5]. The binding of TFIIIA to the promoter takes place through physical binding 
of zinc fingers 4-9 to two specific regions: Box A and the intermediate element 
[6]. In addition to binding to 5S promoters, TFIIIA also binds to 5S RNA itself 
through zinc fingers 4-7 [7-9]. The fact that we found MOAG-2/LIR-3 to be 
frequently bound to 5S promoters suggests that it may also act as a recruitment 
factor, recruiting other components of the RNA Pol III complex to Box A and 
Box B. Furthermore, the resemblance of motifs within its structure to the zinc 
fingers of TFIIIA opens up the possibility that MOAG-2/LIR-3 might bind directly 
to rRNA or to any other type of RNA, a prospect that will have to be assessed in 
future studies. 
5. Do aggregation-prone proteins alter binding of MOAG-2/LIR-3 to 
its transcriptional targets?
We have shown that MOAG-2/LIR-3 binds to the promoters of snRNA, snoRNA 
and tRNA genes to promote their transcription. One open question stemming 
from this work is how the presence of aggregation-prone proteins modifies 
the binding of MOAG-2/LIR-3 to its transcriptional targets. We propose that 
polyglutamine sequesters MOAG-2/LIR-3 or modifies its localization, thereby 
preventing MOAG-2/LIR-3 binding to its DNA targets such that it can no 
longer transcribe small ncRNAs with the same efficiency as that in wild type 
animals. This could explain why we observe lower levels of small ncRNAs in 
the presence of aggregation-prone proteins. Indeed, it would be interesting 
to verify whether MOAG-2/LIR-3 can still retain its function as a transcriptional 
regulator in polyglutamine-expressing animals, a hypothesis which will require 
testing in additional ChIP seq experiments.
The identification and characterization of MOAG-2/LIR-3 in C. elegans offers 
a major contribution to our understanding of the aggregation pathway in 
neurodegenerative diseases, and in particular how benign cellular proteins 
can convert their function to an aggregation-promoting factor. A second major 
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step focused on the effects of protein aggregation at the transcriptional level. In 
Chapter V, we showed that the presence of polyglutamine-expansion proteins 
induced the expression of stress response genes involved in: 1) oxidative 
stress; 2) the ER-associated unfolded protein response (UPR); and 3) the innate 
immune response. Oxidative stress results from the imbalance between the 
production and clearance of reactive oxygen species (ROS), which can cause 
damage to DNA, proteins and other cellular components (reviewed in [10]). 
Our results come in line with previous published work implicating oxidative 
stress in Huntington’s disease [11, 12]. It would be interesting to further explore 
this correlation and determine what specific cellular events lead to oxidative 
stress (e.g. mitochondrial dysfunction? overproduction of ROS? insufficient 
antioxidant production?). 
If unfolded proteins accumulate in the ER, the UPR is responsible for restoring 
protein homeostasis by fine-tuning protein-folding load with protein-folding 
capacity (reviewed in [13]). Previous published work showed that the UPR 
contributes to neuroprotection in a C. elegans model expressing alpha-synuclein 
in the dopaminergic neurons [14]. Although polyglutamine expansion proteins 
are not expected to enter the secretory pathway, it is still reasonable to consider 
that their accumulation at the ER (perhaps immediately after protein synthesis) 
would be sufficient to trigger the UPR as protective response to aggregation-
prone proteins.
A surprising finding was the involvement of the innate immune response to 
polyglutamine expansion proteins. Several genes that encode antimicrobial 
peptides were upregulated in our study, suggesting that aggregation-prone 
proteins can also elicit a systemic effect in the organism. It is possible that 
aggregation-prone proteins are perceived by the organism as a pathogen 
and thereby elicit the immune system to counteract their toxicity. Indeed, 
the involvement of the cellular stress responses described here show that 
the organism takes advantage of distinct cellular defense mechanisms at its 
disposal to combat the pathogenic presence of aggregation-prone proteins. 
Following this line of thought, it would be interesting to investigate whether 
there is a cross talk between these cellular responses to aggregation-prone 
proteins.
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Lastly, we saw that the effects of aggregation-prone proteins go beyond cellular 
stress responses and can also delay C. elegans development. Polyglutamine 
diseases are not known to be associated with impaired development, therefore 
suggesting that the developmental delay observed in our polyglutamine 
model may be specific to nematodes.
A final major step in our understanding of protein aggregation is well under 
way as a result of our work with MOAG-4 and its mammalian orthologs, SERF1A 
and SERF2. Below we discuss the contributions made by our study on SERF2 
in the brains of mice (Chapter VI) and discuss plans for future experiments in 
mouse models of Alzheimer’s disease.
The aggregation-prone protein most commonly associated with Alzheimer’s 
disease (AD) is amyloid-beta (reviewed in [15, 16]). We and others have 
previously shown that aggregation of amyloid-beta is promoted both in vitro 
and in vivo by MOAG-4/SERF [17, 18]. In a C. elegans model of amyloid-beta, 
the transgene is expressed intracellularly in the body wall muscle, where it 
accumulates and contributes to progressive paralysis in the worm [19]. We 
have shown that deletion of MOAG-4 ameliorates this paralysis phenotype by 
reducing the amount of seeding-competent amyloid-beta [17]. In addition, 
our studies in human cell models have shown that the function of MOAG-4 is 
conserved in two mammalian orthologs, SERF1A and SERF2 [17]. This led us 
to hypothesize that SERF proteins could be driving amyloid-beta aggregation 
in the AD brain. To test this hypothesis, we generated a Serf2 knockout mouse 
and crossed it with an AD mouse model. In Chapter VI, we discovered that 
a full body knockout of Serf2 results in embryonic lethality with incomplete 
penetrance. Since this does not allow us to study the role of Serf2 in adult mice, 
we generated brain-specific Serf2 knockout mice instead. As a next step in this 
project, we plan to mate these animals with AD mouse models.
The aim of generating a brain-specific Serf2 knockout mouse in an AD 
background is to find out whether the function of MOAG-4/SERF in 
proteotoxicity is conserved from C. elegans to mammals. Specifically, we want to 
know whether removing SERF from the brain in AD mouse models suppresses 
amyloid aggregation and neurotoxicity. We also want to find out whether 
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changes in proteotoxicity are accompanied by changes in motor and cognitive 
functions. The experimental design is depicted in Figure 1. Brain-specific Serf2 
knockout mice – Sox1 Cre+ Serf2-/- – will be mated with two distinct AD mouse 
models. The first strategy involves mating the Sox1 Cre+ Serf2-/- mice with the 
APPPS1 mouse model [20]. In this model, the human amyloid precursor protein 
(APP) harboring the K595N/M596L “Swedish” mutation (otherwise known as 
K670N/M671L) and the human presenelin 1 (PS1) protein harboring the L166P 
mutation are co-expressed under the Thy1 promoter, which directs transgene 
expression to the postnatal brain [20]. Both mutations are associated with early 
onset AD in humans. In this model, amyloid-beta deposition is seen as early as 
six weeks of age, with cognitive impairment appearing at 7 months of age [20, 
21]. From the mating between the Sox1 Cre+ Serf2-/- mice and the APPPS1 mice, 
we expect to obtain progeny in Mendelian proportions with the following 
characteristics: 1) wild type for all transgenes; 2) transgenic for APPPS1; 3) wild 
type lacking SERF2 in the brain; and 4) transgenic for APPPS1 and lacking SERF2 
in the brain (Figure 1). Here, we will focus predominantly on brain histology 
and immunohistochemistry to study the effect of a lack of Serf2 in the brain on 
amyloid-beta deposition (Figure 1).
In the second strategy, we will mate Sox1 Cre+ Serf2-/- mice with the APPswe/
PSEN1dE9 mouse model, from which we also expect to obtain all four desired 
phenotypes in Mendelian proportions (Figure 1) [22]. In this model of AD, a 
chimera of mouse and human APP harboring the K595N/M596L “Swedish” 
mutation (APPswe) is co-expressed with the exon-9-deleted (delta E9) variant 
of human mutated PS1 protein (PSEN1dE9), the latter also associated with early 
onset AD [22]. The expression of both transgenes is under the mouse prion 
promoter, which restricts their expression to the neurons of the central nervous 
system [22]. In APPswe/PSEN1dE9 mice, amyloid-beta plaques typically appear 
at 4-6 months of age, and  plaque accumulation progresses up to 12 months 
of age, when cognitive deficits also start to appear [23, 24]. We will subject 
these mice to a battery of behavioral tests to assess spatial memory reference 
(e.g. Morris water maze), exploration and anxiety (e.g. open field) and motor 
capacity (e.g. grip strength) (Figure 1). In parallel, we will perform histological 
and immunohistochemical assays to assess amyloid deposition and neuronal 
toxicity. Since AD is a progressive disorder, we want to learn how aggregation 
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formation, neurotoxicity and cognition are affected during aging. For this 
reason, we will include both 3 to 4 and 6 to 7-month old animals in our analysis.
In all, we hope to uncover the function of Serf2 in the brain and determine 
whether it acts as a genetic modifier of proteotoxicity and cognition in AD. 
Results from these studies will provide insight into how the brain copes with 
protein aggregation during aging and whether this is accompanied by changes 
in behavior. Ultimately, this study may reveal Serf2 to be a potential therapeutic 
target for modulation of neurodegeneration.
Figure 1. Diagram representing the generation of a brain-specific Serf2 knockout mouse (Sox1 Cre+ Serf2-/-) 
in two different AD mouse models. In the “APPPS1” strategy, the brain-specific Serf2 knockout mice will be 
mated with the APPPS1 mice and focus on histological and immunohistochemical analyses at both 1 and 
3 months of age. In the “APPswe/PSEN1dE9” strategy, the brain-specific Serf2 knockout mice will be mated 
with the APPswe/PSEN1dE9 mice. A set of behavioral tests will be performed parallel to histological and 
immunohistochemical analyses to 3 to 4 and 6 to 7-month old mice.
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Outlook
In this thesis, we have demonstrated that aggregation-prone proteins influence 
ncRNA homeostasis, thereby introducing the concept that aggregation-prone 
proteins have effects that go beyond protein homeostasis. This demonstrates 
that it may be worth examining how the non-coding genome is altered in 
neurodegenerative diseases. We have also identified a new aggregation-
promoting factor and hope to have uncovered yet another mechanism 
exemplifying how protein homeostasis can go awry during pathogenesis. 
Finally, we have provided a starting point for translational research, in which 
we intend to explore the possibility of a genetic modifier – discovered in 
C. elegans and conserved throughout evolution – being a potential therapeutic 
target for neurodegenerative diseases. 
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Aging-associated neurodegenerative diseases – including Alzheimer’s, 
Parkinson’s and polyglutamine diseases – are projected to be among the top 
four causes of burden of disease by 2030 (World Health Organization, 2006). 
This demands investment in biomedical research to find disease-modifying 
treatments and to improve quality of life in the long term.
One of the hallmarks of neurodegenerative diseases is the presence of protein 
aggregates in the brains of affected patients. At the cellular and molecular level, 
protein aggregation results from the disruption of protein homeostasis, which 
is essential to maintain the correct synthesis, folding, shuttling and clearance 
of proteins in the cell. One major hurdle in the field is that we do not know 
why protein aggregation occurs and how it correlates to pathogenesis. What 
we do know is that specific aggregation-prone proteins have been identified 
for the different neurodegenerative diseases, and genetic studies have enabled 
the identification of key mutations in their corresponding genes. Currently, 
efforts are being made at the genomic, transcriptomic and proteomic level 
to understand what drives protein aggregation and how it is mechanistically 
linked to disease.
In this thesis, my motivation was to understand what drives protein aggregation 
and toxicity. Specifically, my aim was to discover what cellular mechanisms occur 
as a reaction to the presence of an aggregation-prone protein in the cell. In 
Chapter II, we provide a comprehensive overview of different cellular strategies 
used to cope with aggregation-prone proteins. We show how small model 
organisms – including yeast, nematodes, and flies – can be valuable tools to 
identify the genes involved in protein aggregation and toxicity. Importantly, we 
show that many of these genes are conserved in mice, allowing more complex 
studies that can be potentially extrapolated to humans. We then introduce 
an emerging concept – namely the contribution of the non-coding genome 
to neurodegeneration – and describe the progress made in this field towards 
a better understanding of the mechanisms of disease. We demonstrate how 
recently published work has revealed the link between RNA metabolism and 
neurological and neurodegenerative diseases, and describe how microRNAs, 
tRNAs and other types of non-coding RNA are dysregulated in these diseases. 
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One unresolved issue is the lack of a mechanistic explanation for how impaired 
RNA metabolism determines pathogenesis.
In Chapter III, we highlight the model organism C. elegans as a versatile 
tool for for gene function studies. In particular, we focus on “humanized” 
models of C. elegans for neurodegenerative diseases – including Alzheimer’s, 
Parkinson’s and polyglutamine diseases – and describe how they can be 
used in forward genetic screens (with ethyl methane sulfate) and in reverse 
genetics (genome-wide RNAi screens). One aspect of these models worth 
mentioning is that protein aggregation can be uncoupled from protein 
toxicity. Next, we present a selection of genetic screens performed in 
C. elegans and show that the genetic modifiers of proteotoxicity identified 
in these screens are often involved in general cellular processes (e.g. protein 
quality control system, RNA metabolism, cell cycle), demonstrating that protein 
aggregation and toxicity can result from different levels of cellular dysregulation.
In line with this, Chapter IV describes our work that stemmed from a genetic 
screen performed in a C. elegans model for polyglutamine aggregation aimed 
at finding genes that promoted protein aggregation and toxicity. This led to 
the discovery of the novel genetic modifier of aggregation moag-2 (modifier 
of aggregation-2), a gene that when mutated suppresses protein aggregation 
up to 51%. Whole-genome sequencing revealed the causative gene of 
moag-2 to be lir-3. We found that moag-2/lir-3 encodes a protein with a 
predicted nuclear localization signal and two non-canonical zinc finger 
domains, which are homologous to those in the transcription factor for RNA 
Polymerase III A (TFIIIA). Indeed, our data revealed that MOAG-2/LIR-3 binds 
to the same genomic regions as does the RNA Polymerase III machinery in 
its regulation of the transcription of small non-coding RNAs, including small 
nuclear RNAs, small nucleolar RNAs and transfer RNAs. These small non-
coding RNAs are largely involved in the regulation of gene expression or in the 
modification of other RNA molecules. Once we had determined the function of 
MOAG-2/LIR-3, we were surprised to learn that MOAG-2/LIR-3 promotes 
polyglutamine aggregation in a manner that is independent of its function as 
a transcriptional regulator. We thereby propose a scenario where aggregation-
prone proteins can trigger a switch of function in cellular proteins and hijack 
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them to promote aggregation. Another unprecedented finding from this 
work is that the presence of polyglutamine expansion proteins induces the 
downregulation of snRNA, snoRNA and tRNA genes in wild type animals. 
Although we do not yet know the biological consequences of this observation, 
it suggests that aggregation-prone proteins can also affect the homeostasis of 
non-coding RNA.
In Chapter V, we explore the transcriptional changes that occur in the cell when it 
is exposed to aggregation-prone proteins. By performing whole-transcriptome 
profiling in a C. elegans model of polyglutamine diseases, we found that the 
expression of aggregation-prone proteins delays animal development and, at 
the same time, triggers genes involved in cellular stress responses. 
One important aspect of identifying modifiers of aggregation in small model 
organisms is their subsequent validation in human cells and mouse models. 
Previous work from our group identified MOAG-4/SERF as a positive regulator 
of proteotoxicity in C. elegans models of polyglutamine disease, Parkinson’s 
and Alzheimer’s disease. In Chapter VI, we describe the generation of a 
knockout mouse for SERF2, one of the human orthologs of MOAG-4. We found 
that eliminating Serf2 is not favorable for mouse development, as it frequently 
results in embryonic lethality. We then explain how this finding led us to 
generate a brain-specific Serf2 knockout mouse instead, which yielded viable 
and fertile animals. We further validate the potential use of these knockout 
mice by demonstrating that SERF2 was successfully eliminated from the brain 
without affecting its expression in other organs. Finally, we propose that these 
brain-specific Serf2 knockout mice be used to further study the role of SERF2 
as a modifier of aggregation in the brain by mating it with mouse models of 
neurodegenerative diseases (Chapter VII). 
In this thesis, we have identified a new genetic regulator of protein aggregation. 
The findings described here will improve not only the exploration of new 
mechanisms but also our understanding of the complex protein aggregation 
process. This work has also provided a starting point for transposing findings 
from small model organisms to mammalian systems, paving the way for 
translational research in the long term.
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Volgens voorspellingen van de World Health Organization dringen 
neurodegeneratieve ziekten, zoals de ziekten van Alzheimer en Parkinson, 
in 2030 door tot de top vier van de aandoeningen die de meeste ziektelast 
veroorzaken (World Health Organization, 2006). Biomedisch onderzoek naar 
aangrijpingspunten voor therapie en naar mogelijkheden om de kwaliteit van 
leven te verbeteren is daarom van groot belang. 
Een van de kenmerken van neurodegeneratieve ziekten is de aanwezigheid 
van eiwitaggregaten in de hersenen van getroffen patiënten. Op cellulair en 
moleculair niveau wordt eiwitaggregatie veroorzaakt door een verstoring 
van de eiwithomeostase in de cel, normaal een samenspel van controle op 
de synthese, de vouwing, het transport en de afbraak van eiwitten in de cel. 
Een belangrijk probleem in het veld is dat we niet weten wat eiwitaggregatie 
aandrijft of hoe het verband houdt met de pathogenese. Wat we wel weten is 
dat er bij de verschillende neurodegeneratieve ziekten, specifieke aggregatie-
gevoelige eiwitten een rol spelen en dat mutaties in hun overeenkomstige 
genen de oorzaak zijn van erfelijke varianten van deze ziekten. Momenteel 
wordt veel genetisch, celbiologisch en biochemisch onderzoek gedaan om te 
achterhalen wat de oorzaak is van de toxiciteit en aggregatie van deze ziekte-
eiwitten.  
Het doel van mijn proefschrift was om te begrijpen welke biologische 
processen eiwitaggregatie en toxiciteit aandrijven en welke cellulaire 
mechanismen optreden als reactie op de aanwezigheid van aggregerende 
eiwitten in de cel. In Hoofdstuk II, geven we een uitgebreid overzicht van 
de verschillende cellulaire strategieën die gebruikt worden om aggregatie-
gevoelige eiwitten aan te pakken. We laten zien hoe kleine modelorganismen 
– zoals gist, nematoden, en vliegen – waardevol kunnen zijn om genen te 
ontdekken die betrokken zijn bij eiwitaggregatie en de toxiciteit. We laten 
zien dat veel van deze genen evolutionair geconserveerd zijn in zoogdieren, 
wat betekent dat de vindingen potentieel kunnen worden geëxtrapoleerd 
naar mensen. Vervolgens introduceren we de bijdrage van het niet-coderende 
genoom aan neurodegeneratie en beschrijven recente inzichten op dit gebied. 
Wij beschrijven de relatie tussen RNA metabolisme en neurologische en 
neurodegeneratieve ziekten, en geven een overzicht van de betrokkenheid 
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van microRNAs, tRNA’s en andere vormen van niet-coderende RNA bij deze 
ziekten. Er is nog geen mechanistische verklaring voor hoe een verstoord RNA 
metabolisme bijdraagt aan de pathogenese.
In Hoofdstuk III, hebben we aandacht voor het modelorganisme C. elegans 
als een veelzijdig diermodel om de functie van genen te ontdekken. In het 
bijzonder richten we ons op “gehumaniseerde” C. elegans modellen voor 
neurodegeneratieve ziekten en hoe ze kunnen worden gebruikt in genetische 
screens. Interessant is dat in deze modellen eiwitaggregatie en toxiciteit 
losgekoppeld kunnen zijn. Vervolgens presenteren we een selectie van 
genetische screens die zijn uitgevoerd in C. elegans en die hebben aangetoond 
dat de genetische regulatoren van eiwitaggregatie en toxiciteit vaak betrokken 
zijn bij algemene cellulaire processen (bijvoorbeeld eiwithomeostase, RNA 
stofwisseling, celcyclus), waaruit blijkt dat eiwitaggregatie en toxiciteit kunnen 
voortvloeien uit verschillende niveaus van cellulaire ontregeling. 
Hoofdstuk IV beschrijft een vervolg op een genetische screen in een C. elegans 
model voor polyglutamine aggregatie: de identificatie van de genetische 
mutant moag-2 (modifier of aggregation-2) die eiwitaggregatie voor meer dan 
50% vermindert. Met behulp van genoom sequencing hebben we gevonden 
dat de mutatie in moag-2 ligt in het gen lir-3, waarvan de functie onbekend is. 
MOAG-2/LIR-3 lijkt te coderen voor een eiwit met een nucleair lokalisatiesignaal 
en twee zinkvinger domeinen die verwant zijn aan de zinkvinger domeinen 
in de transcriptiefactor voor RNA Polymerase IIIA (TFIIIA). Met behulp van een 
eiwit-DNA interactiestudie, vonden we dat MOAG-2/LIR-3 bindt aan dezelfde 
DNA sequenties als RNA Polymerase III en ook de transcriptie reguleert van 
kleine niet-coderende RNA’s, waaronder kleine nucleaire RNA’s (snRNAs), kleine 
nucleolaire RNAs (snoRNAs) en transfer RNAs (tRNAs). Deze kleine RNA’s zijn 
betrokken bij de regulatie van genexpressie of bij de bouw van andere RNA-
moleculen. We waren verrast dat MOAG-2/LIR-3 polyglutamine aggregatie 
aanstuurt op een manier die onafhankelijk is van zijn functie als regulator van 
transcriptie. Aggregatie-gevoelige ziekte-eiwitten lijken dus op twee manieren 
een schadelijk effect te kunnen hebben: ze inactiveren belangrijke cellulaire 
eiwitten en gebruiken deze om hun eigen aggregatie te versterken. Een andere 
verrassende ontdekking was dat de aanwezigheid van polyglutamine de 
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hoeveelheid snRNA, snoRNA en tRNA reduceerde in de worm. Hoewel we nog 
niet weten wat de biologische gevolgen hiervan zijn en of dit ook te maken 
heeft met moag-2/lir-3, suggereren de resultaten dat aggregatie-gevoelige 
eiwitten invloed hebben op de homeostase van niet-coderende RNAs.
In Hoofdstuk V verkennen we de transcriptionele veranderingen die optreden 
in C. elegans wanneer deze aggregerende eiwitten aanmaken. Met behulp van 
een transcriptoom analyse in een C. elegans model van polyglutamine ziekte, 
vonden we een effect op de expressie van genen die betrokken zijn bij groei 
en ontwikkeling en op genen die betrokken zijn bij cellulaire reactie op stress.
Om te bepalen of modifiers van aggregatie in kleine modelorganismen ook 
een rol spelen bij ziekten, is het belangrijk om eerst hun rol in menselijke 
cellen en zoogdiermodellen te onderzoeken. Eerder identificeerde we 
MOAG-4/SERF als positieve regulator van eiwitaggregatie en toxiciteit in 
C. elegans modellen voor polyglutamine, Parkinson en Alzheimer. Hoofdstuk 
VI beschrijft hoe we een knockout muis hebben gemaakt voor SERF2, één van 
de humane orthologen van MOAG-4. We vonden dat het uitschakelen van 
SERF2 niet gunstig is voor ontwikkeling van de muis, omdat het meestal leidt 
tot embryonale letaliteit. We leggen uit hoe we vervolgens een brein-specifieke 
SERF2 knockout muis hebben gemaakt die wel levensvatbaar en vruchtbaar is. 
We laten zien dat we SERF2 met succes uit de hersenen hebben gehaald, zonder 
dat de expressie in andere organen is aangetast. Ten slotte stellen wij voor 
dat deze hersenspecifieke SERF2 knockout muizen kunnen worden gebruikt 
voor het verder bestuderen van de rol van SERF2 als modifier van aggregatie 
in de hersenen door ze genetisch te combineren met muismodellen voor 
neurodegeneratieve ziekten (Hoofdstuk VII).
Met de identificatie van een nieuwe genetische regulator van eiwitaggregatie 
opent dit proefschrift mogelijkheden voor onderzoek naar mechanismen die 
eiwitaggregatie en toxiciteit in cellen kunnen verklaren. Bovendien biedt het 
met de generatie van een muismodel een uitgangspunt voor het vertalen van 
bevindingen in C. elegans naar zoogdierenmodellen voor neurodegeneratieve 
ziekten, om in de toekomst toe te werken naar translationeel onderzoek.
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A doença de Alzheimer, a doença de Parkinson e as doenças de expansão 
de poliglutaminas são doenças neurodegenerativas que se prevê virem 
a ser a quarta principal causa de custos de saúde em 2030 (World Health 
Organization, 2006). É, portanto, necessário investir na investigação biomédica 
destas patologias de forma a encontrar tratamentos que permitam melhorar a 
qualidade de vida a longo prazo. 
Uma característica diagnosticante das doenças neurodegenerativas é a 
presença de agregados proteicos no cérebro. Estas estruturas resultam de 
uma incapacidade, a nível celular e molecular, da manutenção da homeostase 
proteica, que decorre por sua vez de disfunções em vias envolvidas na síntese, 
folding, tráfego e degradação de todas as proteínas celulares. Ainda não se 
conhece a razão por que ocorre a agregação proteica observada, e de que 
modo é que esta última está relacionada com a patologia. São, no entanto, 
conhecidas, para determinadas doenças neurodegenerativas, as proteínas que 
têm predisposição para agregar (as chamadas aggregation-prone proteins) e, 
através de estudos genéticos, já foram identificadas mutações nos respectivos 
genes que determinam o desenvolvimento da patologia. Vários estudos 
realizados a nível genómico, transcriptómico e proteómico estão a ser efetuados 
no sentido de compreender os fatores envolvidos na agregação proteica e de 
que modo é que esta está mecanisticamente relacionada com a patologia.
O objectivo principal desta tese foi o estudo dos mecanismos que promovem 
a agregação e toxicidade proteica em doenças neurodegenerativas. Mais 
concretamente, procurou-se compreender como é que a célula reage perante 
a presença de proteínas com predisposição para agregar. O Capítulo II 
descreve as diferentes estratégias celulares que existem para lidar com este 
tipo de proteínas. Nesse capítulo também são sublinhadas as vantagens de 
utilizar modelos animais — nomeadamente leveduras, nemátodes e moscas — 
como ferramentas versáteis para descobrir genes (ou moduladores genéticos) 
envolvidos na agregação e toxicidade proteica. Muitos dos genes descobertos 
nestes organismos estão conservados em ratinhos, o que permite estudos 
mais complexos e cujas descobertas poderão ser potencialmente aplicáveis 
a humanos. No Capítulo II, explora-se ainda o conceito emergente da 
contribuição do genoma não-codificante para a neurodegeneração, e descreve-
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se o progresso realizado nesta área de investigação. São apresentados vários 
exemplos recentes onde se demonstra a relação entre o metabolismo de RNA e 
doenças neurológicas e neurodegenerativas e, mais concretamente, descreve-
se como é que disfunções em microRNAs, tRNAs e outros tipo de RNAs se 
correlacionam com a patologia. A contribuição das disfunções no metabolismo 
do RNA para o desenvolvimento da patologia e os mecanismos envolvidos são 
questões que permanecem em aberto.  
 
No Capítulo III, apresenta-se o modelo animal C. elegans como uma ferramenta 
para descobrir a função de genes. Explora-se como se pode tirar partido de 
modelos de C. elegans para as doenças de Alzheimer, Parkinson ou Huntington, 
e descreve-se como podem ser utilizados em screens genéticos (utilizando 
etil metano sulfonato ou RNA de interferência). Um aspeto a mencionar 
é que, nestes modelos, a agregação e toxicidade proteicas são fenótipos 
que podem ser analisados independentemente um do outro. Ainda no 
Capítulo III são apresentados resultados de screens genéticos nos quais 
se observa que moduladores genéticos de proteotoxicidade estão 
frequentemente associados a funções metabólicas gerais (sistema de controlo 
de qualidade proteica, metabolismo de RNA, ciclo celular, etc.), demonstrando 
que a agregação e toxicidade proteica podem resultar de diferentes níveis de 
disfunção celular. 
 
O Capítulo IV descreve o trabalho desenvolvido a partir de um screen genético 
num modelo de C. elegans para doenças de expansão de poliglutaminas. 
Neste screen procuraram-se genes que promovem a agregação e toxicidade 
proteica, usando a poliglutamina como exemplo de uma proteína com 
predisposição para agregar. Neste capítulo descreve-se também a descoberta 
do modulador genético moag-2 (modifier of aggregation-2) que, quando 
mutado, reduz a agregação proteica até 51%. Após sequenciação, descobriu-
se que o modulador genético moag-2 corresponde ao gene lir-3. O gene 
moag-2/lir-3 codifica uma proteína de função desconhecida, mas a sua 
sequência de aminoacídica contém um sinal de localização nuclear e dois 
domínios com “dedos” de zinco (zinc fingers) homólogos aos do factor de 
transcrição para a RNA Polímerase III A (TFIIIA). Neste estudo, descobriu-se 
ainda  que a proteína MOAG-2/LIR-3 se liga aos mesmos locais genómicos 
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que a maquinaria da RNA Polímerase III para transcrição de pequenos RNAs 
não-codificantes — entre os quais se incluem os small nuclear RNA (snRNA); 
small nucleolar RNAs (snoRNAs) e RNAs de transferência (tRNA). A função 
destes pequenos RNAs não-codificantes é a regulação da expressão genética 
ou modificação de outras moléculas de RNA. Curiosamente, descobriu-se que 
a proteína MOAG-2/LIR-3 promove a agregação de poliglutaminas de uma 
forma que é independente da sua função como factor de transcrição. Assim, 
proteínas com predisposição para agregar conseguirão sequestrar e converter 
proteínas celulares normais em factores que promovem agregação proteica. 
Uma descoberta adicional deste trabalho foi que proteínas com predisposição 
para agregar reduzem a abundância de pequenos RNA não-codificantes em 
animais wild type, nomeadamente snRNAs, snoRNAs e tRNAs. Apesar de serem 
desconhecidas as consequências biológicas desta observação, os resultados 
sugerem que proteínas com predisposição para agregar também podem 
influenciar a homeostase de RNAs não-codificantes.
 
O Capítulo V descreve as alterações transcricionais que ocorrem quando células 
expressam proteínas com predisposição para agregação proteica. Ao comparar 
o perfil transcriptómico de animais wild type com animais que expressam 
poliglutamina, descobriu-se que esta atrasa o desenvolvimento animal — 
consistentemente com observações anteriores de que estes últimos demoram 
normalmente mais tempo a atingir o mesmo estádio de desenvolvimento do 
que animais wild type. Resultados obtidos pelo mesmo estudo revelaram ainda 
quais são as vias de sinalização activadas como consequência da presença 
de poliglutaminas. Mostra-se também que a expressão de proteínas com 
predisposição para agregar induz a activação da unfolded protein response 
(UPR), uma das principais vias envolvidas na manutenção da homeostase 
proteica.
 
Uma vez identificados moduladores em modelos animais como leveduras, 
nemátodes ou moscas, é necessário validar a sua função em mamíferos ou 
cultura de células humanas. A proteína MOAG-4/SERF foi identificada, em 
trabalho previamente publicado pelo nosso grupo, como um modulador 
genético de agregação proteica em modelos de C. elegans para a doença de 
Alzheimer, de Parkinson e de expansão de poliglutaminas. O Capítulo VI, 
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descreve a geração de um modelo de murganho com deleção (knockout) do 
gene SERF2, um dos homólogos de MOAG-4. Descobriu-se que a deleção de 
SERF2 não é favorável para o desenvolvimento animal, uma vez que resultou 
frequentemente em letalidade embrionária com penetrância incompleta. Esta 
observação levou a que se tentassem gerar mutantes condicionais nos quais 
a expressão de SERF2 é eliminada apenas no cérebro. Esta estratégia foi bem 
sucedida uma vez que se obtiveram mutantes condicionais viáveis e férteis. 
Mostra-se ainda que a deleção de SERF2 do cérebro foi conseguida sem afectar 
a sua expressão noutros órgãos. Finalmente, propomos que estes mutantes 
condicionais possam ser cruzados com modelos de murganho para a doença 
de Alzheimer, o que permitirá estudar a função de SERF2 como modulador de 
agregação proteica na doença de Alzheimer (Capítulo VII).
 
Em suma, esta tese descreve a descoberta e caracterização de um novo 
modulador genético para a agregação proteica e propõe mecanismos 
alternativos que podem ajudar a compreender melhor a complexidade do 
processo de agregação proteica. Paralelamente, o trabalho aqui apresentado 
deu início ao processo de validação de um modulador genético descoberto 
em C. elegans e a sua transposição para modelos de Alzheimer em murganhos, 
abrindo caminho a investigação translacional.
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